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 ABSTRACT 
Schizophrenia is a serious stigmatizing illness. Antipsychotic medication is a corner-
stone in treatment. Non-adherence is a predictor of poor outcome leading to relapse, 
poor functioning, high mortality and costs. Reported adherence rates vary (8-86%). 
Most adherence studies are small, short and use subjective adherence measures 
known to underestimate non-adherence. The overall aim of this thesis is to increase 
knowledge about factors related to adherence to oral antipsychotics and to stigma in a 
large cohort of patients with schizophrenia or schizophrenia-like psychosis, followed 
for one year. The specific aims are: to examine adherence to antipsychotics and to 
compare objective and subjective measures of adherence; to investigate predictors of 
adherence; to explore stigma and discrimination and to test for potential associations 
between a) different types of stigma and b) stigma and adherence; to study stigma 
experiences and the relationship between associated stigma and burden in relatives to 
persons with schizophrenia. 
  
Adherence was monitored for a year in 117 outpatients at Sahlgrenska University 
Hospital, Gothenburg, Sweden. Adherence was determined by the Medication Event 
Monitoring System (MEMS®), considered the reference standard, pill count, a 
composite measure of plasma levels and adherence to lab visits, and patient, staff, 
psychiatrist and close informant ratings. Symptom burden, insight, cognition, 
psychosocial function (PSP) and side effects were rated (n=112). Experiences of 
stigma (n=111) and drug attitude (using the Drug Attitude Inventory, DAI-10) of 
patients (n=112) and informants (n=65), as well as burden in relatives (n=65) were 
assessed. 
 
Non-adherence (MEMS® adherence ≤ 0.80) was observed in 27% of the patients. In 
Study I MEMS® adherence was highly correlated with pill count but very poorly 
correlated with the plasma level measure. In Study II low patient-rated DAI-10 scores 
and poor function emerged as predictors of non-adherence. Positive symptom 
burden, psychiatric side effects, lack of insight and low DAI-10 informant scores also 
predicted non-adherence. No association between stigma and adherence could be 
shown in Study III. Almost two-thirds of the patients reported discrimination in social 
relationships and “anticipated stigma”. One-half felt discriminated against by mental 
health staff. In Study IV a fifth of the relatives avoided situations that might elicit 
stigma, but there was no association between experienced or anticipated stigma and 
burden. Stigma impact regarding the relatives’ personal quality of life was associated 
with overall burden. 
 
In conclusion, structured pill count might be a useful clinical tool to objectively 
follow adherence. The large discrepancy between MEMS® and the plasma level 
measure needs further study. Positive drug attitude in combination with good 
psychosocial functioning emerged as predictors of MEMS® monitored adherence. 
Associations were found neither between stigma and adherence nor the relatives’ 
stigma and burden, and both phenomena need to be investigated further. 
 
Keywords: schizophrenia, adherence, Medication Event Monitoring System, 
antipsychotics, pill count, drug attitude, stigma, discrimination, relatives’ burden 
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 SAMMANFATTNING PÅ SVENSKA 
Schizofreni är en allvarlig stigmatiserande sjukdom. Antipsykosläkemedel utgör en 
hörnsten i behandlingen. Bristande läkemedelsföljsamhet (adherence) försämrar 
prognosen, vilket leder till återfall, funktionsnedsättning, ökad dödlighet och 
kostnader. Rapporterad grad av adherence varierar (8-86%). I de flesta studier, som 
är små och korta, används subjektiva mått, vilka ofta överskattar adherence.  
Det övergripande syftet med denna doktorsavhandling är att öka kunskapen om 
faktorer relaterade till adherence till antipsykosläkemedel och till stigma vid 
schizofreni. De specifika delarbetena avser att: undersöka graden av non-adherence 
och att jämföra subjektiva och objektiva adherencemått; studera kliniska prediktorer 
som kan förutsäga non-adherence; skatta stigma och diskriminering och testa 
eventuella samband mellan a) olika typer av stigma samt b) stigma och adherence; 
hos närstående till personer med schizofreni studera upplevelsen av stigma och att 
undersöka associationen mellan stigma och upplevd närståendebörda. 
Under ett år följdes adherence hos 117 psykosöppenvårdspatienter vid Sahlgrenska 
universitetssjukhuset i Göteborg. Elektroniska läkemedelsburkar (MEMS®), som 
anses utgöra referensstandard, och plasmanivåer (kompositmått på plasmanivåer och 
följsamhet till laboratoriebesök), pillerräkning och skattning av patient, närstående, 
psykiater och behandlare utgjorde adherencemått. Symtombörda, biverkningar, 
sjukdomsinsikt, kognition och psykosocial funktion skattades. Läkemedelsattityd 
(n=112) och upplevelse av stigma hos både patient (n=111) och närstående (n=65) 
samt närståendebörda mättes. 
Sänkt adherence noterades hos 27% av patienterna (MEMS® adherence ≤ 0.80). 
Enligt studie I hade adherence mätt med pillerräkning mycket hög samstämmighet 
med MEMS® adherence. Däremot hade plasmanivåmåttet lägst samstämmighet. 
Patientens läkemedelsattityd, i kombination med psykosocial funktion, predicerade 
adherence i studie II. Biverkningar, psykossymtom, bristande insikt och negativ 
läkemedelsattityd hos närstående var också relaterade till sänkt adherence. Inget 
direkt samband mellan stigma och adherence sågs i studie III. Närmare två 
tredjedelar av patienterna kände sig socialt diskriminerade och angav att de undviker 
sådant de förväntar sig kan leda till stigma. Hälften kände sig diskriminerade av 
psykiatrisk personal. I studie IV rapporterade en femte del av de närstående att de 
undviker situationer som kan föranleda stigma, men inget samband sågs mellan 
upplevd eller förväntad stigmatisering och närståendebörda. Stigma medförde 
minskad livskvalitet både för de närstående och för berörda familjer och i bägge 
fallen sågs en association till närståendebörda. 
Sammanfattningsvis antyder den höga samstämmigheten mellan pillerräkning och 
MEMS® att pillerräkning kan vara en enkel och billig objektiv metod för att mäta 
adherence i kliniken. Plasmanivåmåttet behöver studeras närmare. Kombinationen 
läkemedelsattityd och psykosocial funktion predicerade MEMS® adherence. Ingen 
relation kunde påvisas mellan stigma och adherence, eller mellan närståendebörda 
och stigma, och sambanden behöver undersökas närmare. 
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DEFINITIONS IN SHORT 
 
DALY Disability-Adjusted Life Years for a disease 
or health condition (DALYs) are calculated as 
the sum of the Years of Life Lost (YLL) due 
to premature mortality in the population and 
the Years Lost due to Disability (YLD) for 
people living with the health condition or its 
consequences. 
DUP The Duration of Untreated Psychosis (DUP) 
was in this thesis defined as the time from the 
first documentation of psychotic symptoms in 
the medical files until registered onset of 
antipsychotic treatment.  
Effectiveness The ability of an intervention to produce the 
desired beneficial effect in actual use. 
Efficacy The ability of an intervention to produce the 
desired beneficial effect in expert hands under 
ideal circumstances. 
NNT The Number Needed to Treat (NNT) is the 
number of patients that need to be treated to 
prevent one additional negative outcome. 
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1. INTRODUCTION 
1.1 The concept of adherence 
1.1.1 Therapeutic and medication adherence  
According to NICE guidelines [1] between a third and a half of medicines 
that are prescribed for any long-term conditions are not taken as intended. 
Furthermore, poor adherence is not limited to medication taking alone and is 
commonly divided into therapeutic and medication adherence [2]. 
Therapeutic adherence encompasses non-pharmaceutical treatment 
recommendations, for example exercise and diet, and this is defined by the 
World Health Organization (WHO) [3] as “the extent to which a person’s 
behavior corresponds with agreed recommendations from a health care 
provider”. Medication adherence, on the other hand, can be defined as the 
extent to which a patient’s medication-taking matches that which is agreed 
with the prescriber. Several alternative terms have been used, including 
treatment compliance, concordance and fidelity. Adherence is currently 
favored partly because of its neutrality whereas, for example, compliance 
implies an unequal power balance between the  prescriber and patient [4].  
1.1.2 Medication non-adherence is common 
Non-adherence is a problem in all medical conditions and not only in severe 
mental illness. Results from a meta-analysis [5] of 569 studies, reporting 
adherence to medication prescribed by non-psychiatrist physicians, found an 
average non-adherence rate of 24.8% (Table 1). In physical illness adherence 
rates were found to be higher in smaller, more recent studies, and in adult 
samples including medical regimens. A much cited review [6] of non-
adherence in schizophrenia, with mean non-adherence rates of 40.5%, is used 
as a comparison. 
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Table 1: Non-adherence in various medical conditions and in schizophrenia 
Condition Number of studies Non-/poor adherence 
Schizophrenia   39 40.5% 
Medical condition      
Diabetes mellitus 23 32.5% 
Pulmonary disease 41 31.2% 
End-stage renal disease 20 30.0% 
Eye disorder 15 27.4% 
Infectious disease 34 26.0% 
Obstetric and gynecological disorder 19 25.2% 
Ear, nose, throat and mouth disorder 30 24.9% 
Cardiovascular disease 129 23.4% 
Skin disorder 11 23.1% 
Genitourinary/sexually transmitted diseases 17 23.0% 
Cancer 65 20.9% 
Gastrointestinal disorder 42 19.6% 
Arthritis 22 18.8% 
HIV/AIDS 8 11.7% 
Data based on DiMatteo, M.R. (2004) and Lacro, J.P. (2002). 
 
1.1.3 Cut-off for non-adherence in research 
Medication adherence lies on a spectrum ranging from individuals who take 
no medication, despite agreeing to do so with the prescribing clinician, to 
those who take each dose precisely on time. Some patients take more than 
prescribed. This can cause side effects leading to secondary non-adherence as 
the negative medication experience may cause consequent mistrust of 
medicines. Varying degrees of adherence, so-called partial adherence, where 
patients take some medication from time to time but not consistently as 
prescribed is the most common [7].  
Adherence is usually dichotomized for research purposes with non-adherence 
defined as missing ≥ 20% of prescribed medication [8-11]. This cut-off has 
validity in predicting subsequent hospitalization across several chronic 
conditions. The 80% cut-off for non-adherence has been challenged in a 
current study that showed that patients with schizophrenia, with an 
objectively monitored adherence rate of 80-99.9%, had more somatic 
concerns, greater psychopathology and were more disoriented compared to 
patients with full (100%) adherence [12]. The authors claim that full 
adherence should be a treatment goal for “adherent” patients in order to 
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optimize outcome. Thus, an adherence rate of 80% is not assumed to equal 
“adherence”.  
For individual patients the degree of non-adherence that affects health 
outcomes will depend on many factors. These include the condition, its 
severity and the risk of recurrence, the relative effectiveness of the 
medication and its dose, mode of delivery and frequency of administration, 
how the individual patient metabolizes the medication and the effects of 
concomitant medications, smoking, etc.  
Different cut-offs have been used and some, mostly earlier, studies define 
adherence as taking as low as 75% or as high as 95% of the prescribed 
medication [11]. This, together with population studied and methods used, 
should be taken into account when comparing adherence data. Still, the most 
recent studies use 80% as the cut-off for adherence. 
1.1.4 Factors influencing adherence 
The Health Belief Model 
Theoretical paradigms of adherence, such as the Health Belief Model [13], 
were developed and adopted in the 70’s in order to identify factors that might 
determine adherence behavior. According to this model, everything revolves 
around the presumed likelihood that the patient will adhere to treatment 
recommendations. The patient’s decision to adhere to treatment or not is 
assumed to stem from the implicit, subjective assessment of the pros and 
cons of medicating. If the advantages are expected to outweigh the 
disadvantages the patient will most likely be adherent, i.e. the patient’s 
decision is influenced by the assumed individual risks and susceptibility 
connected to adhering to the treatment.  The patient makes decisions based on 
his or her beliefs about the illness as well as the treatment. With physical 
illness, it has been shown that patients’ beliefs about the medicine are of 
crucial importance [14]. In line with the Health Belief Model this study found 
that the necessity of taking medication was weighed against the fear of 
potential adverse effects from medicating. The patient’s beliefs were found to 
predict adherence significantly better than clinical and sociodemographic 
factors. 
Intentional and unintentional non-adherence 
Non-adherence can be divided into intentional and unintentional non-
adherence. In the case of intentional non-adherence the patient has made a 
deliberate decision not to take the medicine according to the prescription. The 
patient usually finds the disadvantages of medicating greater than the 
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advantages. This could be due to poor understanding of the illness or the 
experience of side-effects (for example those connected to chemotherapy 
treatment in the final stages of cancer providing only a very limited 
prolongation of life). Unintentional non-adherence refers to an inability to 
follow the prescription, for example due to cognitive deficits, unclear 
instructions, expense of medication or difficulty collecting the medicine at 
the pharmacy. Unintentional and intentional non-adherence can both occur in 
the same patient.  
1.1.5 The history of non-adherence 
The prescription of medicines is a core element of the modern health care 
system [1]. Non-adherence has existed as long as treatments have been 
prescribed. As early as the 4th century BC Hippocrates documented that 
some patients did not take their prescribed medicine and that others 
complained that their treatment was ineffective [15]. Hippocrates stated the 
risk of non-adherence with the following words: “Keep watch also on the 
faults of the patients which often make them lie about the taking of things 
prescribed” [16]. While Hippocrates may be rather extreme in his wording, 
our views of the reasons for non-adherence have hopefully evolved. But the 
problem of non-adherence undoubtedly remains important. 
In the 19th century, Robert Koch, the father of modern bacteriology, was 
critical of patients with tuberculosis who did not follow the instructions given 
to fight their serious infection [15]. In 1955, not long after the introduction of 
antibiotics, it was found that approximately one-third of patients with acute 
pharyngitis or otitis media did not complete a one-week course of oral 
penicillin [17]. Non-adherence was thus, as already mentioned, found early 
on to be not only a problem within psychiatry, but a widespread feature of 
human behavior [18].  
The basis for understanding the perhaps even more complex aspects of non-
adherence in schizophrenia is familiarity not only with the basic concept of 
non-adherence in general, but also with the symptomatology and the 
consequences of the schizophrenia syndrome. Outcomes in schizophrenia, 
antipsychotics and the stigmatization of and within psychiatry, and of 
antipsychotics as well as of mental illness itself will also be discussed. 
1.2 Outcome in schizophrenia 
Schizophrenia is a complex and debilitating mental illness [19]. The clinical 
syndrome of variable, but profoundly disruptive, psychopathology involves 
cognition, emotion, perception, and other aspects of behavior. Multiple 
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factors, such as drug abuse, stigma, discrimination and social deprivation, 
which are all common in schizophrenia, contribute to a poor prognosis [20]. 
Relapses do not only seem to be associated with a considerable psychosocial 
risk, but also to morphological changes of the brain and to treatment 
refractoriness [21].  
Schizophrenia is seen as a severe neurodegenerative disorder involving 
recurring and chronic psychotic episodes with relapses leading to 
deterioration of cognition and psychosocial functioning. This widespread 
view that schizophrenia causes progressive brain changes and cognitive 
deficits makes outcome a key concern [22]. One consequence of the gloomy 
Kraepelinian estimate of the long-term outcome, based on institutional 
experiences before the introduction of antipsychotics, is a persisting negative 
outlook on the prognosis of schizophrenia [23]. This view has influenced the 
development of diagnostic manuals as well as the content of textbooks, 
lectures and psycho-education. Together with the frequently negative public 
view of psychiatry, this may have both compromised social inclusion and 
rehabilitation of patients and added to the burden and stigmatization of 
patients and families. It may also have negatively impacted the 
implementation of modern evidence based psychiatric practices and 
treatments, including the optimal use of psychiatric medications.  
The way antipsychotics have been viewed has been influenced by earlier 
pessimistic views of outcome, the anti-psychiatry movements and a lack of 
trust in evidence based treatments [24]. Psychiatrists and psychiatric staff are 
themselves stigmatized. In a newly published international survey [25] of 
stigmatization of psychiatrists (n=1,893) and general practitioners (n=1,238), 
the psychiatrists reported significantly more perceived stigma and 
discrimination. This may affect recruitment, funding and consequently 
quality of psychiatric care and these are directly connected to outcome in 
schizophrenia [26]. 
1.2.1 Psychiatric outcome measures 
There is a need for improvement in psychiatric outcome measures [27]. 
Psychiatry is often criticized for using “soft” subjective measures and rating 
scales as opposed to “hard” outcomes, such as death or major events (for 
example heart attack) often used in other medical specialties [28]. In this 
meta-analysis it was pointed out that neither high blood pressure nor 
cholesterol levels lead to suffering and thus should not be the primary 
outcome, but instead their long-term consequences. Other somatic drugs 
directly reduce primary symptoms from the disease (for example oesophagitis 
or migraine) but the pathophysiological disease progress in these somatic 
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illnesses is not death. This is unlike medications for many severe psychiatric 
conditions where the disease progress is fatal.  
Traditionally in psychiatric research, unlike somatic medicine, death (such as 
suicide) has not generally been seen as an outcome to be measured but has 
more often been reported as an adverse event. Instead, common primary 
outcome measures for schizophrenia are reduction of illness severity, degree 
of hallucinations and hospitalizations. With recent increased recognition of 
the reduced life expectancy in severe mental illness of more than 20 years 
[29], mortality is now proposed as a routine and legitimate outcome measure 
in psychiatric studies. Thus, death and suicide should always be reported 
along with further improvements of psychiatric outcome measures [27].  
1.2.2 Is adherence an outcome measure? 
Antipsychotic medication is a cornerstone in treatment of schizophrenia [4, 
30, 31] and the basis for psychosocial interventions [11]. Despite the 
increased availability of evidence based treatments and pharmacological 
treatment options during the last decades, the recovery rates have not 
improved, as shown by a recent Finnish systematic review and meta-analysis 
[32]. Only 1 in 7 individuals with schizophrenia met the study criteria for 
recovery (both clinical and social recovery for at least two years and absence 
of, or only mild, symptoms). 
This might partly be due to the known association between non-adherence 
and poor prognosis, where missed medication leads to a significantly 
increased risk of relapse and suicide [33, 34]. A large Cochrane review [35] 
showed that continuous treatment with antipsychotics was superior to 
intermittent treatment in regard to relapse prevention. Despite this, several 
studies with non-adherence as a primary intervention target have shown that 
even if adherence improved, clinical outcome did not get better [36]. Thus, 
adherence in itself is not a sufficient treatment goal. Instead adherence should 
be considered as an important tool to achieve the treatment goals [37]. 
Accordingly, adherence to antipsychotics is a predictor of outcome and is 
only of interest as it affects outcome.  
 
1.3 Modern schizophrenia treatment 
Antipsychotic medication is acknowledged as the basis in schizophrenia 
treatment. However, it has been established that medication alone is not 
sufficient [11]. For optimal outcome antipsychotics need to be combined with 
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psychosocial interventions in community based psychiatry. Treatments 
should be prioritized, selected and followed-up based on structured ratings 
and clinical interviews. Patients’ attitudes, insights and subjective 
experiences (for example of medication and potential side effects) need to be 
acknowledged. These treatment components are all crucial for alliance, 
treatment adherence and optimal outcome [31] and are part of a tailor-made, 
person-centered approach to evidence based community mental health [38].  
Assertive Community Treatment (ACT) with case management has 
previously been shown to improve medication adherence [39]. This care 
delivery system, the continuity and (if called for) the higher frequency of 
contacts with the patients and the social network are all of importance [7]. 
These facilitate the patients’ adjustment and problem solving in everyday life 
as the basis for finding alternative strategies despite cognitive deficits or 
withdrawal symptoms of schizophrenia. The strategies are assumed to be of 
use both when having to cope with stigma and when taking medication [40]. 
Still, the question of which pharmacological and psychosocial interventions 
specifically improve outcome within integrated care models (and for whom) 
is still largely unanswered.  
One Swedish study found that an integrated care model improved social 
function and consumer satisfaction [38]. In a review [41] of eight randomized 
controlled trials (RCTs) and 21 non-RCT studies published between 2011 to 
2013, the authors suggest that person-centered integrated care models should 
be offered for  treatment of complications, such as non-adherence to 
antipsychotics, continuous psychopathology or service disengagement. This 
mode of working was associated with improvement of symptoms, better 
functioning, quality of life, adherence, patient satisfaction and reduced 
caregiver’s stress. This is in line with the suggestion of a further review [42] 
that a shared discussion between patients and health care professionals about 
the patient’s beliefs and attitudes about medication could facilitate the 
integration of psychopharmacology and psychological treatments and help 
reduce the stigma of having to medicate.  
 
A recent systematic review [43] concluded that the evidence supports a team-
oriented approach as it improves adherence and reduces relapse rates, 
hospitalization and costs. The multidisciplinary team thus plays an important 
role in identifying and overcoming patients’ barriers to adherence. Finally, 
medication, outcome and quality of life can be optimized by also involving 
the informal caregivers as their burden [44], and most likely their impact on 
the outcome, is quite substantial in schizophrenia. 
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psychosocial interventions in community based psychiatry. Treatments 
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1.3.1 Is antipsychotic medication efficacious? 
Psychotropics versus somatic medication 
Responding to frequent claims that psychotropic drug efficacy (i.e. the degree 
to which an antipsychotic brings about a specific result) is very small or 
altogether non-existent, Leucht and coworkers recently reviewed 94 meta-
analyses [28]. They aimed to compare the efficacy of major somatic drugs 
versus psychotropic medications. The review found that effect sizes obtained 
by psychiatric pharmacotherapy were in the same range as most general 
medical drugs and this was also the case for antipsychotics. Still, it is 
underlined that with differences in both outcomes and diseases the results can 
only be interpreted qualitatively and in the light of percentage of patients 
helped by a specific drug.  
 
The efficacy of antipsychotics 
Large meta-analyses of placebo controlled trials show that antipsychotics in 
acute and maintenance treatment of schizophrenia are efficacious. A meta-
analysis [45] of 38 RCTs that compared second generation antipsychotics 
(SGA) to placebo in the acute phase showed a moderate effect size of 
approximately 0.5 with a number needed to treat (NNT) of 6 for response 
(NNT=the number of patients that need to be treated to prevent one 
additional negative outcome). In another meta-analysis [30] of 65 trials, 
patients were stabilized on antipsychotics before being randomized to 
continued medication or switched to placebo. Antipsychotics reduced the rate 
of relapse from between 7 and 12 months compared to placebo with a NNT 
to benefit of 3. Patients treated with antipsychotic medication were re-
hospitalized to a lesser extent and they were not as likely to drop out as a 
consequence of lack of effect or for any other reason.   
1.3.2 Compound and mode of delivery 
The differences in efficacy between the first generation antipsychotics (FGA) 
and SGA are small, but the metabolic, extrapyramidal and sedating side 
effect profiles generally differ considerably. Previous studies regarding 
differences in non-adherence rates for SGA and FGA are inconclusive, but 
often show no significant difference [45-47]. A more recent systematic 
review [48] and meta-analysis of relapse prevention found a difference in 
relapse rates between SGA (29.0%) versus FGA (37.5%) treatment. The 
SGAs were more likely to prevent hospitalization and relapse at the 3, 6 and 
12 month follow-up and fewer dropped out due to medication intolerability.  
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Findings regarding the cost effectiveness of SGAs are contradictory. The 
results and clinical implications of two large clinical trials, CATIE (Clinical 
Antipsychotic Trials of Intervention Effectiveness) and CUtLASS (Cost 
Utility of the Latest Antipsychotic drugs in Schizophrenia Study), were 
analyzed in one study [49]. In CATIE the all-cause discontinuation rate was 
74% before 18 months, with a median time to discontinuation of 4.6 months. 
The overall efficacy of FGAs and SGAs in both study populations was 
similar and few differences between the groups were detected. Still, it is 
concluded that there is no single optimal antipsychotic suitable for all 
patients, but the lower risk of tardive dyskinesia and the better subjective 
effects favor SGAs. 
During the last decade there has been an increasing focus on the metabolic 
side effects of antipsychotics and a concern that concomitant use of several 
antipsychotics, discussed below, might increase mortality among patients 
with psychotic disorders [50]. Data regarding the mortality rate associated 
with FGA versus SGA are inconclusive [51]. A ten-year follow up study of 
more than 1,600 patients found FGAs to be associated with doubled mortality  
[52], even if SGAs have been shown to be associated with more weight gain 
and worsening of metabolic parameters [53]. Pharmacoepidemiological 
research that includes all individuals residing in a country is made possible 
by the unique personal identity codes used in Finland, Denmark and Sweden. 
Nationwide register studies were performed in Finland to investigate the 
relationship between antipsychotics and mortality more thoroughly [29, 54-
56]. Tiihonen and co-workers found that the use of any antipsychotic lowered 
mortality rates compared to no antipsychotic, and clozapine appeared 
superior. However the SGAs are a highly heterogeneous group [29], as 
shown in a meta-analysis [57] that questions the division between FGA and 
SGA altogether proposing a division based on side effect profiles. 
An additional concern, apart from the profile of the actual compound is the 
treatment regimen and delivery system. Prescribed dose frequency is an 
important factor for predicting medication adherence to antipsychotics [58]. 
The number of daily doses have been found to be inversely associated with 
adherence [59] and single daily dosage to be preferred.  
The administration of long acting injectables (LAI) has been shown to be 
associated with lower risk of hospitalizations compared to use of the same 
compound as an oral formulation [55]. With LAIs there is clear evidence of 
whether the patient has received the prescribed medication or not. If the 
patient misses an appointment to receive an LAI the professional caregiver is 
given an immediate opportunity to act in order to facilitate adherence by 
offering psychoeducation, cognitive support or home visits, etc. [60]. 
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Similarly, the informal caregiver will have a window of opportunity to act as 
well as seek the support of the professional health care system to hopefully 
avoid an exacerbation.  
Nevertheless, many patients are not offered or informed about the option of 
an LAI. The reasons might be the attitudes of the psychiatrists and other 
health care professionals towards LAIs or the prescribers’ beliefs that patients 
might be negative to injectables [61, 62]. Some patients prefer oral 
medication and in the clinic the available medication options need to be 
readily available and the optimal treatment tailor made for each patient.  
1.3.3 Polypharmacy 
Clinicians have, for some decades, been advised against polypharmacy. 
However, a recent Finnish database study [56] revealed that concomitant use 
of several antipsychotics did not increase mortality in comparison with 
antipsychotic monotherapy. Instead a two-fold risk of death was observed for 
patients who did not use any antipsychotic. These results confirmed findings 
in earlier database studies by Tiihonen and coworkers [29, 54, 55]. An 
additional finding was that antidepressants did not increase mortality, but 
instead decreased the risk of suicide. On the other hand, a two-fold increase 
of overall mortality was seen during treatment with benzodiazepines with 
long elimination half-life regardless of other concomitant medication. In line 
with the Finnish results, a current US study [63] in a large integrated health 
care setting found that benzodiazepines used for insomnia were associated 
with a three-fold mortality rate compared to no benzodiazepine use. The 
observed excess mortality could not be explained by control of selective 
prescription of benzodiazepines for patients in poor health. The results from 
the Finnish register studies are also supported by a large Danish register 
study [64] of 28,000 patients with schizophrenia and treatment with 
antipsychotics, where adjunctive benzodiazepine use was associated with a 
1.8-fold risk of natural death. In the same study it was also shown that the use 
of antipsychotics reduced the risk of death due to natural causes in middle-
aged patients with schizophrenia. 
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1.4 Schizophrenia 
1.4.1 The history of schizophrenia 
In general, illnesses are defined in terms of their clinical presentation plus 
their course and outcome. The identification of what was later to be called 
schizophrenia was distinguished in 1896 as “dementia praecox” by Emil 
Kraepelin (1856-1926). He identified it as a distinct syndrome separate from 
the broad spectrum of psychoses he studied in his mental hospital [65]. The 
major distinction was made between dementia praecox and recurring 
affective episodes or manic depressive disorder, now known as bipolar 
disorder [66]. Kraepelin thus laid the foundation for a rational classification 
of psychiatric disorders. Interestingly enough he could not speak the language 
of his patients at the hospital where he conducted his research in Dorpat, in 
what is today Estonia. Therefore, his identification of dementia praecox 
rested primarily on his observations of the course and outcome alone [22]. 
According to his observations recovery was extremely rare and deterioration 
inevitable.  
 
In 1911 Eugen Bleuler (1857-1939) renamed the illness schizophrenia [67] 
and published Dementia praecox oder die Gruppe der Schizophrenien [68]. 
The title refers to the heterogeneity of persons with schizophrenia and to his 
famous “four A’s”, i.e. Autism (withdrawal), Ambivalence (lack of direction 
and motivation), Association disturbance (thought disorder, i.e. different 
associations or meanings being attached to words) and Affective flattening 
(mood disturbances). This is the first report of the importance of psychosocial 
functioning in schizophrenia. None of these symptoms are, however, 
mandatory or specific for a diagnosis of schizophrenia today. Bleuler’s 
approach has been superseded by an emphasis on the so-called positive 
symptoms of schizophrenia (delusions, hallucinations, thought disorder) due 
to their easy and reliable identification and responsiveness to antipsychotic 
medication.  
Contrary to Kraepelin, who spent his work life treating chronic inpatients 
without recovery in sight, Bleuler had extensive conversations with both 
discharged and partially recovered patients. This might have been the start of 
understanding the importance of building relationships in psychiatric care 
[24]. He was able to capture not only the course and outcome of a wider 
variety of the schizophrenia spectrum, but also more of the various clinical 
presentations. Bleuler presented a more optimistic outlook on outcome in 
schizophrenia. This development, of incorporating various aspects of the 
illness, has lead some researchers of today to present the trajectory of 
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schizophrenia as an integrated sociodevelopmental-cognitive model [69]. 
This takes into consideration not only the possible impact of 
neurodevelopment, dopamine and cognition, but also integrates them as a 
basis for successful treatment. 
1.4.2 The epidemiology of schizophrenia  
Epidemiological research on psychosis has to date focused primarily on the 
incidence, prevalence, risk factors and etiology, course and outcome [70]. 
The disorder exhibits substantial heterogeneity with regard to severity and 
course of illness [71], but the typical features of its natural history support the 
theory of a neurodevelopment genesis with an important genetic contribution 
[72]. The liability to develop the disorder is inherited rather than the certainty 
of developing it [70].  
 
In chronic disorders such as schizophrenia, categorical outcome measures 
(e.g., recovered vs. persistent illness) are less operational [73]. Dimensional 
symptom outcomes (e.g., positive or negative symptoms of schizophrenia 
with hallucinations, affective flattening, or impoverishment of speech and 
language) and measures of disability (e.g., employment, social functioning) 
tend to fluctuate over time and show divergent trajectories. Compared with 
measuring incidence and prevalence, assessing clinical outcomes in 
schizophrenia is much more of a challenge. 
Incidence and prevalence of schizophrenia 
The prevalence is the existing number of cases of a condition at a single point 
in time as a percentage of that population. The prevalence of schizophrenia is 
about 0.7% with estimates in various countries ranging from 0.2-2.0% [74]. 
The one-year prevalence of schizophrenia was 3.7/1,000 in a recent Swedish 
population-based study [75] using comprehensive health care registers in 
Stockholm County. This can be compared to a reported prevalence of 
6.7/1,000 for non-affective psychoses. 
The modal age of onset is between 18 and 25 years in men, and between 25 
and 35 in women [76]. The incidence is defined as the number of new cases 
of a condition over a given period of time as a percentage of the population. 
Geographical differences in the incidence of schizophrenia may be due to 
variations in definitions as well as different ratings or diagnostic manuals 
used. In a Swedish multi-generation register study [77] which contained 
information about all children, their parents and the hospital discharge 
register (all public psychiatric inpatient admissions), an average incidence 
rate of 0.2% per year was estimated. The incidence rate appeared to be fairly 
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stable across a wide range of cultures, climates and ethnic groups. The 
general lifetime risk of schizophrenia was approximated as less than 1%. 
Heredity increased the relative risk (RR) for schizophrenia when the proband 
had schizophrenia: RR 9.9, (95% CI 8.5-11.6) for parent to offspring and RR 
9.0, (95% CI 8.1-9.9) for sibling to sibling.  
Opposite to the findings in the Swedish multi-generation study a large review 
[73] found that the incidence rate fluctuated due to key variables, such as 
migrant status and latitude. Compared with native-born persons, migrants had 
an increased incidence and prevalence of schizophrenia. The distribution of 
incidence rates differed significantly and the migrant versus native-born rate 
ratio median was 4.6. The illness was found to be more frequent in men, with 
a male:female ratio of 1.4:1. The frequency measures also varied with 
urbanicity, economic status and latitude.  
In an earlier review [78] the distribution of estimates did not differ according 
to economic status. The median incidence rates per 100,000 people for the 
least developed countries of 20.0 (0.4-35.0), emerging economies 11.0 (5.0-
26.0), and developed countries 16.0 (8.0-48.0) showed no significant 
differences. Urbanicity was shown to be associated with an increased 
incidence of schizophrenia in a more recent review [20]. It was concluded 
that social drift alone could not account for these findings, where differences 
were found even between different neighborhoods. The variability of 
incidence and prevalence in schizophrenia should be taken into account when 
interpreting research results, as conclusions drawn need to be interpreted in 
the light of the sociodemographics of the population studied. 
1.4.3 Disability and cost of schizophrenia 
The World Health Organization has rated schizophrenia as the eighth leading 
cause of disability- adjusted life years (DALYs) worldwide in the group of 
15-44 year olds [79]. DALYs are calculated as the sum of lost years of life 
due to premature mortality in the population and years lost due to disability. 
In 2004, the World Health Organization [19] estimated that over 26 million 
people suffered from schizophrenia and was in the top 20 illnesses 
contributing to the global burden of illness. In addition to the direct burden 
there is a substantial burden on the relatives of persons with schizophrenia 
[80]. In a European review schizophrenia and schizophrenia-like psychoses 
were among the most expensive “disorders of the brain”, with the highest 
yearly and lifetime costs [81]. The unemployment rate for patients with 
schizophrenia was almost 90%. Schizophrenia, due to both short-and long-
term impairments and disabilities, was considered a great emotional, financial 
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and social burden to both patients and their families. The recommendation 
was to optimize schizophrenia treatment as it would be highly beneficial for 
both health- and socioeconomic reasons [41]. 
Reported costs of schizophrenia vary depending on methods used and 
expenses included. In one WHO report [19] the cumulative cost of 
schizophrenia was 39.0%, a cost larger than for example war (32.9%) or for 
road traffic accidents (19.6%). In a recent Swedish study [82] that combined 
hospital-based registry data with national registry data, an average annual (in 
2008) cost of 42,700 € per patient with schizophrenia was found. For 
community mental health care an additional cost of 12,400 € was to be added, 
giving a total cost of 55,100 €. Improving the psychosocial functioning of the 
patient and avoiding hospitalizations would, according to the authors, not 
only reduce the suffering and burden of the patient and relatives or other 
informal caregivers, but directly cut the societal costs of schizophrenia. 
1.4.4 Mortality and reduced life expectancy 
Based on the standardized mortality ratio (a ratio between the observed 
number of deaths in a study population and the expected number of deaths 
based on age and gender), people with schizophrenia have a two to three-fold 
increased risk of premature death [73]. This differential gap in mortality has 
increased over the last decades. In a national Swedish cohort study [83] that 
included more than 8,000 people with schizophrenia who were followed for 
seven years, men died 15 and women 12 years earlier than the rest of the 
population. This was not accounted for by unnatural deaths (such as suicide 
and accidents). The main cause of the markedly premature mortality in this 
study was ischemic heart disease and cancer. These conditions were largely 
underdiagnosed in patients with schizophrenia (diagnostic overshadowing), 
despite having more health care contacts than average. The physical 
symptoms were mistakenly assumed to be accounted for by the mental 
illness, overseen or not prioritized. Stigma of mental illness is also known to 
contribute to diagnostic overshadowing and lack of treatment (treatment 
overshadowing) [84]. These findings were supported by a review [51] where 
the main causes of mortality in schizophrenia were suicide, cancer and 
cardiovascular disease.  
 
Lack of antipsychotic medication was also associated with increased 
mortality in the Swedish cohort study [83]. These data are in line with the 
results from a previous large population-based 11-year follow-up cohort 
study [29] of almost 67,000 Finnish patients with schizophrenia. In this study 
long-term treatment with any antipsychotic was associated with lower 
mortality compared with no antipsychotic. It was also concluded that the 
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newer SGAs are a heterogeneous group of drugs and their association with 
mortality needs further study. The use of clozapine was associated with a 
substantially lower mortality compared to any other antipsychotic 
medication. These mortality data showed a decreased life expectancy of 25 
years in 1996 and 22.5 years in 2006, compared to the general public.  
1.4.5 Suicide 
Following cardiovascular disorders, suicide is the second most common 
cause of mortality in schizophrenia [85], but the contribution of suicide to 
mortality varies dependent on type of study, age of the study cohort and 
length of follow-p  [51]. A recent systematic literature review [86] found that 
suicide risk in schizophrenia was mainly related to affective symptoms, 
previous suicide attempts and number of psychiatric hospitalizations. 
Additional risk factors were younger age, male gender, early phase of the 
illness, having a first episode later in life, substance abuse and proximity to 
time of discharge. Additionally, mortality due to suicide can be assumed to 
be higher than measured as about 25% of undetermined or accidental deaths 
are suicides [87]. 
 
In a Swedish study [88] the one-year prevalence of suicide was high 
(3.6/1,000). The odds ratio (OR) corrected for gender and age was around 10, 
which was compatible with another recent estimate in the literature, 8.5 [89]. 
An earlier review [90] found that 10% of patients with schizophrenia 
eventually will commit suicide and that the rate of suicide attempts were two 
to five times that of the completed suicides. In a more recent meta-analysis 
[91] the lifetime risk of suicide was found to be half (4.9%) of that previously 
reported, with an increased risk near the onset of illness. A similar result was 
found in a later review [92] where the lifetime risk of suicide in 
schizophrenia also was approximately 5%.  
 
The authors claim that suicide prevention is complex and that increased 
efforts need to be put into adherence to medication, as the only consistent 
protective factor for suicide was being both offered medication and being 
adherent to effective treatment. This result is in line with a finding of a 
current population-based cohort study [93] of all patients in Sweden who had 
received treatment for schizophrenia between 2006 and 2009. The longer a 
patient refrained from taking an antipsychotic the greater the risk of death by 
suicide.  
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1.5 Stigmatization and mental illness 
1.5.1 A mark of shame 
Schizophrenia is not only a severe chronic illness with high mortality rates. It 
is also one of the most stigmatized mental disorders [94, 95]. Stigma places a 
significant burden on patients and their relatives or other informal caregivers 
[96-98].  
The word stigma originally referred to the mark left on the skin after a sharp 
sting, sometimes used to mark slaves and vagabonds [84]. Furthermore, the 
marks left in the hands of Jesus Christ after the crucifixion have been referred 
to as stigmata. These various kinds of marks led to today’s metaphorical use 
of the word stigma, referring to stained or marked individuals who somehow 
are considered morally diminished. The word stigma has come to mean “any 
attribute, trait or disorder that marks an individual as being unacceptably 
different from the ‘normal’ people with whom he or she routinely interacts, 
and that elicits some form of community sanction” [99, 100]. Stigma is thus 
closely tied to feelings of shame and of being of lesser worth. 
1.5.2 Different types of stigma 
The term stigma overarches problems of knowledge (ignorance), attitudes 
(prejudice) and behavior (discrimination) [101]. The concept is divided into 
various types of stigma [102]: Public stigma refers to the negative views of 
mental illness by the general public and this has been the most common type 
of stigma studied in psychiatric research, where patients traditionally have 
not been asked about their own experiences; self-stigma describes the 
phenomenon when a patient, due to stigmatizing and discriminatory 
experiences related to the mental illness, incorporates the stigma as being a 
true reflection of themselves and starts feeling shame; anticipated stigma, on 
the other hand, refers to when stigmatizing experiences lead to avoidance of 
situations that might elicit stigma.  
Similarly, relatives and others with close social connections can experience 
stigma and this is called associated stigma. Various studies show different 
results with 50 [103] to 80% [104] of the relatives reporting associated 
stigma. Experiences of associated stigma increase the overall burden of both 
the patient and the entire family and thus leads to poor function and 
exacerbates recovery [105]. Furthermore, structural stigma and 
discrimination encompasses the widespread exclusion and rejection of 
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persons with mental illness affecting every aspect of personal, social and 
occupational life. Structural discrimination refers to, for example, unfair 
legislation, unevenly distributed medical research funds not prioritizing 
psychiatric research projects, budget cuts and politically under-dimensioned 
financial plans concerning psychiatric hospital beds and expenses for optimal 
medication.  
1.5.3 Is a diagnosis of schizophrenia stigmatizing? 
The recent more strictly biogenetic view of schizophrenia has in a review 
[96] been claimed to negatively label the illness as being caused by definite 
and perhaps treatment refractory brain changes. This has been thought of as a 
reason for the stigmatization of schizophrenia. However, a later study showed 
that mentioning schizophrenia as a mental illness and using the word 
schizophrenia in itself did not increase social distance and stigma [98]. On 
the other hand a recent review and meta-analysis [106] concluded that the 
acceptance of mental illness by the general public has not improved despite a 
greater understanding of the biological correlates. More research in this field 
is needed.  
1.5.4 Social consequences of stigma 
According to the World Psychiatric Association [107] stigma creates a 
vicious cycle of discrimination and social exclusion for those who suffer 
from a mental illness and all of those who are associated with them “Stigma 
is the single most important barrier to quality of life of mental health 
consumers and family members-more so than the illness itself-and is a major 
impediment to mental health reform and development”.  
Negative public opinions are assumed to potentially have even more potent 
consequences for patients and their families since the shift from psychiatric 
care in mental institutions to treatment in community settings [84]. This is, at 
least partially, caused by the demand for more frequent social interactions 
and for independent living. Additionally, the consequences of stigma, such as 
unemployment, lack of housing, diminished self-esteem and weak social 
support, can be major obstacles to recovery, influence long term prognosis 
and promote disability. Stigma and the expectation of stigma is also assumed 
to cause serious disruptions in family relationships and reduce normal social 
interactions because of a desire for secrecy. 
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1.5.5 Stigma and help-seeking 
Regardless of the high prevalence of discrimination and the need to conceal 
the diagnosis, more patients with schizophrenia than with other mental 
disorders still receive protracted care and are prescribed medication [108]. 
Despite this almost half of patients with schizophrenia experience 
considerable levels of stigma and two-thirds report perceived discrimination 
due to their mental illness [109]. Stigma reduces the rate of seeking help and 
contributes to diminished access to care, deficient treatment, social exclusion 
and financial hardship [110, 111]. The lack of social networks is likely to be 
aggravated by stigma and discrimination [112]. A recent study [113] found 
that self-stigmatization, especially the feeling of being alienated from society, 
contributed to a negative attitude towards taking prescribed antipsychotic 
medication. 
1.5.6 Stigma and health care 
Negative attitudes towards the mentally ill, as well as towards their 
antipsychotic medication, may also be present in the individual’s social 
environment and might even be found among health care providers [114]. 
Additionally, psychiatric medication is commonly stigmatized and often 
considered ineffective by the general public [95]. In a recent large 
international multicenter survey [25], psychiatrists reported significantly 
higher levels of experienced stigma and discrimination than general 
practitioners. This negative image of both psychiatrists and psychiatry reveals 
multiple layers of problems regarding the improvement of access to care and 
treatment itself in psychiatry [115].  
To conclude, for the benefit of the patients the reputation of psychiatry and 
psychiatric treatments need to be improved. The specialty should be able to 
attract and keep qualified staff, receive an adequate (i.e. larger) proportion of 
the hospital budget, and continuously conduct clinical research as a basis for 
improved services [84]. Patients with schizophrenia would benefit directly by 
reduced stigma and better psychiatric and physical health [116]. The common 
delay in getting appropriate medical diagnoses (diagnostic overshadowing) 
and adequate treatment (treatment overshadowing) due to stigma would most 
likely be reduced [117]. 
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1.6 Symptomatology and functioning in 
schizophrenia 
In this doctoral thesis the DSM-IV diagnostic system (Diagnostic and 
statistical manual of mental disorders) [76] was used to define schizophrenia. 
In order to fulfill DSM criteria the disorder has to last for at least six months 
with a minimum set of characteristic signs and symptoms present for at least 
one month (active phase). Schizophrenia is characterized by positive 
symptoms (such as overt delusions and perceptual abnormalities with 
hallucinations, thought disorders, paranoid ideation and hostility), as well as 
negative symptoms (such as avolition, blunted affects and social withdrawal), 
often paralleled by general psychiatric symptoms (such as anxiety and 
depression). Additionally, cognitive impairment commonly occurs in 
individuals with schizophrenia contributing to the decline of occupational and 
social functioning. A majority of individuals with schizophrenia are not able 
to sustain full time competitive employment or complete higher education. 
Many patients need supported living and assistance in activities of daily 
living. 
In spite of remarkable progress in the field of psychopharmacology for 
treating positive symptoms, clinical challenges remain in the management of 
negative and cognitive symptoms. These are at least equally as important as 
the successful treatment of positive symptoms when it comes to predicting 
real world functional outcome and subjective quality of life. Finally, the 
management of non-adherence is crucial in schizophrenia treatment [31]. 
 
1.7 Non-adherence in schizophrenia 
The phenomenon of non-adherence is especially challenging in 
schizophrenia. The reasons are several: lack of illness awareness (including 
lack of insight as well as attitudes and beliefs about the nature of 
schizophrenia itself); direct and debilitating impact of symptoms (psychotic 
symptoms and cognitive deficits); further social exclusion; stigma; co-morbid 
disorders (such as substance abuse); and finally, the frequent fragmentation 
of psychiatric health care services. Also, studies on medication adherence in 
psychosis are limited by mostly including multi-episode patients and the 
demand for an  informed consent, and thus a certain degree of medication 
adherence at study entry [118].  
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The key factors associated with non-adherence can further be summarized 
from research findings [4, 31, 119]. They encompass the illness, the treatment 
and medication, the organization of the health care services as well as 
attributes of the patient, the health care providers and the relatives or other 
informal caregivers. Use of compulsory supervision and inclusion in clinical 
trials can also affect adherence rates.  
Factors associated with non-adherence in schizophrenia, based on a current 
review [4], are shown in Fig 1. Most of these factors are, in a slightly 
modified form (such as type of symptomatology or medication prescribed), 
valid in all medical conditions. 
 
Figure 1. Key factors associated with non-adherence in schizophrenia. Modified 
from Haddad, Brain, Scott (2014). 
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1.7.1 Prevalence of antipsychotic non-adherence  
Antipsychotic medication is the first-line treatment in schizophrenia [30, 
120]. The optimal medication, dose, and route of administration vary 
according to stage of illness, individual patient characteristics and the clinical 
and social situation. In out-patient clinics up to 55% of first-episode patients 
are non-adherent to prescribed medication [46], which is associated with a 
five-fold risk of relapse [121, 122]. In general higher rates of non-adherence 
are more common in first-episode patients and a 3-year follow-up study of 
this population found medication non-adherence to be the only factor 
predictive of relapse [123]. Relapses are deleterious as recurrent psychotic 
episodes at all stages of illness are associated with aggravation of functional 
disability, cognitive decline, brain atrophy, hospitalization and higher risk of 
suicide [46, 88, 124, 125]. In multi-episode schizophrenia only about half of 
patients take their antipsychotic medication as prescribed [11] and non-
adherence is associated with five year relapse rates of 80% [18, 126]. Partial 
adherence with medication gaps as short as 1-10 continuous days during a 
12-month period is associated with a two-fold increase in hospitalization and 
increased risk of cognitive decline and poor outcome [112]. Frequently 
relapsing patients are often referred to as “revolving door” patients as they 
keep being readmitted.  
Antipsychotic medication is no panacea. It has several drawbacks, such as 
side effects, a main medication effect only on positive symptoms and 
treatment resistance. Maintenance antipsychotic treatment does not eliminate 
the risk of psychotic relapses, but there is strong evidence that the risk is 
substantially reduced. A systematic Cochrane database review showed that 
continuous antipsychotic treatment decreased the risk of relapse by about 
two-fold or more in all stages of schizophrenia compared to intermittent 
treatment [35]. This data underlines the importance of adherence enhancing 
interventions in the clinic as well as the consideration of LAIs to improve 
adherence and reduce the risk of rehospitalization in schizophrenia [55].  
1.7.2 The measurement of adherence 
The magnitude of reported non-adherence in schizophrenia varies widely in 
research studies depending on definition of adherence, cohorts studied and 
methods employed for the measurement [6, 127]. Adherence rates as high as 
86% [2] and as low as 8% [128] have been reported when defining adherence 
as ≥ 80% of the prescribed dose correctly taken. 
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Various adherence measurements have been used in schizophrenia studies 
and the most common are self-reports and clinician ratings. Some studies also 
use diaries and rating scales. These subjective measurements are often quick 
and easy to use, but tend to overestimate adherence rates [129]. The Expert 
Consensus Guideline [11] recommends the use of objective measures, 
including electronic monitoring, pill count, plasma levels and pharmacy refill 
records. As objective measures are more time consuming and expensive, the 
literature regarding these measures is sparse. Most studies of adherence in 
schizophrenia in general, and especially studies using objective measures, are 
short and use small samples. 
The Medication Event Monitoring System ([MEMS®], Aprex Corporation, 
Fremont, CA, USA) [130, 131] is generally considered the reference standard 
for recording adherence. The MEMS® has a medication bottle cap equipped 
with a microprocessor that records the occurrence and time of each bottle 
opening.  The reliability and predictive validity for MEMS® has been shown 
to be high [132]. However, the approach has its drawbacks. It requires regular 
monitorings and cannot detect discarding of pills [121, 133]. 
Two other objective adherence measures are pill count and plasma levels. 
Studies that have either used pill count as an adherence measure or have 
compared adherence measured by pill count and MEMS® have yielded 
disparate results [2, 128]. Plasma levels of antipsychotics are commonly used 
in the clinic to monitor adherence. The interpretation of the results is 
problematic as it may not reflect long-term adherence but be influenced 
disproportionately by recent use [134]. Intra-individual variability in plasma 
levels is considerable. A complicating factor in the clinical setting is that the 
time of last intake of the antipsychotic might not be recorded at the 
laboratory, making the interpretation of the result impossible. Patients may 
also increase their medication intake prior to the assay by taking so called 
loading doses to conceal poor adherence (“white coat adherence”). 
Additional factors such as concomitant medications, medication metabolism 
and smoking can affect the result. Data regarding what therapeutic plasma 
levels to use is limited regarding SGA [135]. 
1.7.3 Predictors of adherence  
The reasons for non-adherence are multifactorial. In one study the risk of 
relapse following treatment for first episode psychosis was significantly 
increased by most of all non-adherence to antipsychotics, but also by 
persistent substance use, caregivers’ criticism and poorer pre-morbid 
adjustment [136]. Medication tolerability, including side effects, as well as 
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drug effectiveness have previously been shown to contribute to non-
adherence [137]. One study showed that all previous or present antipsychotic 
side effects can have a durable negative impact on drug attitude and 
adherence [138]. Several other studies have shown inconclusive results where 
side effects have had no influence on adherence [8, 132, 139]. Several 
antipsychotics cause metabolic side effects with weight gain. The findings are 
mixed regarding the association between body mass index (BMI) and non-
adherence. High correlations have been found both between high BMI and 
poor adherence [140] and high BMI and good adherence [141].  
A negative drug attitude in both first [142] and multiple episode 
schizophrenia [128] is a known risk factor for non-adherence, but the extent 
to which the frequently used 10-item Drug Attitude Inventory (DAI-10) [143] 
can be used as a proxy measure for adherence remains unclear [144]. A 
prolonged structured assessment of drug attitude has to date not been 
performed using MEMS® as an objective measure of adherence. Furthermore, 
knowledge is lacking regarding the influence of informant (relative or other 
significant relationship) drug attitude on the medication regimen of the 
patient. One previous study showed that in patients with poorer executive 
function the attitude of the informant, rather than the patient’s executive 
function, affected subjectively approximated adherence [145]. 
Clinical factors [146] including non-adherence [147] have been shown to be 
associated with lack of insight. Studies exploring the relationship between 
neurocognitive dysfunction and non-adherence on the other hand have been 
inconclusive [148]. Specific cognitive domains have been associated with 
non-adherence in some studies [149], but not in others [128]. Some suggest 
that cognitive deficits of schizophrenia may interfere with the complexity of 
medication taking [150]. However, a more recent study found individuals 
with higher cognitive function more likely to be non-adherent [141]. The 
findings underline the need for further studies using objective adherence 
measures in combination with standardized test of neurocognition.  
 
1.8 Summary 
The complexity of schizophrenia itself and the stigmatization of the illness 
and its treatments require special attention. Mortality rates and societal costs 
are high. Medication non-adherence is common due to illness, patient and 
treatment related factors and leads to relapse and poor psychosocial 
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functioning. Further, evidence based treatment methods may be difficult to 
employ in non-adherent, unremitted patients with psychotic symptoms and 
cognitive decline. Patients and their families are faced with burden and 
stigma. Increased knowledge and future clinical research within the field of 
schizophrenia is needed, to improve psychiatry and to improve the lives of 
those affected. 
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2. AIMS OF THE THESIS 
 
The overall aim of this thesis is to increase knowledge about factors related to 
adherence to oral antipsychotic medication and to stigma in a large cohort of 
outpatients with schizophrenia and schizophrenia-like psychosis, followed for 
one year. The specific aims are: 
Study I 
To examine adherence to antipsychotics and to compare objective and 
subjective measures of adherence. 
 
Study II 
To investigate predictors of adherence to antipsychotics. 
 
Study III 
To explore stigma and discrimination and to test for potential associations 
between a) different types of stigma and b) stigma and adherence to 
antipsychotics. 
 
Study IV 
To study experiences of stigma in relatives to persons with schizophrenia in a 
treatment setting where outpatient practices include components of Assertive 
Community Treatment. Further, to examine the relationship between 
relatives’ stigma experiences and overall burden. 
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3. MATERIAL AND METHODS 
3.1 Subjects Study I-III 
Studies I-III of this doctoral thesis are based on preplanned analyses of 
patient data from the naturalistic, prospective study Cognition, Adherence 
and Stigma in Schizophrenia (COAST). All patients in the COAST study 
were treated at state-financed urban psychiatric outpatient clinics specializing 
in psychotic disorders. The clinics are geographically distributed and, as 
customary in Sweden, located throughout the city and each with its own 
catchment area. This organization can facilitate collaborations between local 
authorities, social services, physical health care (through general 
practitioners) and the community mental health care. 
Two hundred and fifty consecutive patients at eight psychiatric outpatient 
clinics at Sahlgrenska University Hospital in Gothenburg, Sweden were 
approached. The patients were initially identified by their psychiatrists and 
case managers as fulfilling the inclusion criteria of this study and they were 
asked if they would be interested in receiving additional information about 
the study.  
The inclusion criteria were: age 18-65, prescription of unsupervised oral 
antipsychotics and a clinical diagnosis by the prescribing psychiatrists of 
schizophrenia or schizophrenia-like psychosis according to the DSM-IV 
(Table 2). The term “schizophrenia-like” was used in cases where the 
psychiatrist described psychopathology in accordance with DSM-IV criteria 
for schizophrenia without having formally made the diagnosis. 
Schizophrenia-like also refers to delusional disorders and psychotic disorders 
NOS (i.e. not otherwise specified). Delusional disorders were included, but 
not schizoaffective disorders due to frequent diagnostic difficulties 
differentiating them from bipolar disorder in the clinic. All diagnoses are 
henceforth referred to as schizophrenia. Exclusion criteria were: 
hospitalization for substance abuse in the year preceding the study, acute 
suicide risk, need for an interpreter, severe learning difficulties leading to 
special educational needs, treatment with LAIs and dispensation of 
antipsychotics by pillbox.  
In the next step the patients were approached and informed, both orally and 
with written information, about the study by the research psychiatrist and one 
of the two study nurses. Out of the 250 approached patients, 131 eligible 
patients chose to participate, and gave written informed consent. However, 14 
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of the enrolled declined to use the electronic medication bottle (MEMS®) and 
thus 117 initiated medication monitoring (Figure 2). All initially included 
patients (n=131) were asked if they had a close informant (family member, 
close friend or other significant person) who might be willing to fill out a 
postal questionnaire at baseline. The informants received written information 
about the study and signed an informed consent.  
 
 
Figure 2. Flow Chart for Participants and MEMS® 
Study I (comparison of adherence measures study): Of the 117 patients, five 
discontinued MEMS® monitoring at some point during the study. Three of 
these were deemed as adherent using a last-value-carried-forward procedure. 
One other adherent patient died a natural death (cardiac arrest) after the 10-
month monitoring. Five patients were hospitalized during the study and only 
one of these was deemed as adherent based on case records and data from the 
previous MEMS® monitoring. Three patients were switched to LAIs by their 
psychiatrists and were regarded as non-adherent for the purpose of this study. 
Study II (predictors of adherence study): Five of the 117 patients who were 
MEMS® monitored for a year were excluded due to missing data on various 
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adherence predictors, leaving a total cohort of 112 patients for inclusion in 
this study. Demographic and clinical characteristics of the study cohort at 
baseline are shown in Table 2. Mean duration of illness was 19.5 years 
defined as the time from the first documentation of psychotic symptoms in 
the medical files until the study inclusion. The mean Duration of Untreated 
Psychosis (DUP) was 3.4 years and defined as the time from the first 
documentation of psychotic symptoms in the medical files until registered 
onset of antipsychotic treatment. Ninety-nine of the included MEMS® 
monitored patients (n=117) identified a close informant willing to participate 
and 61 (62%) returned their questionnaires.  
Study III (adherence and stigma study): Of the initial 117 patients who 
started the MEMS® monitoring, five discontinued and did not provide stigma 
data. One other patient gave incomplete responses in the stigma rating. A 
total of 111 patients provided a full year of MEMS® monitorings and 
completed stigma ratings.  
 
3.2 Subjects Study IV 
Study IV (associated stigma and burden in relatives): Of the 131 eligible 
patients in the COAST study, 111 (85%) gave contact information to a close 
informant who might be willing to respond to a postal questionnaire. In the 
next step questionnaires were sent out to the 111 persons and returned by 75 
(68%). Three of these were excluded because the respondents were the 
patient’s professional caregiver and a further seven were excluded due to 
missing data, leaving a cohort of 65 (59%). Table 3 shows sociodemographic 
characteristics of the 65 respondents (henceforth referred to as relatives), as 
well as data pertaining to the patients. 
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Table 2: Characteristics of patients at baseline: The 
COAST study. 
    Patients 
Variable (n = 131) 
Gender (male/female), n 83/48 
Age, years 46 (21 - 65) 
Education, years n (<12 / >12) 60/71 
Marital status, n (%)  
 Single 99 (75.6) 
 Married 4 (3.1) 
 Divorced/separated 18 (13.7) 
 Relationship 10 (7.6) Living situation, n (%)  
 Independent 68 (51.9) 
 Custodial care 39 (29.8) 
 Institution 24 (18.3) Employment, n (%)  
 Regular 17 (13.0) 
 Supported/sheltered/volunteer 20 (15.3) 
 No employment 94 (71.8) Sick-leave, disability retirement 109 (83.2)  
Duration of illness, years 19.5 (0 - 55) 
Duration of untreated psychosis, years 3.3 (0 - 31) 
Exacerbations 7.6 (0 - 38) 
Diagnosis (DSM-IV), n (%)  
 Paranoid schizophrenia 23 (17.6) 
 Undifferentiated schizophrenia 56 (42.7) 
 Residual schizophrenia 12 (9.2) 
 Delusional Disorder 10 (7.6) 
 Psychotic Disorder NOS 30 (22.9) Symptom and function ratings  
 
PANSS, total 62.3 (35 - 122) 
 
PANSS, positive symptoms 15.5 (7 - 33) 
 
PANSS, negative symptoms 17.6 (7 - 37) 
 
GAF, total  44.6 (25 - 76) 
 CGI-S, median 3 (1 - 5) 
Values denote mean (range) if not specified otherwise. 
Impression-Severity. 
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Table 3: Characteristics of the participating relatives and their ill 
family members (patients) 
Variable n % Mean   SD 
Relatives (n=65) 
    
 
Male 22 33.8 
  
 
Age 
  
61 ±14.4 
 
Education, ≤ 12 years 21 32.3 
  
 
Parent 34 52.3 
  
 
Sibling 13 20 
  
 
Child 3 4.6 
  
 
Other relative 3 4.6 
  
 
Other relationship 12 18.5 
  
 
Living together 6 9.2 
  
 
Time spent together, hours/week 
  
14.5 ±14.9 
 Practical help, hours/week   1.9 ±5.4 Patients (n=65) 
    
 
Male 46 70.7 
  
 
Age 
  
45.6  ±10.9 
 
Education ≤ 12 years 23 35.3 
  
 
Regular employment 10 15.4 
  
 
Supported/sheltered/volunteer 11 16.9 
  
 
No employment 44 67.7 
  
 
Independent living 38 58.4 
  
 
Duration of illness, years 
  
19.2 ±12.7 
Diagnosis (DSM-IV) 
    
 
Paranoid schizophrenia 10 15.4 
  
 Undifferentiated schizophrenia 30 46.2   
 
Residual schizophrenia 5 7.7 
  
 
Delusional Disorder 4 6.2 
  
 
Psychotic Disorder NOS 16 24.6 
  Symptom and function ratings 
    
 
PANSS total 
  
58.7 ±13.7 
 
PANSS positive 
  
13.6 ±5.0 
 
PANSS negative 
  
15.8 ±5.5 
  GAF function     48.1 ±9.4 
SD = Standard deviation 
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4. STUDY PROCEDURES  
4.1 Procedures Study I-IV 
Patients were fully informed by the research psychiatrist and one of the two 
research nurses about the study protocol, monitoring procedures and about 
the plasma sampling at the university hospital lab at baseline, at 6 months and 
at the 12-month endpoint rating. Eligible patients were entered into the study 
between October 2008 and June 2011, and followed over a period of one 
year. Data regarding current and history of substance and alcohol abuse, 
DUP, duration of illness, number of previous exacerbations and 
hospitalizations as well as sociodemographic information was retrieved from 
medical records. At baseline a medical examination was performed by the 
research psychiatrist and BMI was calculated. Present antipsychotic 
medication was registered.  
Patients brought their oral antipsychotics, prescribed by their psychiatrists, to 
the study clinic. The medication possession ratio (MPR), i.e. percentage with 
a valid antipsychotic prescription the day of inclusion, was thus 100% at the 
MEMS® baseline monitoring. The research psychiatrist rated the symptom 
level and other clinical characteristics at baseline and endpoint.  
The patients, informants, staff and prescribing psychiatrists filled in ratings 
according protocol. The rating frequency and the MEMS® monitoring 
procedure is more closely described below. 
Postal questionnaires to the informants (i.e. relatives in Study IV) were 
distributed at baseline. Up to two postal reminders were sent when 
questionnaires were not returned on time. 
 
4.2 Measurements 
4.2.1 Research psychiatrist-rated instruments 
Symptom severity was rated using the Positive and Negative Syndrome Scale 
for Schizophrenia (PANSS) [151]. The scale consists of 30 items; each is 
rated from 1 (absent) to 7 (extreme). The PANSS item G12 was used to 
assess insight. A person was considered to be in remission if none of the 8 
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items, derived from PANSS and used to identify cases of symptomatic 
remission in accordance with the Structured Clinical Interview for Symptoms 
of Remission (SCI-SR) [71], were scored above 3. The time criterion of 6 
months was unattainable in this study.  
The current level of severity of the psychotic disorder was rated using the 7-
point scale (1=normal/not at all ill, 7=extremely ill) Clinical Global 
Impression scale-Severity of illness (CGI-S) [152]. Psychosocial function 
was evaluated using the Personal and Social Performance Scale (PSP) [40] 
and the Global Assessment of Functioning (GAF) [153]. Both GAF and PSP 
are 100-point rating scales, where a higher score indicates better functioning. 
The PSP scale measures functioning in four areas of life: self-care, social 
activities, personal and social relations, disturbing and aggressive behavior.  
The Discrimination and Stigma Scale (DISC 12) [154, 155] is a structured 
interview for assessing all the patient’s past experiences or anticipation of 
stigma and discrimination since the first appearance of a mental illness. The 
scale developers gave access to the scale at the time of the endpoint visit and 
the scale was translated into Swedish and back translated. A focus group 
(patients with schizophrenia not included in the study) ensured that the 
terminology was well adapted to both Swedish language and context. DISC 
was used in Study III and the 32 items were scored according to the scale 
developers [155] on a 4-point scale and anchored at 0 (not at all) and 3 (a lot). 
A not applicable category was included for questions irrelevant to the patient, 
such as in relation to having children. The scale has four subscales: patient 
experienced discrimination (item 1-21), anticipated discrimination (item 22-
25), overcoming stigma (item 26: “Have you made friends with people who 
don’t use mental health services?”, and item 27: “Have you been able to use 
your personal skills or abilities in coping with stigma and discrimination?”), 
and positive treatment due to mental illness (item 28-32). Discrimination 
refers to unfair treatment and unjust distinction in how different people are 
being treated by others. Anticipated discrimination was defined as to which 
extent the patients limit their involvement in important aspects of daily life 
due to the anticipation of stigma. Subscale mean scores were calculated by 
summing the rating (0-3) for each item and dividing by the number of 
applicable items responded to. For frequency reports of the DISC items a 
rating of ≥ 1 (i.e. a little or more) was used to define endorsed discrimination. 
4.2.2 Self-rated instruments 
Patient self-ratings were performed at baseline and endpoint. The patients’ 
attitude, experience and beliefs about antipsychotics were assessed using the 
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10-item self-report Drug Attitude Inventory (DAI-10) [143]. Scores ranged 
from -10 (very poor attitude) to +10 (best possible attitude).  
Unwanted side effects were rated 0-3 using the Udvalg for Kliniske 
Undersøgelser side effect self-rating scale (UKU-SERS-Pat) [156] examining 
four categories: psychiatric (including sedation, depression and sleep 
disorders), neurological (including movement disorders, tremor and 
akathisia), autonomic (including gastrointestinal symptoms, dry mouth or 
hyper salivation) and others (including sexual and metabolic side effects).  
4.2.3 Informant questionnaires 
In order to assess the informants’ attitudes, experiences and beliefs regarding 
antipsychotics the research psychiatrist slightly modified the DAI-10 [143]. 
The same questions and the rating described above for the patient version of 
DAI were used, but the questions addressed the informant instead of the 
patient. 
Further, a close informant version of the Inventory of Stigmatizing 
Experiences (ISE) [157] was translated into Swedish and back translated and 
used in study IV. The ISE consists 15 sociodemographic items followed by 
the Stigma Experience Scale (item 16-32) and the Stigma Impact Scale (item 
33-34). The Stigma Experience Scale measures the frequency of personal 
experiences of stigma, both actual and anticipated stigma, along with 
thoughts on public views on mental illness and coping strategies. Responses 
for items 16-20 are ascertained with a 5-point Likert-type scale 
(never/rarely/sometimes/often/always for 5 items), and items 25-27, 29-32 
have categorical responses (yes/no/unsure). There are also five items with 
qualitative free text answers but these were not analyzed in this thesis. 
Responses on the Stigma Experience Scale were recoded into binary 
variables where 1 reflects high expectancy of stigma (sometimes, often, 
always or yes) and 0 reflects low expectation (never, rarely or no). The 
Stigma Impact Scale quantifies the impact of stigma on quality of life, social 
contexts, family relations and self-esteem. Item 33 focuses on personal 
impact and item 34 on familial impact. Responses for the Stigma Impact 
Scale range from 0 (no impact) to 10 (highest amount of impact).   
In study IV the relatives’ perceived burden was rated with the Burden 
Inventory for Relatives to persons with Psychotic disturbance (BIRP) [158], a 
10-item instrument focusing on both practical and emotional burden, and 
own health. Each item has four response alternatives (1=no, 2=sometimes, 
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3=often, 4=always); scores are summed to yield a total score (10-40 points), 
where a higher score reflects a higher burden. 
4.2.4 Measurements of adherence 
Medication Event Monitoring System (MEMS®) 
The 117 patients that initiated MEMS® monitoring were instructed to take 
their medication as prescribed by their psychiatrists. The MEMS®  bottle was 
monitored 6 times and refilled by a study nurse at approximately 2, 4, 6, 8, 10 
and 12 months (no refill at endpoint). For patients prescribed several 
antipsychotics, separate bottles were employed for the monitored 
antipsychotics (Table 4).  
Table 4: Antipsychotic medication 
monitored by MEMS® across study period. 
  Patients 
MEMS® medication, n (%) (n = 117) 
Aripiprazole 26 (19.8) 
Olanzapine 25 (19.1) 
Clozapine 24 (18.3) 
Risperidone 17 (13.0) 
Quetiapine 16 (12.2) 
Paliperidone 13 (9.9) 
Flupentixol  7 (5.3) 
Haloperidol 6 (4.6) 
Ziprasidone 5 (3.8) 
Zuclopenthixol 5 (3.8) 
Perphenazine 1 (0.8) 
Sertindole 1 (0.8) 
Percentages do not sum up to 100 percent 
because of polypharmacy and change of 
medication during study period. 
 
Patients unable to attend the study center were monitored by the study nurse 
at their ordinary outpatient clinic or in their home. Antipsychotic dosing 
regimens varied from once (n=91, 76%), twice (n=26, 22%) to three (n=2, 
2%) times daily. Patients who received treatment with depot injectables at 
any point of the study were regarded as non-adherent, i.e. they were not 
excluded from the sample but were rated as non-adherent in terms of the 
outcome measure. 
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MEMS® adherence was mathematically defined as the number of days which 
the patient took at least the prescribed dose divided by the number of dosing 
days. The possible range of this continuous measure is 0.00 to 1.00. A value 
of 1.00 is given for more than prescribed bottle openings. In cases with more 
than one bottle, the MEMS® adherence measure for the bottle with the lowest 
adherence was used. Calculations of adherence were made for every calendar 
day with a cut-off at midnight. Mean adherence was calculated based on all 
six two-month periods. MEMS® adherence was dichotomized into two 
categories, adherent ( > 0.80) vs. non-adherent ( ≤ 0.80) [8].  
Pill count 
Pills remaining in the MEMS® device at each monitoring were counted prior 
to refill. Pill counts were calculated by means of inter- and extrapolations if 
intervals between monitoring visits deviated from the intended two months. 
Mean pill count over the study period was calculated and dichotomized at the 
same cut-off as that used  for MEMS®, i.e. ≤ 0.80 vs. > 0.80. It should be 
noted that pill count is a more global measure of adherence for the whole two 
month period and not restricted to a single day as MEMS®. 
Plasma level measure 
At least one plasma sample was available for 96 of the patients with MEMS® 
recordings. A composite measure of plasma levels and adherence to lab visits 
was used. Two senior psychiatrists independently rated whether plasma 
levels for each lab visit were in accordance with the prescribed dosage (a 
“No”/”Yes” rating for each sample). The number of samples with adequate 
levels was summed (0-3), with a value of 3 indicating adherence. 
Inadequately low plasma levels at any of the three lab visits and/or two 
missed laboratory visits were assumed to indicate non-adherence. For those 
with one missing visit (n=32), a revised last-value-carried-forward procedure 
was applied. For example, if two levels were adequate, the missing value was 
also regarded as adequate and the patient received an assumed value of “3”. 
If one or two levels were inadequate, the missing value was also regarded as 
inadequate. The inter-rater reliability for the plasma level adherence measure 
was very high (Κ= 0.92, p < 0.001). An inconsistency was found for four 
patients and this was solved by consensus to use the lower value. Three blood 
samples were collected from 51 patients. Two samples were collected from 
32 patients, out of which 17 (53%) patients were considered adherent. Fifteen 
patients left only one blood sample. A drop-out analysis revealed that 52% of 
those without any blood sample and 22 % of those with blood samples were 
found to be non-adherent according to MEMS® (χ2=8.07, p=0.005).  
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Subjective ratings of adherence  
The patients were asked to rate their adherence at each monitoring visit and a 
mean rating was calculated. Ratings of adherence were also made by the 
patients’, clinical staff (case manager) and prescribing psychiatrist at baseline 
and endpoint and once by an informant. A 5-point scale (1=“0-20%”, 2=“21-
40%”, 3=“41-60%”, 4=“61-80%”, and 5=“81-100%”) was used. For the 
dichotomous adherence variable, category 5 was considered adherent.  
Adherence class 
With the division similar to the 5-point subjective scale of adherence (1=“0-
20%”, 2=“21-40%”, 3=“41-60%”, 4=“61-80%”, and 5=“81-100%”) 
adherence classes were created (Table 3). The values in each of the five 
classes denote percentages of patients classified by prescribed dosages 
correctly taken. The highest class (81-100%) represents the adherent group. 
All adherence measures were divided into five classes except the plasma 
level measure, which was rated in four classes (0-3) with 3 indicating 
adherence. 
4.2.5 Cognitive Assessment 
The semi-computerized neuropsychological test battery consisted of standard 
neuropsychological tests, comprising tests of speed and attention, learning, 
memory and executive function. The test battery was administered at baseline 
and endpoint. All cognitive tests were administered in a standardized 
sequence [159-161] and conducted in one to two sessions each lasting 60-120 
minutes. 
The Rey Auditory Verbal Learning Test (RAVLT) [159] was used to 
measure verbal learning and memory. The test consists of a 15-word list that 
was presented by the rater and the patient was asked to recall as many words 
as possible. This was repeated five times; thereafter an interference list was 
presented, followed by a request to recall the original list without further 
presentation. Finally, a delayed recall test was presented after 20 minutes. 
The number of words correctly recalled was summarized as a measure of the 
verbal learning memory. 
The Continuous Performance Test-Identical Pairs version (CPT-IP) [161, 
162] is a computerized vigilance test. Stimulus (the second of a pair of a four-
digit number) was flashed on the computer screen at a constant rate. The 
patient was asked to respond as fast as possible to the stimulus using the 
mouse button, measuring the participants’ ability to discriminate targets from 
 
 37 
 
non-targets. The test is constructed in three sequences, each with 150 trials. 
The total score for the 450 trials was used as a measure of vigilance. 
The Trail-Making Test (TMT) [163] consists of two subtests. The TMT-A 
was used to measure visuomotor processing speed and efficacy, while TMT-
B was used to measure cognitive flexibility. The patient was asked to, as fast 
as possible, connect numbers (TMT-A) or number and letters (TMT-B) on a 
paper. The time for completing the test correctly is the scoring point [164]. 
The Letter-Number Sequencing test (LNS), now a subtest in the Wechsler 
Adult Intelligence Scale-Third Edition (WAIS-III) [165], is often used to 
assess the auditory working memory performance [166]. The patient was 
verbally presented with a row of numbers and letters and asked to sort them 
out in a specific order and to separately recall the letters and numbers in 
successive order. The test starts with a series of two digits; the next level is 
three digits, etc.  
The Vocabulary subtest of the Wechsler Adult Intelligence Scale-Revised 
(WAIS-R) [167] has been recognized to measure both verbal and general 
mental abilities  The patient was presented with a word and asked to describe 
it’s meaning, starting with easy words and proceeding with increasing 
difficulty. Answers were assessed and graded (0 point=no or incorrect 
description, 1 point =partially correct description, 2 points=correct 
description). The sum of all points was used to measure the verbal facility. 
Executive functions were measured with The Wisconsin Card Sorting Test 
(WCST) [168]. The test consists of 4 stimulus cards that depict figures, 
colors, and numbers. The patient was given 128 response cards with the task 
to match each response card with one of the stimulus cards. The computer 
lets the patient know whether the match is correct or not. The computer will 
change the sorting principle during the test, varying among the three possible 
ways to sort according to a predetermined pattern. Scores on Categories 
Completed, Total Errors, Preservative Responses, and Conceptual Level 
Responses are used to describe test performance. 
A global composite score for cognitive function [169] was created from tests 
within the following cognitive domains: verbal learning [159]; sustained 
attention [161]; visuomotor processing speed and cognitive flexibility [163]; 
working memory [166]; verbal facility [167]; and executive functioning 
[168]. The composite cognition score was created by transforming individual 
test scores to z-scores using the patient sample and then averaging across 
tests [170]. 
36 
 
Subjective ratings of adherence  
The patients were asked to rate their adherence at each monitoring visit and a 
mean rating was calculated. Ratings of adherence were also made by the 
patients’, clinical staff (case manager) and prescribing psychiatrist at baseline 
and endpoint and once by an informant. A 5-point scale (1=“0-20%”, 2=“21-
40%”, 3=“41-60%”, 4=“61-80%”, and 5=“81-100%”) was used. For the 
dichotomous adherence variable, category 5 was considered adherent.  
Adherence class 
With the division similar to the 5-point subjective scale of adherence (1=“0-
20%”, 2=“21-40%”, 3=“41-60%”, 4=“61-80%”, and 5=“81-100%”) 
adherence classes were created (Table 3). The values in each of the five 
classes denote percentages of patients classified by prescribed dosages 
correctly taken. The highest class (81-100%) represents the adherent group. 
All adherence measures were divided into five classes except the plasma 
level measure, which was rated in four classes (0-3) with 3 indicating 
adherence. 
4.2.5 Cognitive Assessment 
The semi-computerized neuropsychological test battery consisted of standard 
neuropsychological tests, comprising tests of speed and attention, learning, 
memory and executive function. The test battery was administered at baseline 
and endpoint. All cognitive tests were administered in a standardized 
sequence [159-161] and conducted in one to two sessions each lasting 60-120 
minutes. 
The Rey Auditory Verbal Learning Test (RAVLT) [159] was used to 
measure verbal learning and memory. The test consists of a 15-word list that 
was presented by the rater and the patient was asked to recall as many words 
as possible. This was repeated five times; thereafter an interference list was 
presented, followed by a request to recall the original list without further 
presentation. Finally, a delayed recall test was presented after 20 minutes. 
The number of words correctly recalled was summarized as a measure of the 
verbal learning memory. 
The Continuous Performance Test-Identical Pairs version (CPT-IP) [161, 
162] is a computerized vigilance test. Stimulus (the second of a pair of a four-
digit number) was flashed on the computer screen at a constant rate. The 
patient was asked to respond as fast as possible to the stimulus using the 
mouse button, measuring the participants’ ability to discriminate targets from 
 
 37 
 
non-targets. The test is constructed in three sequences, each with 150 trials. 
The total score for the 450 trials was used as a measure of vigilance. 
The Trail-Making Test (TMT) [163] consists of two subtests. The TMT-A 
was used to measure visuomotor processing speed and efficacy, while TMT-
B was used to measure cognitive flexibility. The patient was asked to, as fast 
as possible, connect numbers (TMT-A) or number and letters (TMT-B) on a 
paper. The time for completing the test correctly is the scoring point [164]. 
The Letter-Number Sequencing test (LNS), now a subtest in the Wechsler 
Adult Intelligence Scale-Third Edition (WAIS-III) [165], is often used to 
assess the auditory working memory performance [166]. The patient was 
verbally presented with a row of numbers and letters and asked to sort them 
out in a specific order and to separately recall the letters and numbers in 
successive order. The test starts with a series of two digits; the next level is 
three digits, etc.  
The Vocabulary subtest of the Wechsler Adult Intelligence Scale-Revised 
(WAIS-R) [167] has been recognized to measure both verbal and general 
mental abilities  The patient was presented with a word and asked to describe 
it’s meaning, starting with easy words and proceeding with increasing 
difficulty. Answers were assessed and graded (0 point=no or incorrect 
description, 1 point =partially correct description, 2 points=correct 
description). The sum of all points was used to measure the verbal facility. 
Executive functions were measured with The Wisconsin Card Sorting Test 
(WCST) [168]. The test consists of 4 stimulus cards that depict figures, 
colors, and numbers. The patient was given 128 response cards with the task 
to match each response card with one of the stimulus cards. The computer 
lets the patient know whether the match is correct or not. The computer will 
change the sorting principle during the test, varying among the three possible 
ways to sort according to a predetermined pattern. Scores on Categories 
Completed, Total Errors, Preservative Responses, and Conceptual Level 
Responses are used to describe test performance. 
A global composite score for cognitive function [169] was created from tests 
within the following cognitive domains: verbal learning [159]; sustained 
attention [161]; visuomotor processing speed and cognitive flexibility [163]; 
working memory [166]; verbal facility [167]; and executive functioning 
[168]. The composite cognition score was created by transforming individual 
test scores to z-scores using the patient sample and then averaging across 
tests [170]. 
38 
 
 
4.3 Statistical methods used 
Study I: All variables were summarized with standard descriptive statistics. 
Categorical variables including adherence (non-adherent vs. adherent) were 
analyzed with Pearson’s χ2 -method or with Fisher’s exact test. Kappa (“Κ”) 
coefficients describe the agreement between MEMS® and another adherence 
measure, as well as inter-rater reliability for the plasma level adherence 
measure. Means of MEMS®, pill count, the plasma level measure and patient 
ratings were calculated in order to capture adherence across the entire period. 
Concordance was measured, i.e. the frequency of patients that were identified 
as adherent according to both MEMS® monitoring and another specified 
measure of adherence. Differences between groups regarding symptom 
scores, CGI-S, and GAF were analyzed with Mann-Whitney U tests. Change 
in adherence over the study year was analyzed with an analysis of variance 
for repeated measurements. The continuous measures of adherence were also 
entered in a principal component analysis with Oblimin rotation, assuming a 
relationship between the variables. SPSS 20.0 was used. 
Study II: Group comparisons were carried out using the Student’s t-test for 
continuous variables. The χ2 test was used for categorical variables. 
Spearman's rank correlation coefficient was employed to estimate the 
correlation between variables. Univariate logistic regression analyses were 
performed to estimate the odds of MEMS® non-adherence by each predictor 
variable. In order to reduce the number of variables a composite score for 
cognitive function, regarded as a measurement of the global level of 
cognitive performance, was created. Individual test scores were transformed 
to z-scores using the patient sample and then averaging across tests. The 
composite score was also stratified by tertiles, which were entered in a 
separate univariate logistic regression model as a categorical variable to test 
for non-linear associations. The method of purposeful selection was used 
[171] when building a multivariate logistic regression model for adherence 
according to MEMS®. To assess performance of the identified predictors of 
adherence, a receiver-operating characteristic curve (ROC) was used. The 
area under the curve (AUC) was calculated and compared to a curve obtained 
by chance using the Wilcoxon statistic. R version 2.15.2 and SAS 9.3 were 
used for all statistical analyses.  
Study III: Group comparisons were carried out using the Student’s t-test for 
continuous variables. The χ2 test was used for categorical variables. 
Spearman's rank correlation coefficient was employed to estimate the 
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correlation between variables. Univariate logistic regression analyses were 
performed to estimate associations between DISC mean subscale scores and 
MEMS® non-adherence. In a second step multivariate logistic regression 
models were fitted for each DISC subscale mean score, adjusted for DAI-10 
and PSP. The latter two were included as it was previously shown (in Study 
II, the predictors of adherence study) that drug attitude (DAI-10) and 
psychosocial function (PSP) are associated with non-adherence after 
analyzing a broad range of candidate factors. The number of confounders was 
limited to two due to the relatively small number of non-adherent patients. 
All measures included in the analyses were from the endpoint rating. 
Multicollinearity was tested for in the multivariate models using the Variance 
inflation factor (VIF). A VIF-value of 2.5 or higher was used as a cut-off 
indicating problematic multicollinearity. R 3.0.1. and IBM SPSS 21.0 was 
used for all analyses. 
Study IV: Group comparisons were carried out using the Student’s t-test for 
continuous variables. For categorical variables differences in proportions 
were tested with the χ2 test. Ordinal logistic regression was used to analyze 
associations between specific ISE items and BIRP score tertiles. For the 
analysis of the relationship between associated stigma and relatives’ overall 
burden focus was put on an item that captured the relatives’ own experience 
of stigma. Item 19 (“Have you experienced stigma due to your relative’s 
illness?”) was deemed to be the item that best captured this phenomenon, and 
those who responded “sometimes/often/always” were considered to be the 
exposed group. Similarly, item 29 (“Do you avoid situations that might be 
stigmatizing for the family?”) was considered to be the item that best 
captured anticipated stigma on the part of the relative. As frequency but not 
severity is quantified for both these items, measures of impact were included. 
Therefore, as items 33 and 34 deal directly with the impact of stigma on the 
individual (item 33) and on the entire family (item 34), these items were 
considered to be of particular interest when testing for associations with 
relative’s burden. In a first step individual ISE variables were analyzed in 
univariate ordinal logistic regression models. In a second step they were 
analyzed in separate ordinal logistic regression models, adjusting for 
confounders. The potential confounders age, gender, symptom burden in 
patients (PANSS total) and patient function (GAF) were screened separately 
in univariate ordinal logistic regression models and variables with p-values 
lower than 0.2 were used as confounders. R 3.0.1. and IBM SPSS 21.0 were 
used for all analyses. 
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4.3 Statistical methods used 
Study I: All variables were summarized with standard descriptive statistics. 
Categorical variables including adherence (non-adherent vs. adherent) were 
analyzed with Pearson’s χ2 -method or with Fisher’s exact test. Kappa (“Κ”) 
coefficients describe the agreement between MEMS® and another adherence 
measure, as well as inter-rater reliability for the plasma level adherence 
measure. Means of MEMS®, pill count, the plasma level measure and patient 
ratings were calculated in order to capture adherence across the entire period. 
Concordance was measured, i.e. the frequency of patients that were identified 
as adherent according to both MEMS® monitoring and another specified 
measure of adherence. Differences between groups regarding symptom 
scores, CGI-S, and GAF were analyzed with Mann-Whitney U tests. Change 
in adherence over the study year was analyzed with an analysis of variance 
for repeated measurements. The continuous measures of adherence were also 
entered in a principal component analysis with Oblimin rotation, assuming a 
relationship between the variables. SPSS 20.0 was used. 
Study II: Group comparisons were carried out using the Student’s t-test for 
continuous variables. The χ2 test was used for categorical variables. 
Spearman's rank correlation coefficient was employed to estimate the 
correlation between variables. Univariate logistic regression analyses were 
performed to estimate the odds of MEMS® non-adherence by each predictor 
variable. In order to reduce the number of variables a composite score for 
cognitive function, regarded as a measurement of the global level of 
cognitive performance, was created. Individual test scores were transformed 
to z-scores using the patient sample and then averaging across tests. The 
composite score was also stratified by tertiles, which were entered in a 
separate univariate logistic regression model as a categorical variable to test 
for non-linear associations. The method of purposeful selection was used 
[171] when building a multivariate logistic regression model for adherence 
according to MEMS®. To assess performance of the identified predictors of 
adherence, a receiver-operating characteristic curve (ROC) was used. The 
area under the curve (AUC) was calculated and compared to a curve obtained 
by chance using the Wilcoxon statistic. R version 2.15.2 and SAS 9.3 were 
used for all statistical analyses.  
Study III: Group comparisons were carried out using the Student’s t-test for 
continuous variables. The χ2 test was used for categorical variables. 
Spearman's rank correlation coefficient was employed to estimate the 
 
 39 
 
correlation between variables. Univariate logistic regression analyses were 
performed to estimate associations between DISC mean subscale scores and 
MEMS® non-adherence. In a second step multivariate logistic regression 
models were fitted for each DISC subscale mean score, adjusted for DAI-10 
and PSP. The latter two were included as it was previously shown (in Study 
II, the predictors of adherence study) that drug attitude (DAI-10) and 
psychosocial function (PSP) are associated with non-adherence after 
analyzing a broad range of candidate factors. The number of confounders was 
limited to two due to the relatively small number of non-adherent patients. 
All measures included in the analyses were from the endpoint rating. 
Multicollinearity was tested for in the multivariate models using the Variance 
inflation factor (VIF). A VIF-value of 2.5 or higher was used as a cut-off 
indicating problematic multicollinearity. R 3.0.1. and IBM SPSS 21.0 was 
used for all analyses. 
Study IV: Group comparisons were carried out using the Student’s t-test for 
continuous variables. For categorical variables differences in proportions 
were tested with the χ2 test. Ordinal logistic regression was used to analyze 
associations between specific ISE items and BIRP score tertiles. For the 
analysis of the relationship between associated stigma and relatives’ overall 
burden focus was put on an item that captured the relatives’ own experience 
of stigma. Item 19 (“Have you experienced stigma due to your relative’s 
illness?”) was deemed to be the item that best captured this phenomenon, and 
those who responded “sometimes/often/always” were considered to be the 
exposed group. Similarly, item 29 (“Do you avoid situations that might be 
stigmatizing for the family?”) was considered to be the item that best 
captured anticipated stigma on the part of the relative. As frequency but not 
severity is quantified for both these items, measures of impact were included. 
Therefore, as items 33 and 34 deal directly with the impact of stigma on the 
individual (item 33) and on the entire family (item 34), these items were 
considered to be of particular interest when testing for associations with 
relative’s burden. In a first step individual ISE variables were analyzed in 
univariate ordinal logistic regression models. In a second step they were 
analyzed in separate ordinal logistic regression models, adjusting for 
confounders. The potential confounders age, gender, symptom burden in 
patients (PANSS total) and patient function (GAF) were screened separately 
in univariate ordinal logistic regression models and variables with p-values 
lower than 0.2 were used as confounders. R 3.0.1. and IBM SPSS 21.0 were 
used for all analyses. 
40 
 
5. ETHICAL CONSIDERATIONS 
All patients, independent of diagnosis, are in a subordinate position in 
relation to the health care system. Special caution is a necessity when asking 
persons with schizophrenia to take part in a research study. Many have 
previously been subject to involuntary treatment and may suffer from 
debilitating psychotic or cognitive symptoms, as well as poor self-esteem due 
to stigma and discrimination. With these aspects in mind patients were first 
approached through, and thus with the approval of, their staff or treating 
psychiatrists in the outpatient clinics. This procedure might have introduced a 
selection bias towards more well-functioning and adherent patients, but was 
considered to be the most ethical. 
The Ethics Committee for Medical Research at the University of Gothenburg 
approved of the COAST study. In accordance with the provisions of the 
Helsinki Declaration, informed consent was obtained from the patients after 
they had received oral and written information about the study. Informants 
were only approached after the approval of the patients. Thereafter the 
informants received written information and an offer to receive additional 
oral information. Informants willing to fill in study related questionnaires 
also gave their written informed consent. Both patients and informants were 
assured that they could withdraw from the study at any time without having 
to explain the reason for withdrawal and that this would not in any aspect 
affect their care. 
The baseline and endpoint clinical investigations, including the sessions for 
cognitive testing, were time-consuming and often strenuous for the patients. 
Most patients needed one or several breaks during sessions and sometimes 
the investigations had to be scheduled in several consecutive sessions. 
Patients were therefore offered a light meal of a total value of 60 Swedish 
crowns (about 6 €) and single tickets for the city public transportation system 
at these visits.  
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6. RESULTS 
6.1 Results Study I 
6.1.1 Drop-out analysis 
The group of 14 patients who declined MEMS® monitoring did not differ 
from those who participated with regard to gender (χ2=0.44, p=.507) and age 
(χ2=0.001, p=.976). A larger proportion of the participants had education 
beyond 12 years (χ2=6.781, p=.009). The drop-outs had a more severe illness 
(CGI-S: z=2.10, p=.035; and PANSS total: z=2.538, p=.011), but no 
significant difference in functioning as measured by GAF (z=1.412, p=.158).  
6.1.2 Subjectively and objectively measured 
adherence 
Non-adherence (MEMS® ≤ 0.80) was observed in 27% of the patients, which 
was almost identical to the pill count non-adherence (29%). Half (56%) of the 
patients were judged to be adherent with the plasma based measure that 
included adherence to lab visits. Among the subjective measurements, the 
highest figure was observed for the self-rated measure (mean adherence 
92%), and the lowest for the psychiatrist-rated measure (58%) (Table 5). As 
adherence class does not apply to the composite plasma measure, the values 
denoting the percentages of patients classified are not evenly distributed in 
the table format. 
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6.1.3 Relationship between adherence measures 
The relationships between MEMS® adherence and each of the other measures 
are shown in Table 5. MEMS® adherence was highly correlated with pill 
count (concordance=89% and K=0.72, p <.001). Only 13 patients were 
differently classified: six patients as adherent according to pill count and non-
adherent according to MEMS®, and vice versa for seven patients. 
Concordance and K were lower for all other adherence measures and very 
low for the relationship between MEMS® adherence and the plasma level 
measure (concordance=56% and K=0.05, p=.607). Forty-four percent of the 
patients were differently classified, 31(32%) were classified as adherent 
according to MEMS® and non-adherent according to the plasma level 
measure, and vice versa for 11 (12%). Adherence measures were also entered 
into a principal component analysis in order to analyze interrelationships 
between all measures. Three components were yielded (Table 6). MEMS® 
recordings, pill count and informant ratings had their highest loadings in the 
first component, the plasma level measure alone in the second and patient, 
psychiatrist and staff ratings in the third. The component analysis confirms 
the results from the analysis of concordance. 
 
Table 6: Principal component analysis with Oblimin rotation of 
adherence measures.  
  Component   
Measure of adherence I II III h2 
Adherence, pill count 0.93 0.24 0.43 0.87 
Adherence, MEMS® 0.85 0.03 0.57 0.77 
Adherence rating, informant 0.79 0.21 0.32 0.63 
Adherence, plasma levels, consensus 0.25 0.99 0.10 0.98 
Adherence rating, staff 0.51 0.02 0.90 0.82 
Adherence rating, psychiatrist 0.31 0.08 0.85 0.73 
Adherence rating, patient 0.65 -0.01 0.82 0.77 
Total variance explained 0.52 0.16 0.12 0.82 
The highest component loading is in bold, and loadings above 0.50 in 
italics. h2 is the communality or the proportion of the variance of the 
variable that is explained by the components. 
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6.1.3 Relationship between adherence measures 
The relationships between MEMS® adherence and each of the other measures 
are shown in Table 5. MEMS® adherence was highly correlated with pill 
count (concordance=89% and K=0.72, p <.001). Only 13 patients were 
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according to MEMS® and non-adherent according to the plasma level 
measure, and vice versa for 11 (12%). Adherence measures were also entered 
into a principal component analysis in order to analyze interrelationships 
between all measures. Three components were yielded (Table 6). MEMS® 
recordings, pill count and informant ratings had their highest loadings in the 
first component, the plasma level measure alone in the second and patient, 
psychiatrist and staff ratings in the third. The component analysis confirms 
the results from the analysis of concordance. 
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6.1.4 One year MEMS® and pill count adherence 
A comparison between MEMS® and pill count mean adherence over time is 
shown in Figure 3. Mean adherence across the study period for MEMS® was 
84% (95% C.I. 73 to 88%) and as measured by pill count 82% (95% C.I. 77 
to 87%). Mean adherence for MEMS® and for pill count both showed non-
significant drops during the last monitoring period.   
 
Figure 3. Comparison between mean adherence as measured by MEMS® 
and pill count at each two month assessment across study period.  
 
6.2 Results Study II 
6.2.1 Drop-out analysis 
Nineteen of the initially recruited 131 patients either declined to use the 
MEMS® bottle or lacked sufficient data for the predictor analyses. They did 
not differ from the 112 included patients in terms of age, gender or education. 
However they had lower level of function (GAF, t=2.75; p=.009; PSP, 
t=3.10; p=.004) and greater symptom severity (PANSS positive, t=-2.16; 
p=.040; PANSS negative, t=-2.44; p=.023; PANSS general, t=-2.16; p=.042).  
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6.2.2 Predictors of MEMS® non-adherence 
Non-adherence (MEMS® adherence ≤ 0.80) was observed in 31 of the 112 
patients (27%). Sixty-five of the adherent patients (80.2%) had antipsychotic 
monotherapy at baseline and 16 (19.7%) had ≥ 2 different MEMS® monitored 
antipsychotics at baseline. Of the 31 non-adherent patients, 21 (67.7%) had 
monotherapy and 10 (32.3%) had ≥ 2 antipsychotics. 
In univariate regression models (Table 7) a more negative drug attitude (low 
scores on DAI-10), higher positive symptom burden (PANSS positive 
subscale), poor function (PSP), psychiatric side effects (UKU-SERS-Pat) and 
lack of insight (G12) predicted non-adherence. There was no association 
between global cognitive function, substance abuse, BMI, DUP, duration of 
illness, number of exacerbations, type of antipsychotic (FGA/SGA) or 
medication regimen and non-adherence. In the adherent sub-group 49 
(60.5%) were in remission compared to 15 (48.4%) in the non-adherent 
group, but no association with adherence was found. 
In the informant subsample (n=61), where ratings with the slightly modified 
DAI-10 were performed, a more negative drug attitude in informants was 
associated with non-adherence in a univariate logistic regression analysis, 
with an OR (0.82; 95% CI: 0.68-0.97; p=.024) similar to that observed for the 
DAI-10 patient version. A weak, though significant correlation (rho=.350; p= 
.006) was observed between DAI-10 informant and patient ratings. 
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6.2.2 Predictors of MEMS® non-adherence 
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In multivariate regression models, low patient-rated DAI-10 and PSP scores 
emerged as predictors of non-adherence (Table 8).  
 
Table 8: Age and gender adjusted multivariate 
logistic regression model predicting MEMS®  
non-adherence by clinical measurements. 
Variable OR CI95% p-value 
Age 0.96 0.92 - 1.03 .070 
Gender 1.77 0.60 - 4.99 .269 
DAI-10  0.71 0.69 - 0.89 <.001 
PSP  0.94 0.90 - 0.98 .007 
 
 
The drug attitude of the patient emerged as a significant predictor of 
adherence in all model configurations and thus an ROC analysis was 
performed to determine the ability of the instrument to correctly diagnose 
adherence status. Figure 4 shows the sensitivity (i.e. the proportion of non-
adherent patients correctly identified as non-adherent) and 1-specificity (i.e. 
the proportion of adherent patients falsely identified as non-adherent) of the 
DAI. The area under the curve (AUC) was 0.73, indicating a performance 
significantly better than chance (p < .001). At the “optimal” cut-off of 4 the 
sensitivity was 0.68 and the specificity was 0.32. 
A somewhat larger AUC (0.78, p < .001) was observed when the ROC 
procedure was applied to the multivariate regression model including DAI-
10, PSP, age and gender. For the subgroup with informant data (n=61), the 
AUC for the DAI-10 informant version was 0.68 (p=.021). 
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Adherent Non-adherent 
Variable (n = 81) (n = 31)
Male, n (%) 47 (58) 22 (71) 0.57 (0.23 - 1.38)
Age 46.9 (21.5 - 65.9) 43.5 (22.4 - 65.7) 0.97 (0.94 - 1.01)
Body mass index 30 (20.0 - 63.6) 28.7 (16.4 - 43.5) 0.97 (0.91 - 1.02)
Living situation, n (%)
Custodial care 19 (23.5) 7 (22.6) 1.24 (0.44 - 3.49)
Institution 8 (9.9) 8 (25.8) 3.38 (1.09 - 10.42)
Substance and alcohol abuse, n (%) 24 (29.6) 11 (35.5) 1.32 (0.44 - 3.93)
Duration of untreated psychosis 3.3 (0 - 22) 4.1 (0 - 31) 1.02 (0.96 - 1.10)
Duration of illness 19.4 (1 - 52) 19.8 (0 - 55) 1.00 (0.97 - 1.04)
Exacerbations 7.3 (1 - 38) 7.5 (2 - 19) 1.01 (0.93 - 1.09)
First generation antipsychotics, n (%) 14 (17.3) 2 (6.5) 3.30 (0.71 - 15.35)
Medication regimen (1/ ≥2 per day), n (%) 58 (72)/23 (28) 22 (71)/9 (29) 1.03 (0.41 - 2.57)
PANSS subscale
positive 20.4 (14 - 37) 22.5 (15 - 33) 1.01 (1.01 - 1.20)
negative 22.5 (14 - 36) 24.5 (14 - 36) 1.10 (1.00 - 1.17)
general psychopathology 45.3 (35 - 62) 46.8 (34 - 58) 1.06 (0.98 - 1.14)
Judgment and insight 3.6 (2 - 6) 4.1 (2 - 6) 1.61 (1.08 - 2.42)
DAI-10 6.2 (-4 - 10) 2.4 (-10 - 10) 0.79 (0.70 - 0.90)
PSP 49.2 (30 - 75) 42.8 (30 - 68) 0.94 (0.91 - 0.99)
SCI-SR, n (%) 49 (60.5) 15 (48.4) 0.61 (0.27 - 1.41)
Side effects
psychiatric 1.6 (1.0 - 3.0) 1.9 (1.0 - 3.20) 3.95 (1.60 - 9.80)
neurological 1.4 (1.0 - 2.88) 1.5 (1.0 - 2.25) 1.35 (0.50 - 3.64)
autonomic 1.4 (1.0 - 2.91) 1.4 (1.0 - 2.18) 0.96 (0.30 - 3.10)
other 1.4 (1.0 - 2.5) 1.3 (1.0 - 2.25) 0.98 (0.35 - 2.80)
Cognitive composite score 0.14 (-1.6 - 1.3) 0.12 (-1.2 - 1.2) 0.95 (0.45 - 1.99)
Values denote mean (range) if not specified otherwise.
Table 7: Univariate logistic regression models predicting MEMS® non-adherence by demographic 
and clinical measurements
OR (CI95%)
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logistic regression model predicting MEMS®  
non-adherence by clinical measurements. 
Variable OR CI95% p-value 
Age 0.96 0.92 - 1.03 .070 
Gender 1.77 0.60 - 4.99 .269 
DAI-10  0.71 0.69 - 0.89 <.001 
PSP  0.94 0.90 - 0.98 .007 
 
 
The drug attitude of the patient emerged as a significant predictor of 
adherence in all model configurations and thus an ROC analysis was 
performed to determine the ability of the instrument to correctly diagnose 
adherence status. Figure 4 shows the sensitivity (i.e. the proportion of non-
adherent patients correctly identified as non-adherent) and 1-specificity (i.e. 
the proportion of adherent patients falsely identified as non-adherent) of the 
DAI. The area under the curve (AUC) was 0.73, indicating a performance 
significantly better than chance (p < .001). At the “optimal” cut-off of 4 the 
sensitivity was 0.68 and the specificity was 0.32. 
A somewhat larger AUC (0.78, p < .001) was observed when the ROC 
procedure was applied to the multivariate regression model including DAI-
10, PSP, age and gender. For the subgroup with informant data (n=61), the 
AUC for the DAI-10 informant version was 0.68 (p=.021). 
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Adherent Non-adherent 
Variable (n = 81) (n = 31)
Male, n (%) 47 (58) 22 (71) 0.57 (0.23 - 1.38)
Age 46.9 (21.5 - 65.9) 43.5 (22.4 - 65.7) 0.97 (0.94 - 1.01)
Body mass index 30 (20.0 - 63.6) 28.7 (16.4 - 43.5) 0.97 (0.91 - 1.02)
Living situation, n (%)
Custodial care 19 (23.5) 7 (22.6) 1.24 (0.44 - 3.49)
Institution 8 (9.9) 8 (25.8) 3.38 (1.09 - 10.42)
Substance and alcohol abuse, n (%) 24 (29.6) 11 (35.5) 1.32 (0.44 - 3.93)
Duration of untreated psychosis 3.3 (0 - 22) 4.1 (0 - 31) 1.02 (0.96 - 1.10)
Duration of illness 19.4 (1 - 52) 19.8 (0 - 55) 1.00 (0.97 - 1.04)
Exacerbations 7.3 (1 - 38) 7.5 (2 - 19) 1.01 (0.93 - 1.09)
First generation antipsychotics, n (%) 14 (17.3) 2 (6.5) 3.30 (0.71 - 15.35)
Medication regimen (1/ ≥2 per day), n (%) 58 (72)/23 (28) 22 (71)/9 (29) 1.03 (0.41 - 2.57)
PANSS subscale
positive 20.4 (14 - 37) 22.5 (15 - 33) 1.01 (1.01 - 1.20)
negative 22.5 (14 - 36) 24.5 (14 - 36) 1.10 (1.00 - 1.17)
general psychopathology 45.3 (35 - 62) 46.8 (34 - 58) 1.06 (0.98 - 1.14)
Judgment and insight 3.6 (2 - 6) 4.1 (2 - 6) 1.61 (1.08 - 2.42)
DAI-10 6.2 (-4 - 10) 2.4 (-10 - 10) 0.79 (0.70 - 0.90)
PSP 49.2 (30 - 75) 42.8 (30 - 68) 0.94 (0.91 - 0.99)
SCI-SR, n (%) 49 (60.5) 15 (48.4) 0.61 (0.27 - 1.41)
Side effects
psychiatric 1.6 (1.0 - 3.0) 1.9 (1.0 - 3.20) 3.95 (1.60 - 9.80)
neurological 1.4 (1.0 - 2.88) 1.5 (1.0 - 2.25) 1.35 (0.50 - 3.64)
autonomic 1.4 (1.0 - 2.91) 1.4 (1.0 - 2.18) 0.96 (0.30 - 3.10)
other 1.4 (1.0 - 2.5) 1.3 (1.0 - 2.25) 0.98 (0.35 - 2.80)
Cognitive composite score 0.14 (-1.6 - 1.3) 0.12 (-1.2 - 1.2) 0.95 (0.45 - 1.99)
Values denote mean (range) if not specified otherwise.
Table 7: Univariate logistic regression models predicting MEMS® non-adherence by demographic 
and clinical measurements
OR (CI95%)
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Figure 4. ROC-curve demonstrating the accuracy of the DAI-10 to predict 
non-adherence to antipsychotic treatment (mean MEMS® ≤ .80) across the 
one year study period (n = 112, AUC = 0.73). Markers on the curve denote 
DAI-10 scores. 
 
6.3 Results Study III 
The 20 drop-outs who had initially accepted participation in the COAST 
study did not differ from the 111 patients with both stigma and adherence 
data in terms of age, gender or education. However they had greater total and 
general symptom severity, as has been described in the drop-out analysis 
(section 6.2.1) for Study II. Out of the 112 patients included in Study II one 
patient left incomplete DISC responses, leaving a cohort of 111 patients for 
Study III. 
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6.3.1 Level of stigma and discrimination 
Of the 111 included patients the proportions with a rating of “a little”, 
“moderate” or “a lot” ( ≥ 1) per DISC subscale were as follows: experienced 
discrimination 31.5% (n=35), anticipated discrimination 64.8% (n=72), 
overcoming stigma 63.1% (n=70), and positive treatment 5.4% (n=6). The 
mean DISC subscale scores (SD) were: experienced discrimination 0.7 (0.4), 
anticipated discrimination 1.4 (0.7), overcoming stigma 1.1 (0.8), and 
positive treatment 0.3 (0.3).  
The reported proportion of experienced stigma and discrimination on the 
single DISC item level is shown in Figure 5. The highest proportion included 
experienced discrimination in social relationships and mostly in 
making/keeping friends (71%) and in the neighborhood (69%). Almost two-
thirds (62%) of the patients reported having been avoided because of their 
mental health problems. About half of the patients experienced 
discrimination by their families, in intimate relationships, regarding 
employment and by mental health staff. More than one-third (36%) had been 
treated unfairly when seeking medical attention for physical health issues. 
Due to anticipated stigma most patients (88%) wanted to conceal their mental 
health problems from others and 70% stated that anticipated discrimination 
resulted in avoidance of close personal relationships. About half reported that 
they avoided applying for work (51%) or education (43%) for fear of unjust 
treatment because of their mental illness. Most patients (78%) claimed to 
have at least some personal strategy and skill to overcome and cope with 
stigma. Experiences of positive treatment by family or other significant 
person because of the patient’s mental illness was experienced by 51%. 
The experienced and anticipated discrimination subscales were positively 
correlated (rho=.503; p < .001), while anticipated discrimination was 
observed to be inversely associated with overcoming stigma (rho=-.365; p < 
001). Moderate correlations were observed between PSP and anticipated 
discrimination (rho=.311; p=.001) and PSP and overcoming stigma 
(rho=.487; p < .001). The correlation between DAI-10 and overcoming 
stigma (rho=.242; p=.010) was also moderate. No other correlation between 
independent variables reached significance.  
6.3.2 Association between stigma and adherence 
Non-adherence (MEMS® adherence ≤ 0.80) was observed in 30 patients 
(27.3%). When DISC subscale mean scores were entered in separate 
regression models (including all 111 patients in Study III) neither 
experienced nor anticipated stigma was associated with adherence. An 
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inverse association was shown between overcoming stigma and non-
adherence, i.e. patients who reported lower skills in coping with stigma were 
more likely classified as non-adherent. 
After adjusting the logistic regression models for DAI-10 and PSP, none of 
the DISC subscale mean scores reached significance in association with non-
adherence in the multivariate model. 
 
 
Figure 5. Proportions of DISC items. N refers to applicable/valid item 
responses. ED = Experienced discrimination subscale; AD = Anticipated 
discrimination subscale; OS = Overcoming stigma subscale P = Positive 
treatment subscale; MHP = Mental health problem; MHS = Mental health 
service 
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6.4 Results Study IV 
6.4.1 Drop-out analysis 
Patients with (n=65) and without (n=66) participating relatives did not differ 
in terms of age, gender or function. However, patients without data from 
relatives had fewer years of education (χ2=5.6; p=.028) and higher total 
scores on the PANSS (63.8 vs. 58.7 t=2.1; p=.037).   
6.4.2 Ratings of stigmatizing experiences 
According to the first part of the ISE (Stigma Experience Scale) most 
relatives, (n=56, 93%) thought that “people think less of those who have 
mental illness.” An identical proportion responded that they thought that “the 
average person is afraid of someone with serious mental illness.” Almost half 
of the responding relatives (n=30) reported that their relative with 
schizophrenia was sometimes, often or always stigmatized. Own experiences 
of stigma (item 19) were reported sometimes, often or always by 11 (18%). 
Slightly over one quarter (n=16) acknowledged that other family members 
had been stigmatized. Anticipated stigma (item 29) was experienced by one 
fifth (n=13) of the relatives. One quarter (n=15) stated that their “experiences 
with stigma had stimulated a family member to speak out for the rights of the 
mentally ill” and 9 (15%) actually took part in programs to increase public 
knowledge about stigma.  
The second part of the ISE (Stigma Impact Scale) showed that for both the 
impact of stigma on the personal level (item 33) and on the family as a whole 
(item 34), the highest impact was found on family relations and quality of 
life. 
6.4.3 Ratings of relatives’ burden 
Relatives’ responses to each BIRP item are shown by frequency category in 
Figure 6. The mean total per respondent (all ten items) was 14.2; the range 
was broad (10-30). The highest burden ratings (on a single item level) were 
expressed in item 2, i.e. the area of needing to help the mentally ill relative to 
occupy him/herself (mean 1.72), and in item 7, i.e. in feeling strain because 
of his/her mental problem (mean 1.83). Relatively few expressed worry that 
the patient would harm someone (item 5, mean 1.03) or commit suicide (item 
6, mean 1.18).  
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Figure 6. Proportions of respondents reporting burden by frequency 
categories in accordance with the Burden Inventory for Relatives of persons 
with Psychotic disturbances. 
 
6.4.4 Relationships between stigma and burden 
Neither experienced nor anticipated stigma was associated with level of 
burden (Table 9). Higher stigma impact ratings on items related to personal 
quality of life and self-esteem were associated with higher overall burden, as 
were higher ratings on familial impact on quality of life, social contacts and 
family relation. Findings from adjusted models are also shown in Table 8. 
Out of potential confounders, PANSS and GAF were strongly correlated 
(rho=-.60) and due to the small sample size PANSS was left out and only 
GAF and patient age were included as confounders. Both personal and 
familial stigma impact on quality of life remained associated with relatives’ 
burden after adjustment for patient age and level of functioning (GAF). 
 
 53 
 
 
OR 95% CI p  value OR 95% CI p  value
2.71 0.78 – 9.39 .116 1.89 0.52 - 6.94 .337
0.26 0.04 – 1.71 .162 0.31 0.04 - 2.14 .232
Quality of life 1.30 1.08 - 1.56 .006 1.24 1.03 - 1.50 .024
Social contacts 1.08 0.91 - 1.29 .355 1.03 0.86 - 1.24 .740
Family relations 1.14 0.97 - 1.35 .103 1.11 0.94 - 1.31 .226
Self-esteem 1.18 1.00 - 1.39 .041 1.13 0.96 - 1.34 .136
Quality of life 1.35 1.11 - 1.66 .003 1.26 1.03 - 1.56 .026
Social contacts 1.20 1.00 - 1.43 .047 1.11 0.92 - 1.33 .277
Family relations 1.26 1.04 - 1.52 .017 1.16 0.95 - 1.42 .135
Table 9: Ordindal regression models demonstrating relationships between selected 
ISEa variables and levels of burden (BIRPb) in relatives to persons with schizophrenia.
Variables
Univariate Adjusted c
Experienced stigma (n=60) 
cAdjusted for patient age and GAF (function)
Anticipated stigma (n=57)
Personal impact (n=59)
Family impact (n=53)
aInventory of Stigmatizing Experiences
bBurden Inventory for Relatives to Persons with psychotic disturbance
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7. DISCUSSION 
7.1 Main findings of the COAST study 
Almost one-third of the patients taking part in the COAST study were non-
adherent to their oral antipsychotics according to the reference standard 
MEMS®.  
In the study comparing adherence measures (Study I), MEMS® and pill count 
were found to be highly correlated. The poorest concordance was found 
between MEMS® and the plasma level measure. Adherence was 
underestimated by the prescribing psychiatrists, whereas patients and 
informants overestimated it. 
In the predictors of adherence study (Study II) a positive drug attitude, in 
combination with good psychosocial function, emerged as the best predictors 
of MEMS® monitored adherence across the 12-month study period in 
adjusted models. Higher positive symptom burden, poor insight, psychiatric 
side effects and negative informant drug attitude were also related to non-
adherence.  
Almost two-thirds of the patients in the stigma and adherence study (Study 
III) reported experienced or anticipated stigma and discrimination, especially 
in social relationships. Half felt discrimination by mental health staff. Coping 
with stigma was associated with adherence in univariate analysis, but no 
association was found between stigma and adherence in adjusted models. 
In the associated stigma and burden in relatives study (Study IV) one-fifth of 
the relatives avoided situations that might elicit stigma, but there was no 
association between experienced and anticipated stigma and burden. Stigma 
impact regarding both the relative’s personal quality of life and quality of life 
for the whole family were both significantly associated with overall burden in 
adjusted models.  
 
7.2 Strengths of this study 
We believe that this is the largest and longest study of any medical diagnosis 
measuring adherence using MEMS® for a full year. Also, it is to our 
knowledge the first study to combine an objective measure of adherence and 
the use of a valid and psychometrically strong measure of patient experienced 
stigma and discrimination, and to employ structured instruments to examine 
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the relationship between experiences of both stigma and burden in relatives to 
persons with schizophrenia.  
The overall strengths of this naturalistic non-interventional study were the 
long observation period of a whole year and the multiple monitorings with an 
objective measure of adherence. As adherence fluctuates over time due to 
clinical and environmental factors, the clinical variations of adherence might 
be more adequately captured by a prolonged monitoring period. Other 
strengths were the few exclusion criteria, home visits to reduce the risk of 
missing data, the same research psychiatrist performed all the clinical ratings 
and few patients lost to follow-up. Also, plasma levels are commonly used in 
clinical practice but to date only a few studies have compared plasma level 
adherence measures with other objective measures of adherence.  
Finally this is, as far as we know, the first study to include a structured rating 
of close informant drug attitude to test if the drug attitude of the informant is 
a potential predictor of patient adherence. Informants were also asked to rate 
the patients’ adherence and to fill in questionnaires regarding their own 
experiences of stigma and burden in relation to having a relative with 
schizophrenia. This approach is in line with modern evidence based 
community psychiatry emphasizing the importance of including informal 
caregivers, such as relatives [172]. 
 
7.3 Limitations of this study  
7.3.1 Considerations regarding the adherence rate 
The power of the COAST study to detect potential predictors of non-
adherence might have been affected by the relatively low number of patients 
with non-adherence (n=31; 27%). MEMS® is generally considered the 
reference standard for adherence measurement [134] and the ≤ 0.8 cut-off for 
MEMS® non-adherence was chosen as it is commonly used for research 
purposes [8]. Nevertheless it might not be a true reflection of real world non-
adherence. Also, eligible patients were identified by their case managers or 
clinical psychiatrists and this might have introduced a selection bias towards 
more adherent patients. These patients may therefore also have reported less 
experiences of stigma. Another consideration is that staff might have been 
less likely to suggest the inclusion of patients with a previous record of non-
adherence and several relapses due to fear of introducing study related stress 
and increased risk of exacerbations.  
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At baseline all patients had filled prescriptions from their psychiatrists and 
came to the first monitoring with their medication. Also, the regular 
monitorings of adherence could have increased adherence rates. Similarly, 
the heightened focus on adherence, like in any other adherence study, might 
have decreased the overall non-adherence rates of the study patients. On the 
other hand this would not be expected to impact differently on the various 
adherence measures. Further, due to inclusion of only baseline data and mean 
adherence of the twelve month study period, no conclusion about the 
temporal relationship between the predictors of adherence and the medication 
taking behavior can be made.  
7.3.2 Adherence measure considerations 
There are some obvious limitations concerning the adherence measures. 
MEMS® and pill count cannot detect discarding of pills, but by also including 
other frequently used subjective and objective adherence measures in the 
same study the likelihood of capturing non-adherence increased.  
One important limitation concerns the plasma level measure. Plasma was 
sampled only three times because four samplings were not considered 
realistic as the patients had to travel to the lab at the university hospital. Also, 
plasma level adherence was rated in four categories (0-3) rather than five for 
the other adherence measures and therefore the adherence class (percentage 
of patients classified by prescribed dosages correctly taken) does not apply 
for plasma level adherence. In some previous studies adherence has been 
defined as a plasma level variability of less than 30% between samples [11]. 
This definition captures stability over time, but does not reflect whether the 
levels are appropriate in regard to the prescribed dosage. Further, partial non-
adherence may be missed. Since there is no reference standard for the 
evaluation of plasma levels as a long term adherence measure, we 
constructed a composite measure to take into consideration not only the 
plasma level as such but also adherence to lab visits.  
There are several general drawbacks in the interpretation of plasma levels, 
[11, 135] such as what therapeutic plasma level to use as criterion for SGA, 
concomitant medication, metabolism, smoking and loading doses (increasing 
intake before a lab visit to hide non-adherence). Intra-individual variability in 
plasma levels is considerable. Additionally, a composite measure that 
includes deciding the adequacy of plasma levels in accordance to prescribed 
dose might be difficult to replicate in future studies.  
Nevertheless, the present study is to our knowledge not only the longest and 
largest study measuring adherence also with objective measures but one of 
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few [2, 119] comparing a plasma level adherence measure to another 
objective measure. 
7.3.3 Instrument related concerns 
Several scale related considerations deserve attention. While the sensitivity of 
DAI-10 was moderate, the specificity was rather low. As sensitivity increases 
the trade off with false positives becomes larger. According to our data a 
DAI-10 cut-off at 4 can identify the maximum number of true non-adherent 
patients while minimizing the number of false positives. Still, one-third of the 
adherent patients would be falsely identified as non-adherent.  
Alliance was not assessed and a more extensive measure of insight is lacking. 
Data regarding substance and alcohol use was retrieved from the medical 
records only as data from the patient self-rated scales (AUDIT [173], DUDIT 
[174]) lacked power due to missing values and thus could not be included in 
the study. Alcohol and illicit drugs have been previously been shown to be 
associated with non-adherence [141].  
Global cognitive function did not predict non-adherence in our study. The use 
of composite scores may obscure an association between non-adherence and 
specific cognitive domains. A composite score was used as the power of the 
study did not allow for additional co-variates in the analyses. Further studies 
are needed to explore the various cognitive domains and their association to 
non-adherence. 
The stigma scale (DISC) provides a subjective measure of the degree to 
which a range of everyday situations are experienced as stigmatizing, but 
does not capture the frequency of these experiences. Also, the scale does not 
address the impact of discriminative experiences on the individual. On the 
other hand DISC is a valid and psychometrically strong measure of patient 
experienced stigma and discrimination. 
 
The ISE family version was originally validated for persons with various 
diagnoses and not only for families of persons with psychotic disorders, 
whereas the family burden scale (BIRP) was developed and validated 
specifically for relatives to persons with psychotic disorders. Furthermore, it 
can be argued that relatives’ objective burden is underestimated with 
instruments based on recall [44]. An alternative method, such as continuous 
report by diary might not be as suited to the quantification of mental strain 
and other phenomena captured with the BIRP. Both ISE and BIRP ratings 
may be underestimates as patients without data for relatives had higher 
PANSS scores. Symptom severity may impact on relatives’ stigma [103] and 
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burden [175, 176]. Further, relatives of patients with lower education levels 
were underrepresented. It is however unclear how this might affect our 
results. Also, our data is limited to one single relative or close friend chosen 
by the patient him or herself. A person who was not chosen to be the “key” 
person to respond to our questionnaires could experience significant levels of 
stigma and/or burden and no conclusion can be made regarding these. Due to 
the limited sample size gender differences could not be studied. This would 
be of relevance since female and male relatives perceive burden differently 
[177]. 
 
The absence of patients receiving LAI antipsychotics may have resulted in an 
underestimation of both non-adherence and stigma as depot injections are 
traditionally more frequently prescribed to patients with apparent difficulties 
following an oral medication regimen [4]. Similarly, patients prescribed an 
LAI often suffer from more severe psychopathological symptoms, which 
might increase the experienced and anticipated stigma in their relatives [178]. 
 
7.3.4 Potential influence of the health care setting 
Most patients were treated in a community psychiatry setting inspired by 
ACT [38, 179]. This mode of working is known to increase adherence to 
antipsychotics [39, 43] and might partly explain the rather high adherence 
rates in this study as well as the relatively high concordance with several 
subjective measures [180]. The majority of patients were treated with active 
case management, including shared decision making and empowerment of 
the patient. Structured psychoeducation (about mental illness and prognosis, 
psychopharmacology, use of illicit substances, stress reduction and strategies 
for recovery and reintegration) is offered to both patients and their relatives 
(or other persons with a significant relation). Case management and ACT 
approaches might reduce symptom burden and thereby stigma [11]. Also, 
ACT has previously been shown to affect relatives in a positive manner 
regarding both burden and satisfaction with care [191, 192]. Still, the 
influence of ACT components on the results of this study is unknown and the 
relationships were not investigated. 
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7.4 Discussion of the results 
7.4.1 Discussion Study I  
The adherence rate was in the higher end of previously reported adherence 
rates [31], but similar to results shown in studies performed in other settings 
using active ACT strategies such as medication management and shared 
decision making [43].  
The high concordance between pill count and MEMS® adherence is 
comparable to results from a smaller 12-week study [2], suggesting that pill 
count has potential as a routine clinical tool. Pill count could be an easy and 
inexpensive tool for monitoring adherence in the clinic. Even if it would 
seem expected that calculations on the two objective methods based on the 
same medication bottle would be similar, other studies have shown low 
correlations [8, 128].  
The low concordance between MEMS® and the plasma level measure is of 
special interest as the use of plasma levels as a sole measure of adherence is 
common in clinical practice. Also, therapeutic drug monitoring (TDM), 
where plasma levels are used to monitor adherence over time is 
recommended by some [181], but most studies supporting TDM are based on 
the use of FGA only. With the increasing use of SGA due to the often more 
acceptable side effect profile, there is an additional concern as very little data 
on what therapeutic  plasma levels to use as a criterion is available [135]. 
Previously it has been shown in a shorter study that plasma levels-to-
medication dose ratios were not consistent over time [2]. Misinterpretation of 
low plasma levels due to non-adherence can lead to an increase in dosage, 
switching or the prescription of additional medications. Patients might also 
run the risk of being falsely identified as treatment resistant. In order to 
conceal complete or partial non-adherence, patients might take their 
medication (i.e. loading doses) only prior to plasma sampling. The large 
discrepancy found between the MEMS® and the plasma level measure in the 
COAST study points to the complexity of interpreting plasma levels. The 
reasons for the observed discordance could be several as explained in the 
limitations section. 
Most of the subjective measures showed fairly good concordance with 
MEMS® adherence, but as expected the adherence rates were overestimated. 
A surprising finding, contrary to previous research [129], was that adherence 
was underestimated by the prescribing psychiatrists. Approximately half of 
the participants were treated at the same outpatient clinic where the research 
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psychiatrist was clinically active at the time of the study. For about half of 
those study patients (25%) the research psychiatrist was also the treating 
psychiatrist and this may have increased adherence rates.   
The high correlations between MEMS® and pill count and the fairly high 
correlation between the MEMS® and the informant and patient ratings 
indicate the usefulness of combining objective and subjective measures as 
well as the value of close informant involvement. 
 7.4.2 Discussion Study II 
Positive drug attitude, as measured by DAI-10, in combination with 
psychosocial functioning (PSP) emerged as the best predictors of MEMS® 
monitored adherence across the 12-month study period. Furthermore, this is 
to the best of our knowledge the first study to analyze the predictive validity 
of the DAI-10 in multiple episode psychosis using an objective adherence 
measure. The DAI-10 had a moderate sensitivity, i.e. the ability to correctly 
identify non-adherent patients, whereas the specificity was rather low. 
According to the data a maximum number of patients can be correctly 
identified as being truly non-adherent at a cut-off of 4, while the number of 
false positives is minimized. Still, one-third of the adherent would falsely be 
identified as non-adherent. Thus, according to our data, more patients with a 
negative drug attitude should have been expected to be non-adherent 
according to MEMS®. Perhaps other compensatory mechanisms, such as 
treatment alliance and shared decision making, increased the adherence rates 
despite negative medication attitude, but this needs to be studied further. 
Psychiatric side effects and positive symptoms increased the odds of non-
adherence. Other studies have shown inconclusive results with either no 
relationship between symptom severity and adherence [141] or relation to 
various PANSS items or domains [182, 183]. Poor insight and non-adherence 
were associated, confirming the findings of others [11, 184]. Insight is an 
unstable and multidimensional trait, and recognizing lack of insight as a 
contributor to non-adherence underlines the importance of regular 
monitoring. Insight can be measured in various ways, including using the 
PANSS (G 12) item [185] as in the COAST study. Our research group has 
previously performed a pilot study comparing PANSS (G 12) to a Swedish 
translation of the Scale to Assess Unawareness of Mental Disorder [184], 
which is a more comprehensive scale. The PANSS came out favorably and 
was much preferred by patients, but further study is needed. 
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Global cognitive function did not predict adherence in our study. The global 
score was used due to a need to reduce the number of variables and the risk 
of false positives, but it might have obscured an association between non-
adherence and specific cognitive domains. Also, it is conceivable that 
cognitive performance fluctuates over time due to disease progress and 
remission status, which in turn may affect adherence. Perhaps cognitive 
decline, rather than level of cognitive function, may be associated with non-
adherence. Even though complex cognitive tasks may be compromised, 
patients with schizophrenia might manage the practicalities of taking their 
medication by developing compensating strategies if the support system is 
sufficient. However, no measure of premorbid cognitive function was 
available. According to the initial protocol it was intended to gather high 
school report cards from the participating patients as a measure for pre-
morbid cognitive function. Unfortunately there were numerous obstacles 
rendering this undoable. Report cards that had been lost by the patients were 
often not obtainable from the central archives or from the specific schools 
where they sometimes were supposed to still be on file. Also, the overall 
grading system had undergone several changes over the years, which made 
comparisons difficult. In addition, a number of patients did not attend 
Swedish schools. 
The informant version of the DAI-10 might provide a useful additional 
assessment. However, the number of close informants who responded to the 
postal questionnaire was limited and further studies are needed.  
7.4.3 Discussion Study III 
To our knowledge this is the first study to employ an objective measure of 
adherence (MEMS®) and a validated stigma scale (DISC). A high proportion 
of the participants reported at least some experienced and anticipated stigma 
and discrimination, especially within the field of social and intimate 
relationships. Stigma and discrimination changes during the course of 
schizophrenia and more stigma has been found as the illness progresses. This 
was confirmed in a very recent international cross-sectional survey of first-
episode schizophrenia [186]. Nine of the 25 first-episode patients from 
Sweden included in that study were also taking part in the COAST study. 
In univariate analysis overcoming stigma was associated with adherence, but 
none of the DISC mean subscale scores were associated with adherence in 
adjusted models when psychosocial function and drug attitude was taken into 
consideration. As in any adherence study, the inclusion criteria and the 
regular monitorings might have introduced a selection bias towards more 
adherent patients. The relatively high adherence rate of 73% might have 
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affected the power of the study to identify an association between stigma and 
non-adherence. 
More than half of the patients reported that they had felt shunned or socially 
excluded. Most of them felt that they had at least some skills to overcome 
stigma. Still, the most common coping strategy seemed to be avoidance of 
social and occupational interactions and concealing the diagnosis due to fear 
of discrimination. This ostensible coping strategy can be an obstacle in 
patient centered rehabilitation, where social integration is considered to be 
central for both work and family life. Social withdrawal due to fear of stigma 
in combination with poor insight into the psychotic illness underlines the 
importance of psychoeducation and flexible approaches and treatment 
strategies in the psychiatric treatment team. 
Discriminatory and stigmatizing views held by psychiatric and general 
medical staff  need further study as they affect quality of care [114]. In line 
with the findings of another recent study [154] we found that one-third of the 
patients felt discriminated against when seeking physical health care and 
approximately half of the patients felt stigmatized by mental health staff. This 
result is concerning as patients with schizophrenia have increased mortality 
rates and are in great need of both access to and trust in psychiatric and 
physical health care. The difficulties encountered in contact with somatic care 
might be partially explained by a lack of knowledge from those professional 
caregivers as well as by fear and misunderstanding of psychiatric 
symptomatology. 
The mean DISC subscale scores were low and similar to those previously 
reported in a study with mixed diagnoses [154]. The need to conceal the 
diagnosis was higher in our study (88%), perhaps partly due to the higher 
education level in the COAST study, as it has been shown that more highly 
educated patients prefer to conceal their diagnosis to a greater degree than 
those with lower education [187]. 
7.4.4 Discussion Study IV 
To the best of our knowledge, this is the first study to employ structured 
instruments to examine the relationship between experiences of both stigma 
and burden in relatives to persons with schizophrenia. Surprisingly few 
relatives (18%) reported personal experiences of stigma, even if almost half 
thought that their ill relative had been stigmatized at least to some extent. Our 
results showed that the impact of stigma on quality of life of the relatives 
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themselves and the family as a whole was associated with higher overall 
burden in adjusted models. 
In the current study the frequencies of associated stigma was relatively low. 
There are numerous possible explanations to this result. Patients were 
recruited from outpatient clinics and most of them were undergoing voluntary 
treatment in a stable phase of their illness both at the time of inclusion and 
during the study year. The remission rate was 60% in the adherent group of 
patients and almost 50% in the non-adherent group as shown in the predictors 
of adherence study (Study II). The relatives that responded to the 
questionnaires might have been less likely to acknowledge stigma than 
relatives of patients in emergency psychiatric treatment settings or members 
of advocacy groups [104, 188]. Study IV is a preplanned part of the larger 
COAST study, which is primarily focused on medication adherence in 
schizophrenia. Therefore there is a likely selection bias towards including 
more adherent, well functioning and less stigmatized patients in Study IV. 
Further, treatment with LAI is traditionally administered to more severely ill 
patients and being on a depot injection was an exclusion criterion in the 
COAST study.  
Also, as was shown in the drop-out analysis, relatives of patients with a more 
severe burden of illness did not participate either due to the patient’s 
unwillingness to identify relatives that might be able to participate, or refusal 
on the part of the relatives themselves. Some patients could not identify a 
relative suitable for participation.  Additionally, the mean duration of illness 
in this study was long (almost two decades), and this would be expected to 
influence the relatives’ experiences of stigma. However, due to the limited 
sample size, it was not feasible to test for interactions with patient age or 
illness duration. Mostly multiple episode patients were included and thus it is 
expected that they would be both more adherent to their medication [6] and 
perhaps report less stigmatizing experiences [186]. Further, less than one-
tenth of the relatives in our study lived together with their ill relative, a 
proportion considerably smaller than (50%) in the ISE test family sample 
[189]. The likelihood of encountering potentially stigmatizing experiences 
will decrease if less time is spent with the ill person, possibly explaining the 
relatively low rate of anticipated stigma in our study.  
Regarding burden in relatives, the mean BIRP score in the current study 
(14.2) was similar to that (14.8) reported for the “moderate burden” group of 
relatives to persons with psychosis in a study carried out by developers of the 
scale in a neighboring region of Sweden [175]. Relatives’ burden was related 
to stigma impact on a variety of psychosocial factors including family 
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thought that their ill relative had been stigmatized at least to some extent. Our 
results showed that the impact of stigma on quality of life of the relatives 
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themselves and the family as a whole was associated with higher overall 
burden in adjusted models. 
In the current study the frequencies of associated stigma was relatively low. 
There are numerous possible explanations to this result. Patients were 
recruited from outpatient clinics and most of them were undergoing voluntary 
treatment in a stable phase of their illness both at the time of inclusion and 
during the study year. The remission rate was 60% in the adherent group of 
patients and almost 50% in the non-adherent group as shown in the predictors 
of adherence study (Study II). The relatives that responded to the 
questionnaires might have been less likely to acknowledge stigma than 
relatives of patients in emergency psychiatric treatment settings or members 
of advocacy groups [104, 188]. Study IV is a preplanned part of the larger 
COAST study, which is primarily focused on medication adherence in 
schizophrenia. Therefore there is a likely selection bias towards including 
more adherent, well functioning and less stigmatized patients in Study IV. 
Further, treatment with LAI is traditionally administered to more severely ill 
patients and being on a depot injection was an exclusion criterion in the 
COAST study.  
Also, as was shown in the drop-out analysis, relatives of patients with a more 
severe burden of illness did not participate either due to the patient’s 
unwillingness to identify relatives that might be able to participate, or refusal 
on the part of the relatives themselves. Some patients could not identify a 
relative suitable for participation.  Additionally, the mean duration of illness 
in this study was long (almost two decades), and this would be expected to 
influence the relatives’ experiences of stigma. However, due to the limited 
sample size, it was not feasible to test for interactions with patient age or 
illness duration. Mostly multiple episode patients were included and thus it is 
expected that they would be both more adherent to their medication [6] and 
perhaps report less stigmatizing experiences [186]. Further, less than one-
tenth of the relatives in our study lived together with their ill relative, a 
proportion considerably smaller than (50%) in the ISE test family sample 
[189]. The likelihood of encountering potentially stigmatizing experiences 
will decrease if less time is spent with the ill person, possibly explaining the 
relatively low rate of anticipated stigma in our study.  
Regarding burden in relatives, the mean BIRP score in the current study 
(14.2) was similar to that (14.8) reported for the “moderate burden” group of 
relatives to persons with psychosis in a study carried out by developers of the 
scale in a neighboring region of Sweden [175]. Relatives’ burden was related 
to stigma impact on a variety of psychosocial factors including family 
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relations, social contacts and self-esteem. The mechanisms of these 
associations cannot be clarified with the present study design. The lack of 
association between experienced stigma and burden was unexpected and 
might in part be a power issue, but also related to the fact that the ISE 
question picks up on frequency but not intensity. Data for relatives was 
available for only half of the patients who took part in the COAST study and 
among these the number acknowledging stigma experiences was lower than 
anticipated. This further reduced the possibility of detecting significant 
associations. Finally, many of the participating relatives were part of case 
management programs with ACT approaches, such as psychoeducation and 
stress management [190], which are known to decrease burden and positively 
affect satisfaction with care [191, 192]. 
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8. CONCLUSIONS 
In order to help improve the lives of persons with schizophrenia and their 
relatives or other informal caregivers there is a need for an increased 
understanding of both adherence and the impact of stigma and discrimination 
on the course of the illness. The consequences of stigma, such as social 
exclusion, shame and denial of optimal care, seriously impacts on the lives of 
those affected. Also, patients need to receive optimal and individualized 
antipsychotic medication as part of person-centered treatment to improve 
outcome. Oral medication is still preferred by many patients and 
professionals alike, even though the introduction of long-acting depot 
injectables in most cases is superior for adherence. Further research in this 
field is needed to optimize medical treatment and to continuously improve 
psychiatric care. 
The COAST study showed that pill count has obvious advantages for 
measuring adherence, whereas occasional plasma samples probably are not 
true reflections of adherence. The high correlation between pill count and 
MEMS® underlines the importance of continuous clinical monitoring of 
antipsychotics in outpatient settings. Pill count is inexpensive and requires no 
advanced technical equipment. Regular visits to a health care professional 
can promote patient alliance, and may include not only pill count but also 
special focus on side effects and psychoeducation regarding adherence. Pill 
counts can be conducted in all health care settings in conjunction with self-
rated adherence. Smart pill-boxes with reminder functions could also be of 
clinical value as they are similar to the MEMS® bottle, which most patients in 
the study found positive to use. Many study participants expressed that they 
wanted to continue using the MEMS® bottle even after the study ended. 
The study showed that DAI-10 is a predictor of adherence together with 
psychosocial function, but that DAI alone or even combined with measures 
of function, symptoms or psychiatric side effects achieved only a moderate 
level of discrimination between adherence and non-adherence to 
antipsychotic treatment. No conclusion can be made about the temporal 
relationship between the predictors of adherence and medication taking due 
to the inclusion of only baseline data. Still, the DAI-10 inventory is an easily 
performed self-rating scale that patients in the clinical setting appreciate as it 
focuses on potential and otherwise often neglected adverse experiences of 
antipsychotics. It might be used as a screening tool indicating the need for 
more extensive ratings, such as regarding side effects, symptomatology, etc. 
Drug attitude, together with other clinical predictors identified to be related to 
non-adherence, might also indicate when patients need to be offered 
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adherence promoting strategies, for example through motivational 
interviewing, alliance enhancing methods, pill counts and computerized 
reminders. 
Furthermore, the study showed that almost two-thirds of the participants felt 
discriminated against within the area of social relationships and half felt 
discriminated by mental health staff and in employment-related situations. 
Anticipated discrimination caused more than half of the participants to limit 
their activities and to conceal their diagnosis. An association between stigma 
and adherence was not found in the current study, but the relationship needs 
to be investigated further in other contexts.  
Stigma was not only shown to impact patients with schizophrenia, but also 
the quality of life of their relatives and this was associated with overall 
burden. Increased awareness on the part of service providers may decrease 
the impact of stigma in relatives, but relationships need to be examined in 
larger studies in diverse cultures and treatment settings. 
In conclusion, measuring and predicting non-adherence is complex. Regular 
monitorings of adherence using an objective measure, such as pill count, 
might be of clinical use. The large discrepancy between MEMS® and the 
plasma level measure needs to be studied further. Positive drug attitude, in 
combination with good psychosocial function, emerged as the best predictors 
of MEMS® monitored adherence across the one-year study period. 
Associations were found neither between stigma and adherence nor relatives’ 
stigma and burden, and further studies are needed. 
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9. FUTURE PERSPECTIVES 
Based on the results presented in this thesis the following proposed future 
avenues should be pursued: 
 
• The relationship between schizophrenia, adherence and various 
aspects of cognition needs to be investigated further based on the 
COAST database and other datasets. 
 
• Further study and validation of the modified informant version of 
DAI-10 in larger populations and in various social and cultural 
contexts need to be undertaken. The same version of the informant 
scale is currently being used in the UK as part of collaborative studies 
between the respondent/University of Gothenburg and the University 
of Manchester. 
 
• The respondent is an elected member of the World Psychiatric 
Association (WPA), Scientific Section of Stigma and Mental Health. 
The main focus of the WPA network is research within the areas of 
stigma and the evaluation, promotion and implementation of evidence 
based practices in psychiatry. Collaborative studies are ongoing with 
the WPA group through the Institute of Psychiatry in London and the 
Association for Improvement of the Mental Health Programmes, 
Geneva.  
 
• The impact of the Swedish version of ACT used at the clinics taking 
part in the COAST study (so-called Integrated Psychiatry with the 
Resource Group as a central component for person-centered case 
management) on non-adherence rates and cost of schizophrenia need 
to be investigated further. Such studies would be in line with the 
increasing international interest in person-centered care, where 
persons with chronic illnesses are placed in a context at the center of 
health care rather than being considered just as carriers of illness. 
According to the 2012 Geneva Declaration on Person-centered Care 
for Chronic Diseases [193] this view may also help de-stigmatize 
persons affected and those who care for them. The ingredients of ACT 
thus need to be studied in various settings. 
 
 
66 
 
adherence promoting strategies, for example through motivational 
interviewing, alliance enhancing methods, pill counts and computerized 
reminders. 
Furthermore, the study showed that almost two-thirds of the participants felt 
discriminated against within the area of social relationships and half felt 
discriminated by mental health staff and in employment-related situations. 
Anticipated discrimination caused more than half of the participants to limit 
their activities and to conceal their diagnosis. An association between stigma 
and adherence was not found in the current study, but the relationship needs 
to be investigated further in other contexts.  
Stigma was not only shown to impact patients with schizophrenia, but also 
the quality of life of their relatives and this was associated with overall 
burden. Increased awareness on the part of service providers may decrease 
the impact of stigma in relatives, but relationships need to be examined in 
larger studies in diverse cultures and treatment settings. 
In conclusion, measuring and predicting non-adherence is complex. Regular 
monitorings of adherence using an objective measure, such as pill count, 
might be of clinical use. The large discrepancy between MEMS® and the 
plasma level measure needs to be studied further. Positive drug attitude, in 
combination with good psychosocial function, emerged as the best predictors 
of MEMS® monitored adherence across the one-year study period. 
Associations were found neither between stigma and adherence nor relatives’ 
stigma and burden, and further studies are needed. 
 
 67 
 
9. FUTURE PERSPECTIVES 
Based on the results presented in this thesis the following proposed future 
avenues should be pursued: 
 
• The relationship between schizophrenia, adherence and various 
aspects of cognition needs to be investigated further based on the 
COAST database and other datasets. 
 
• Further study and validation of the modified informant version of 
DAI-10 in larger populations and in various social and cultural 
contexts need to be undertaken. The same version of the informant 
scale is currently being used in the UK as part of collaborative studies 
between the respondent/University of Gothenburg and the University 
of Manchester. 
 
• The respondent is an elected member of the World Psychiatric 
Association (WPA), Scientific Section of Stigma and Mental Health. 
The main focus of the WPA network is research within the areas of 
stigma and the evaluation, promotion and implementation of evidence 
based practices in psychiatry. Collaborative studies are ongoing with 
the WPA group through the Institute of Psychiatry in London and the 
Association for Improvement of the Mental Health Programmes, 
Geneva.  
 
• The impact of the Swedish version of ACT used at the clinics taking 
part in the COAST study (so-called Integrated Psychiatry with the 
Resource Group as a central component for person-centered case 
management) on non-adherence rates and cost of schizophrenia need 
to be investigated further. Such studies would be in line with the 
increasing international interest in person-centered care, where 
persons with chronic illnesses are placed in a context at the center of 
health care rather than being considered just as carriers of illness. 
According to the 2012 Geneva Declaration on Person-centered Care 
for Chronic Diseases [193] this view may also help de-stigmatize 
persons affected and those who care for them. The ingredients of ACT 
thus need to be studied in various settings. 
 
 
68 
 
ACKNOWLEDGEMENTS 
I wish to thank everybody that contributed to this doctoral thesis. Especially: 
Participating patients and their relatives for kindly taking part in this study. 
Gittan Sameby and Katarina Allerby; research nurses, study coordinators, and 
co-authors, without whom this study would have been impossible. 
Senior supervisor Margda Waern for her thoroughness, her quick feedback, 
her high bar and for daring to take on a big schizophrenia project. 
Co-supervisors: Tom Burns, for his guest professorship and creating a 
concrete support structure; Eva Lindström and Jonas Eberhard, who both had 
very individual ways of contributing to the study.  
 
Pia Rydell and Sahlgrenska University Hospital for facilitating the study; 
Lennart Lundin, Henriette Noole and all generosity from contributing staff. 
Patrick Quinlan, for co-authorship and support. Co-authors Ulla Karilampi, 
Erik Joas and Nils Sjöström. Gunnar Edman, Erik Joas and Tom Marlow for 
statistical support. Birgitta Rembeck, Inga-Britt Bogren and Lydia Melchior. 
Magdalena Ahnsberg for initiating optimism and the Swedish Schizophrenia 
Fellowship (Schizofreniförbundet) for supporting a common cause. 
Professors Norman Sartorius, Graham Thornicroft and Heather Stuart for 
many years of encouragement and collaboration. 
Nå Ut-teamet, my dear home base for one and a half decade. 
My beloved husband Gary and daughter Celeste for all your support and for 
bearing with me throughout this project. 
My family and friends. 
Finally, the funders of this thesis: The Swedish Research Council (grant No. 
K2009-62X-21079-01-3), the Gothenburg Center for Person Centered Care, 
the Söderström-Königska Foundation (2008-21951, SLS-232731), 
Psykiatrifonden, and the LUA/ALF agreement for biomedical research and 
by unrestricted investigator initiated trial grants from Lundbeck, Eli Lilly, 
Janssen, and AstraZeneca. 
 
 69 
 
REFERENCES 
1. National Institute for Health and Clinical Excellence. Medicines 
adherence : involving patients in decisions about prescribed medicines 
and supporting adherence. NICE clinical guideline 76. January 2009; 
Available from: http://www.nice.org.uk/guidance/CG76. Accessed 
December 1, 2014. 
2. Velligan, D.I., et al., Relationships among subjective and objective 
measures of adherence to oral antipsychotic medications. Psychiatric 
services, 2007. 58(9): p. 1187-92. 
3. Sabaté, E. and World Health Organization. Adherence to long-term 
therapies evidence for action. 2003; Available from: 
http://www.emro.who.int/ncd/Publications/adherence_report.pdf, 
Accessed November 29, 2014. 
4. Haddad, P.M., C. Brain, and J. Scott, Nonadherence with antipsychotic 
medication in schizophrenia: challenges and management strategies. 
Patient Related Outcome Measures, 2014. 5: p. 43-62. 
5. DiMatteo, M.R., Variations in patients' adherence to medical 
recommendations: a quantitative review of 50 years of research. 
Medical care, 2004. 42(3): p. 200-9. 
6. Lacro, J.P., et al., Prevalence of and risk factors for medication 
nonadherence in patients with schizophrenia: a comprehensive review 
of recent literature. The Journal of clinical psychiatry, 2002. 63(10): p. 
892-909. 
7. Vita, A., et al., Factors related to different reasons for antipsychotic 
drug discontinuation in the treatment of schizophrenia: A naturalistic 
18-month follow-up study. Psychiatry research, 2012. 200(2–3): p. 96-
101. 
8. Remington, G., et al., The use of electronic monitoring (MEMS®) to 
evaluate antipsychotic compliance in outpatients with schizophrenia. 
Schizophrenia Research, 2007. 90(1–3): p. 229-237. 
9. Karve, S., et al., Good and poor adherence: optimal cut-point for 
adherence measures using administrative claims data. Current medical 
research and opinion, 2009. 25(9): p. 2303-10. 
68 
 
ACKNOWLEDGEMENTS 
I wish to thank everybody that contributed to this doctoral thesis. Especially: 
Participating patients and their relatives for kindly taking part in this study. 
Gittan Sameby and Katarina Allerby; research nurses, study coordinators, and 
co-authors, without whom this study would have been impossible. 
Senior supervisor Margda Waern for her thoroughness, her quick feedback, 
her high bar and for daring to take on a big schizophrenia project. 
Co-supervisors: Tom Burns, for his guest professorship and creating a 
concrete support structure; Eva Lindström and Jonas Eberhard, who both had 
very individual ways of contributing to the study.  
 
Pia Rydell and Sahlgrenska University Hospital for facilitating the study; 
Lennart Lundin, Henriette Noole and all generosity from contributing staff. 
Patrick Quinlan, for co-authorship and support. Co-authors Ulla Karilampi, 
Erik Joas and Nils Sjöström. Gunnar Edman, Erik Joas and Tom Marlow for 
statistical support. Birgitta Rembeck, Inga-Britt Bogren and Lydia Melchior. 
Magdalena Ahnsberg for initiating optimism and the Swedish Schizophrenia 
Fellowship (Schizofreniförbundet) for supporting a common cause. 
Professors Norman Sartorius, Graham Thornicroft and Heather Stuart for 
many years of encouragement and collaboration. 
Nå Ut-teamet, my dear home base for one and a half decade. 
My beloved husband Gary and daughter Celeste for all your support and for 
bearing with me throughout this project. 
My family and friends. 
Finally, the funders of this thesis: The Swedish Research Council (grant No. 
K2009-62X-21079-01-3), the Gothenburg Center for Person Centered Care, 
the Söderström-Königska Foundation (2008-21951, SLS-232731), 
Psykiatrifonden, and the LUA/ALF agreement for biomedical research and 
by unrestricted investigator initiated trial grants from Lundbeck, Eli Lilly, 
Janssen, and AstraZeneca. 
 
 69 
 
REFERENCES 
1. National Institute for Health and Clinical Excellence. Medicines 
adherence : involving patients in decisions about prescribed medicines 
and supporting adherence. NICE clinical guideline 76. January 2009; 
Available from: http://www.nice.org.uk/guidance/CG76. Accessed 
December 1, 2014. 
2. Velligan, D.I., et al., Relationships among subjective and objective 
measures of adherence to oral antipsychotic medications. Psychiatric 
services, 2007. 58(9): p. 1187-92. 
3. Sabaté, E. and World Health Organization. Adherence to long-term 
therapies evidence for action. 2003; Available from: 
http://www.emro.who.int/ncd/Publications/adherence_report.pdf, 
Accessed November 29, 2014. 
4. Haddad, P.M., C. Brain, and J. Scott, Nonadherence with antipsychotic 
medication in schizophrenia: challenges and management strategies. 
Patient Related Outcome Measures, 2014. 5: p. 43-62. 
5. DiMatteo, M.R., Variations in patients' adherence to medical 
recommendations: a quantitative review of 50 years of research. 
Medical care, 2004. 42(3): p. 200-9. 
6. Lacro, J.P., et al., Prevalence of and risk factors for medication 
nonadherence in patients with schizophrenia: a comprehensive review 
of recent literature. The Journal of clinical psychiatry, 2002. 63(10): p. 
892-909. 
7. Vita, A., et al., Factors related to different reasons for antipsychotic 
drug discontinuation in the treatment of schizophrenia: A naturalistic 
18-month follow-up study. Psychiatry research, 2012. 200(2–3): p. 96-
101. 
8. Remington, G., et al., The use of electronic monitoring (MEMS®) to 
evaluate antipsychotic compliance in outpatients with schizophrenia. 
Schizophrenia Research, 2007. 90(1–3): p. 229-237. 
9. Karve, S., et al., Good and poor adherence: optimal cut-point for 
adherence measures using administrative claims data. Current medical 
research and opinion, 2009. 25(9): p. 2303-10. 
70 
 
10. Velligan, D.I., et al., Assessment of adherence problems in patients 
with serious and persistent mental illness: recommendations from the 
Expert Consensus Guidelines. Journal of psychiatric practice, 2010. 
16(1): p. 34-45. 
11. Velligan, D.I., et al., The expert consensus guideline series: adherence 
problems in patients with serious and persistent mental illness. J Clin 
Psychiatry, 2009. 70 Suppl 4: p. 1-46; quiz 47-8. 
12. Acosta, F.J., Y. Ramallo-Farina, and S.G. Siris, Should full adherence 
be a necessary goal in schizophrenia? Full versus non-full adherence 
to antipsychotic treatment. Comprehensive psychiatry, 2014. 55(1): p. 
33-9. 
13. Becker, M.H. and L.A. Maiman, Sociobehavioral determinants of 
compliance with health and medical care recommendations. Medical 
care, 1975. 13(1): p. 10-24. 
14. Horne, R. and J. Weinman, Patients' beliefs about prescribed 
medicines and their role in adherence to treatment in chronic physical 
illness. Journal of psychosomatic research, 1999. 47(6): p. 555-67. 
15. Lerner, B.H., From careless consumptives to recalcitrant patients: the 
historical construction of noncompliance. Social science & medicine, 
1997. 45(9): p. 1423-31. 
16. Carrick, P., Medical ethics in the ancient world. 2001, Washington, 
D.C.: Georgetown University Press. 
17. Mohler, D.N., D.G. Wallin, and E.G. Dreyfus, Studies in the home 
treatment of streptococcal disease. I. Failure of patients to take 
penicillin by mouth as prescribed. The New England journal of 
medicine, 1955. 252(26): p. 1116-8. 
18. Valenstein, M., et al., Antipsychotic adherence over time among 
patients receiving treatment for schizophrenia: a retrospective review. 
The Journal of clinical psychiatry, 2006. 67(10): p. 1542-50. 
19. Mathers, C., et al. The global burden of disease 2004 update. 2008; 
Available from: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_20
04update_full.pdf. Accessed December 5, 2014. 
 
 71 
 
20. Heinz, A., L. Deserno, and U. Reininghaus, Urbanicity, social 
adversity and psychosis. World psychiatry : official journal of the 
World Psychiatric Association, 2013. 12(3): p. 187-97. 
21. Emsley, R., B. Chiliza, and L. Asmal, The evidence for illness 
progression after relapse in schizophrenia. Schizophrenia research, 
2013. 148(1-3): p. 117-21. 
22. Burns, T., Evolution of outcome measures in schizophrenia. The 
British journal of psychiatry. Supplement, 2007. 50: p. s1-6. 
23. van Os, J., et al., Standardized remission criteria in schizophrenia. 
Acta psychiatrica Scandinavica, 2006. 113(2): p. 91-5. 
24. Burns, T., Our necessary shadow : the nature and meaning of 
psychiatry. 2013: London : Allen Lane. 
25. Gaebel, W., et al., Stigmatization of psychiatrists and general 
practitioners: results of an international survey. Eur Arch Psychiatry 
Clin Neurosci, Epub ahead of print, Sep 6, 2014. 
26. Sartorius, N., et al., WPA guidance on how to combat stigmatization of 
psychiatry and psychiatrists. World Psychiatry, 2010. 9(3): p. 131-44. 
27. Leucht, S., et al., Defining 'response' in antipsychotic drug trials: 
recommendations for the use of scale-derived cutoffs. 
Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology, 2007. 32(9): p. 1903-10. 
28. Leucht, S., et al., Putting the efficacy of psychiatric and general 
medicine medication into perspective: review of meta-analyses. The 
British journal of psychiatry : the journal of mental science, 2012. 
200(2): p. 97-106. 
29. Tiihonen, J., et al., 11-year follow-up of mortality in patients with 
schizophrenia: a population-based cohort study (FIN11 study). Lancet, 
2009. 374(9690): p. 620-7. 
30. Leucht, S., et al., Antipsychotic drugs versus placebo for relapse 
prevention in schizophrenia: a systematic review and meta-analysis. 
Lancet, 2012. 379(9831): p. 2063-71. 
 
70 
 
10. Velligan, D.I., et al., Assessment of adherence problems in patients 
with serious and persistent mental illness: recommendations from the 
Expert Consensus Guidelines. Journal of psychiatric practice, 2010. 
16(1): p. 34-45. 
11. Velligan, D.I., et al., The expert consensus guideline series: adherence 
problems in patients with serious and persistent mental illness. J Clin 
Psychiatry, 2009. 70 Suppl 4: p. 1-46; quiz 47-8. 
12. Acosta, F.J., Y. Ramallo-Farina, and S.G. Siris, Should full adherence 
be a necessary goal in schizophrenia? Full versus non-full adherence 
to antipsychotic treatment. Comprehensive psychiatry, 2014. 55(1): p. 
33-9. 
13. Becker, M.H. and L.A. Maiman, Sociobehavioral determinants of 
compliance with health and medical care recommendations. Medical 
care, 1975. 13(1): p. 10-24. 
14. Horne, R. and J. Weinman, Patients' beliefs about prescribed 
medicines and their role in adherence to treatment in chronic physical 
illness. Journal of psychosomatic research, 1999. 47(6): p. 555-67. 
15. Lerner, B.H., From careless consumptives to recalcitrant patients: the 
historical construction of noncompliance. Social science & medicine, 
1997. 45(9): p. 1423-31. 
16. Carrick, P., Medical ethics in the ancient world. 2001, Washington, 
D.C.: Georgetown University Press. 
17. Mohler, D.N., D.G. Wallin, and E.G. Dreyfus, Studies in the home 
treatment of streptococcal disease. I. Failure of patients to take 
penicillin by mouth as prescribed. The New England journal of 
medicine, 1955. 252(26): p. 1116-8. 
18. Valenstein, M., et al., Antipsychotic adherence over time among 
patients receiving treatment for schizophrenia: a retrospective review. 
The Journal of clinical psychiatry, 2006. 67(10): p. 1542-50. 
19. Mathers, C., et al. The global burden of disease 2004 update. 2008; 
Available from: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_20
04update_full.pdf. Accessed December 5, 2014. 
 
 71 
 
20. Heinz, A., L. Deserno, and U. Reininghaus, Urbanicity, social 
adversity and psychosis. World psychiatry : official journal of the 
World Psychiatric Association, 2013. 12(3): p. 187-97. 
21. Emsley, R., B. Chiliza, and L. Asmal, The evidence for illness 
progression after relapse in schizophrenia. Schizophrenia research, 
2013. 148(1-3): p. 117-21. 
22. Burns, T., Evolution of outcome measures in schizophrenia. The 
British journal of psychiatry. Supplement, 2007. 50: p. s1-6. 
23. van Os, J., et al., Standardized remission criteria in schizophrenia. 
Acta psychiatrica Scandinavica, 2006. 113(2): p. 91-5. 
24. Burns, T., Our necessary shadow : the nature and meaning of 
psychiatry. 2013: London : Allen Lane. 
25. Gaebel, W., et al., Stigmatization of psychiatrists and general 
practitioners: results of an international survey. Eur Arch Psychiatry 
Clin Neurosci, Epub ahead of print, Sep 6, 2014. 
26. Sartorius, N., et al., WPA guidance on how to combat stigmatization of 
psychiatry and psychiatrists. World Psychiatry, 2010. 9(3): p. 131-44. 
27. Leucht, S., et al., Defining 'response' in antipsychotic drug trials: 
recommendations for the use of scale-derived cutoffs. 
Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology, 2007. 32(9): p. 1903-10. 
28. Leucht, S., et al., Putting the efficacy of psychiatric and general 
medicine medication into perspective: review of meta-analyses. The 
British journal of psychiatry : the journal of mental science, 2012. 
200(2): p. 97-106. 
29. Tiihonen, J., et al., 11-year follow-up of mortality in patients with 
schizophrenia: a population-based cohort study (FIN11 study). Lancet, 
2009. 374(9690): p. 620-7. 
30. Leucht, S., et al., Antipsychotic drugs versus placebo for relapse 
prevention in schizophrenia: a systematic review and meta-analysis. 
Lancet, 2012. 379(9831): p. 2063-71. 
 
72 
 
31. Kane, J.M., T. Kishimoto, and C.U. Correll, Non-adherence to 
medication in patients with psychotic disorders: epidemiology, 
contributing factors and management strategies. World psychiatry : 
official journal of the World Psychiatric Association, 2013. 12(3): p. 
216-26. 
32. Jaaskelainen, E., et al., A systematic review and meta-analysis of 
recovery in schizophrenia. Schizophrenia bulletin, 2013. 39(6): p. 
1296-306. 
33. Llorca, P.M., Partial compliance in schizophrenia and the impact on 
patient outcomes. Psychiatry research, 2008. 161(2): p. 235-47. 
34. Masand, P.S., et al., Partial adherence to antipsychotic medication 
impacts the course of illness in patients with schizophrenia: a review. 
Prim Care Companion J Clin Psychiatry, 2009. 11(4): p. 147-54. 
35. Sampson, S., The Cochrane Database of Systematic Reviews - Issue 7 
2013. JEBM Journal of Evidence-Based Medicine, 2013. 6(3): p. 197-
198. 
36. Staring, A.B.P., M. Van der Gaag, and C.L. Mulder, Schizophrenia 
and antipsychotic medication — Better adherence, better outcomes? 
Schizophrenia Research, 2013. 151(1–3): p. 296-297. 
37. Weiden, P.J., Understanding and addressing adherence issues in 
schizophrenia: from theory to practice. The Journal of clinical 
psychiatry, 2007. 68 Suppl 14: p. 14-9. 
38. Malm, U.I., B.A. Ivarsson, and P. Allebeck, Durability of the efficacy 
of integrated care in schizophrenia: a five-year randomized controlled 
study. Psychiatric services, 2014. 65(8): p. 1054-7. 
39. Zygmunt, A., et al., Interventions to improve medication adherence in 
schizophrenia. The American journal of psychiatry, 2002. 159(10): p. 
1653-64. 
40. Morosini, P.L., et al., Development, reliability and acceptability of a 
new version of the DSM-IV Social and Occupational Functioning 
Assessment Scale (SOFAS) to assess routine social functioning. Acta 
psychiatrica Scandinavica, 2000. 101(4): p. 323-9. 
 
 
 73 
 
41. Schottle, D., et al., Integrated care in patients with schizophrenia: 
results of trials published between 2011 and 2013 focusing on 
effectiveness and efficiency. Current opinion in psychiatry, 2013. 26(4): 
p. 384-408. 
42. Seeman, M.V. and N. Seeman, The meaning of antipsychotic 
medication to patients with schizophrenia. Journal of psychiatric 
practice, 2012. 18(5): p. 338-48. 
43. Shuler, K.M., Approaches to improve adherence to pharmacotherapy 
in patients with schizophrenia. Patient preference and adherence, 2014. 
8: p. 701-14. 
44. Flyckt, L., et al., Burden of informal care giving to patients with 
psychoses: a descriptive and methodological study. Int J Soc 
Psychiatry, 2013. 59(2): p. 137-46. 
45. Leucht, S., et al., Second-generation versus first-generation 
antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009. 
373(9657): p. 31-41. 
46. Dolder, C.R., et al., Antipsychotic medication adherence: is there a 
difference between typical and atypical agents? The American journal 
of psychiatry, 2002. 159(1): p. 103-8. 
47. Menzin, J., et al., Treatment adherence associated with conventional 
and atypical antipsychotics in a large state Medicaid program. 
Psychiatric services, 2003. 54(5): p. 719-23. 
48. Kishimoto, T., et al., Relapse prevention in schizophrenia: a systematic 
review and meta-analysis of second-generation antipsychotics versus 
first-generation antipsychotics. Molecular psychiatry, 2013. 18(1): p. 
53-66. 
49. Naber, D. and M. Lambert, The CATIE and CUtLASS studies in 
schizophrenia: results and implications for clinicians. CNS Drugs, 
2009. 23(8): p. 649-59. 
50. Weinmann, S., J. Read, and V. Aderhold, Influence of antipsychotics 
on mortality in schizophrenia: systematic review. Schizophrenia 
research, 2009. 113(1): p. 1-11. 
51. Bushe, C.J., M. Taylor, and J. Haukka, Mortality in schizophrenia: a 
measurable clinical endpoint. Journal of psychopharmacology, 2010. 
24(4 Suppl): p. 17-25. 
72 
 
31. Kane, J.M., T. Kishimoto, and C.U. Correll, Non-adherence to 
medication in patients with psychotic disorders: epidemiology, 
contributing factors and management strategies. World psychiatry : 
official journal of the World Psychiatric Association, 2013. 12(3): p. 
216-26. 
32. Jaaskelainen, E., et al., A systematic review and meta-analysis of 
recovery in schizophrenia. Schizophrenia bulletin, 2013. 39(6): p. 
1296-306. 
33. Llorca, P.M., Partial compliance in schizophrenia and the impact on 
patient outcomes. Psychiatry research, 2008. 161(2): p. 235-47. 
34. Masand, P.S., et al., Partial adherence to antipsychotic medication 
impacts the course of illness in patients with schizophrenia: a review. 
Prim Care Companion J Clin Psychiatry, 2009. 11(4): p. 147-54. 
35. Sampson, S., The Cochrane Database of Systematic Reviews - Issue 7 
2013. JEBM Journal of Evidence-Based Medicine, 2013. 6(3): p. 197-
198. 
36. Staring, A.B.P., M. Van der Gaag, and C.L. Mulder, Schizophrenia 
and antipsychotic medication — Better adherence, better outcomes? 
Schizophrenia Research, 2013. 151(1–3): p. 296-297. 
37. Weiden, P.J., Understanding and addressing adherence issues in 
schizophrenia: from theory to practice. The Journal of clinical 
psychiatry, 2007. 68 Suppl 14: p. 14-9. 
38. Malm, U.I., B.A. Ivarsson, and P. Allebeck, Durability of the efficacy 
of integrated care in schizophrenia: a five-year randomized controlled 
study. Psychiatric services, 2014. 65(8): p. 1054-7. 
39. Zygmunt, A., et al., Interventions to improve medication adherence in 
schizophrenia. The American journal of psychiatry, 2002. 159(10): p. 
1653-64. 
40. Morosini, P.L., et al., Development, reliability and acceptability of a 
new version of the DSM-IV Social and Occupational Functioning 
Assessment Scale (SOFAS) to assess routine social functioning. Acta 
psychiatrica Scandinavica, 2000. 101(4): p. 323-9. 
 
 
 73 
 
41. Schottle, D., et al., Integrated care in patients with schizophrenia: 
results of trials published between 2011 and 2013 focusing on 
effectiveness and efficiency. Current opinion in psychiatry, 2013. 26(4): 
p. 384-408. 
42. Seeman, M.V. and N. Seeman, The meaning of antipsychotic 
medication to patients with schizophrenia. Journal of psychiatric 
practice, 2012. 18(5): p. 338-48. 
43. Shuler, K.M., Approaches to improve adherence to pharmacotherapy 
in patients with schizophrenia. Patient preference and adherence, 2014. 
8: p. 701-14. 
44. Flyckt, L., et al., Burden of informal care giving to patients with 
psychoses: a descriptive and methodological study. Int J Soc 
Psychiatry, 2013. 59(2): p. 137-46. 
45. Leucht, S., et al., Second-generation versus first-generation 
antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009. 
373(9657): p. 31-41. 
46. Dolder, C.R., et al., Antipsychotic medication adherence: is there a 
difference between typical and atypical agents? The American journal 
of psychiatry, 2002. 159(1): p. 103-8. 
47. Menzin, J., et al., Treatment adherence associated with conventional 
and atypical antipsychotics in a large state Medicaid program. 
Psychiatric services, 2003. 54(5): p. 719-23. 
48. Kishimoto, T., et al., Relapse prevention in schizophrenia: a systematic 
review and meta-analysis of second-generation antipsychotics versus 
first-generation antipsychotics. Molecular psychiatry, 2013. 18(1): p. 
53-66. 
49. Naber, D. and M. Lambert, The CATIE and CUtLASS studies in 
schizophrenia: results and implications for clinicians. CNS Drugs, 
2009. 23(8): p. 649-59. 
50. Weinmann, S., J. Read, and V. Aderhold, Influence of antipsychotics 
on mortality in schizophrenia: systematic review. Schizophrenia 
research, 2009. 113(1): p. 1-11. 
51. Bushe, C.J., M. Taylor, and J. Haukka, Mortality in schizophrenia: a 
measurable clinical endpoint. Journal of psychopharmacology, 2010. 
24(4 Suppl): p. 17-25. 
74 
 
52. Dean, C.E. and P.D. Thuras, Mortality and tardive dyskinesia: long-
term study using the US National Death Index. The British journal of 
psychiatry : the journal of mental science, 2009. 194(4): p. 360-4. 
53. McEvoy, J.P., et al., Prevalence of the metabolic syndrome in patients 
with schizophrenia: baseline results from the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) schizophrenia trial and 
comparison with national estimates from NHANES III. Schizophrenia 
research, 2005. 80(1): p. 19-32. 
54. Tiihonen, J., et al., Effectiveness of antipsychotic treatments in a 
nationwide cohort of patients in community care after first 
hospitalisation due to schizophrenia and schizoaffective disorder: 
observational follow-up study. BMJ, 2006. 333(7561): p. 224. 
55. Tiihonen, J., et al., A nationwide cohort study of oral and depot 
antipsychotics after first hospitalization for schizophrenia. The 
American journal of psychiatry, 2011. 168(6): p. 603-9. 
56. Tiihonen, J., et al., Polypharmacy with antipsychotics, antidepressants, 
or benzodiazepines and mortality in schizophrenia. Archives of general 
psychiatry, 2012. 69(5): p. 476-83. 
57. Leucht, S., et al., Comparative efficacy and tolerability of 15 
antipsychotic drugs in schizophrenia: a multiple-treatments meta-
analysis. Lancet, 2013. 382(9896): p. 951-62. 
58. Pfeiffer, P., D. Ganoczy, and M. Valenstein, Dosing frequency and 
adherence to antipsychotic medications. Psychiatric services, 2008. 
59(10): p. 1207-1210. 
59. Claxton, A.J., J. Cramer, and C. Pierce, A systematic review of the 
associations between dose regimens and medication compliance. 
Clinical therapeutics, 2001. 23(8): p. 1296-310. 
60. Pitschel-Walz, G., et al., Psychoeducation and compliance in the 
treatment of schizophrenia: results of the Munich Psychosis 
Information Project Study. The Journal of clinical psychiatry, 2006. 
67(3): p. 443-52. 
61. Hamann, J., W. Kissling, and S. Heres, Checking the plausibility of 
psychiatrists arguments for not prescribing depot medication. 
European neuropsychopharmacology : the journal of the European 
College of Neuropsychopharmacology, 2014. 24(9): p. 1506-10. 
 
 75 
 
62. Patel, M.X., et al., Psychiatrists' use, knowledge and attitudes to first- 
and second-generation antipsychotic long-acting injections: 
comparisons over 5 years. Journal of psychopharmacology, 2010. 
24(10): p. 1473-82. 
63. Kripke, D.F., R.D. Langer, and L.E. Kline, Hypnotics' association with 
mortality or cancer: a matched cohort study. BMJ open, 2012. 2(1): p. 
e000850. 
64. Baandrup, L., et al., Antipsychotic polypharmacy and risk of death 
from natural causes in patients with schizophrenia: a population-based 
nested case-control study. The Journal of clinical psychiatry, 2010. 
71(2): p. 103-8. 
65. Kraepelin, E., Dementia praecox and paraphrenia. 1971, Huntington, 
N.Y.: R.E. Krieger Pub. Co. 
66. Burns, T., A very short introduction. 2006, Oxford: Oxford University 
Press. 
67. Bleuler, E., Dementia praecox, or, The group of schizophrenias. 1950, 
New York: International Universities Press. 
68. Bleuler, M. and R. Bleuler, Dementia praecox oder die Gruppe der 
Schizophrenien: Eugen Bleuler. Br J Psychiatry, 1986. 149: p. 661-2. 
69. Howes, O.D. and R.M. Murray, Schizophrenia: an integrated 
sociodevelopmental-cognitive model. Lancet, 2014. 383(9929): p. 
1677-87. 
70. Tsuang, M.T. and M. Tohen. Textbook in Psychiatric Epidemiology, 
Second Edition. 2002; Available from: 
http://onlinelibrary.wiley.com/book/10.1002/0471234311. Accessed 
December 3, 2014. 
71. Andreasen, N.C., et al., Remission in schizophrenia: proposed criteria 
and rationale for consensus. Am J Psychiatry, 2005. 162(3): p. 441-9. 
72. Lieberman, J.A., et al., The early stages of schizophrenia: speculations 
on pathogenesis, pathophysiology, and therapeutic approaches. 
Biological psychiatry, 2001. 50(11): p. 884-97. 
73. McGrath, J., et al., Schizophrenia: a concise overview of incidence, 
prevalence, and mortality. Epidemiologic reviews, 2008. 30: p. 67-76. 
74 
 
52. Dean, C.E. and P.D. Thuras, Mortality and tardive dyskinesia: long-
term study using the US National Death Index. The British journal of 
psychiatry : the journal of mental science, 2009. 194(4): p. 360-4. 
53. McEvoy, J.P., et al., Prevalence of the metabolic syndrome in patients 
with schizophrenia: baseline results from the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) schizophrenia trial and 
comparison with national estimates from NHANES III. Schizophrenia 
research, 2005. 80(1): p. 19-32. 
54. Tiihonen, J., et al., Effectiveness of antipsychotic treatments in a 
nationwide cohort of patients in community care after first 
hospitalisation due to schizophrenia and schizoaffective disorder: 
observational follow-up study. BMJ, 2006. 333(7561): p. 224. 
55. Tiihonen, J., et al., A nationwide cohort study of oral and depot 
antipsychotics after first hospitalization for schizophrenia. The 
American journal of psychiatry, 2011. 168(6): p. 603-9. 
56. Tiihonen, J., et al., Polypharmacy with antipsychotics, antidepressants, 
or benzodiazepines and mortality in schizophrenia. Archives of general 
psychiatry, 2012. 69(5): p. 476-83. 
57. Leucht, S., et al., Comparative efficacy and tolerability of 15 
antipsychotic drugs in schizophrenia: a multiple-treatments meta-
analysis. Lancet, 2013. 382(9896): p. 951-62. 
58. Pfeiffer, P., D. Ganoczy, and M. Valenstein, Dosing frequency and 
adherence to antipsychotic medications. Psychiatric services, 2008. 
59(10): p. 1207-1210. 
59. Claxton, A.J., J. Cramer, and C. Pierce, A systematic review of the 
associations between dose regimens and medication compliance. 
Clinical therapeutics, 2001. 23(8): p. 1296-310. 
60. Pitschel-Walz, G., et al., Psychoeducation and compliance in the 
treatment of schizophrenia: results of the Munich Psychosis 
Information Project Study. The Journal of clinical psychiatry, 2006. 
67(3): p. 443-52. 
61. Hamann, J., W. Kissling, and S. Heres, Checking the plausibility of 
psychiatrists arguments for not prescribing depot medication. 
European neuropsychopharmacology : the journal of the European 
College of Neuropsychopharmacology, 2014. 24(9): p. 1506-10. 
 
 75 
 
62. Patel, M.X., et al., Psychiatrists' use, knowledge and attitudes to first- 
and second-generation antipsychotic long-acting injections: 
comparisons over 5 years. Journal of psychopharmacology, 2010. 
24(10): p. 1473-82. 
63. Kripke, D.F., R.D. Langer, and L.E. Kline, Hypnotics' association with 
mortality or cancer: a matched cohort study. BMJ open, 2012. 2(1): p. 
e000850. 
64. Baandrup, L., et al., Antipsychotic polypharmacy and risk of death 
from natural causes in patients with schizophrenia: a population-based 
nested case-control study. The Journal of clinical psychiatry, 2010. 
71(2): p. 103-8. 
65. Kraepelin, E., Dementia praecox and paraphrenia. 1971, Huntington, 
N.Y.: R.E. Krieger Pub. Co. 
66. Burns, T., A very short introduction. 2006, Oxford: Oxford University 
Press. 
67. Bleuler, E., Dementia praecox, or, The group of schizophrenias. 1950, 
New York: International Universities Press. 
68. Bleuler, M. and R. Bleuler, Dementia praecox oder die Gruppe der 
Schizophrenien: Eugen Bleuler. Br J Psychiatry, 1986. 149: p. 661-2. 
69. Howes, O.D. and R.M. Murray, Schizophrenia: an integrated 
sociodevelopmental-cognitive model. Lancet, 2014. 383(9929): p. 
1677-87. 
70. Tsuang, M.T. and M. Tohen. Textbook in Psychiatric Epidemiology, 
Second Edition. 2002; Available from: 
http://onlinelibrary.wiley.com/book/10.1002/0471234311. Accessed 
December 3, 2014. 
71. Andreasen, N.C., et al., Remission in schizophrenia: proposed criteria 
and rationale for consensus. Am J Psychiatry, 2005. 162(3): p. 441-9. 
72. Lieberman, J.A., et al., The early stages of schizophrenia: speculations 
on pathogenesis, pathophysiology, and therapeutic approaches. 
Biological psychiatry, 2001. 50(11): p. 884-97. 
73. McGrath, J., et al., Schizophrenia: a concise overview of incidence, 
prevalence, and mortality. Epidemiologic reviews, 2008. 30: p. 67-76. 
76 
 
74. Torrey, E.F., Prevalence studies in schizophrenia. The British journal 
of psychiatry : the journal of mental science, 1987. 150: p. 598-608. 
75. Jorgensen, L., P. Allebeck, and C. Dalman, Prevalence of psychoses in 
Stockholm County--a population-based study using comprehensive 
healthcare registers. Nord J Psychiatry, 2014. 68(1): p. 60-5. 
76. American Psychiatric Association, Diagnostic and statistical manual 
of mental disorders : DSM-IV-TR. 2009, Arlington, VA: American 
Psychiatric Assoc. 
77. Lichtenstein, P., et al., Common genetic determinants of schizophrenia 
and bipolar disorder in Swedish families: a population-based study. 
Lancet, 2009. 373(9659): p. 234-9. 
78. Saha, S., et al., Incidence of schizophrenia does not vary with 
economic status of the country: evidence from a systematic review. 
Social psychiatry and psychiatric epidemiology, 2006. 41(5): p. 338-
40. 
79. World Health Organization. The world health report 2001 mental 
health : new understanding, new hope. 2001; Available from: 
http://www.who.int/whr/2001/en/. Accessed November 30, 2014. 
80. Rossler, W., et al., Size of burden of schizophrenia and psychotic 
disorders. European neuropsychopharmacology : the journal of the 
European College of Neuropsychopharmacology, 2005. 15(4): p. 399-
409. 
81. Gustavsson, A., et al., Cost of disorders of the brain in Europe 2010. 
Eur Neuropsychopharmacol, 2011. 21(10): p. 718-79. 
82. Ekman, M., et al., The societal cost of schizophrenia in Sweden. The 
journal of mental health policy and economics, 2013. 16(1): p. 13-25. 
83. Crump, C., et al., Comorbidities and mortality in persons with 
schizophrenia: a Swedish national cohort study. The American journal 
of psychiatry, 2013. 170(3): p. 324-33. 
84. Thornicroft, G., Shunned : discrimination against people with mental 
illness. 2006, Oxford; New York: Oxford University Press. 
85. Osby, U., et al., Mortality and causes of death in schizophrenia in 
Stockholm county, Sweden. Schizophrenia research, 2000. 45(1-2): p. 
21-8. 
 
 77 
 
86. Popovic, D., et al., Risk factors for suicide in schizophrenia: systematic 
review and clinical recommendations. Acta psychiatrica Scandinavica, 
2014. 130(6): p. 418-26. 
87. Allebeck, P., et al., Are suicide trends among the young reversing? 
Age, period and cohort analyses of suicide rates in Sweden. Acta 
psychiatrica Scandinavica, 1996. 93(1): p. 43-48. 
88. Lindstrom, E., L. Eriksson, and S. Levander, Suicides during 7 years 
among a catchment area cohort of patients with psychoses. Nordic 
journal of psychiatry, 2012. 66(1): p. 8-13. 
89. Kasckow, J., K. Felmet, and S. Zisook, Managing suicide risk in 
patients with schizophrenia. CNS drugs, 2011. 25(2): p. 129-43. 
90. Siris, S.G., Suicide and schizophrenia. Journal of 
psychopharmacology, 2001. 15(2): p. 127-35. 
91. Palmer, B.A., V.S. Pankratz, and J.M. Bostwick, The lifetime risk of 
suicide in schizophrenia: a reexamination. Archives of general 
psychiatry, 2005. 62(3): p. 247-53. 
92. Hor, K. and M. Taylor, Suicide and schizophrenia: a systematic review 
of rates and risk factors. Journal of psychopharmacology, 2010. 24(4 
Suppl): p. 81-90. 
93. Ringback Weitoft, G., et al., Mortality, attempted suicide, re-
hospitalisation and prescription refill for clozapine and other 
antipsychotics in Sweden-a register-based study. 
Pharmacoepidemiology and drug safety, 2014. 23(3): p. 290-8. 
94. Angermeyer, M.C., M. Beck, and H. Matschinger, Determinants of the 
Public's Preference for Social Distance From People With 
Schizophrenia. Canadian Journal of Psychiatry, 2003. 48(10): p. 663-
668. 
95. Corrigan, P.W. On the Stigma of Mental Illness Practical Strategies for 
Research and Social Change. 2004; Available from: 
http://content.apa.org/books/2004-20896-000. Accessed December 3, 
2014. 
96. Read, J., et al., Prejudice and schizophrenia: a review of the 'mental 
illness is an illness like any other' approach. Acta psychiatrica 
Scandinavica, 2006. 114(5): p. 303-18. 
76 
 
74. Torrey, E.F., Prevalence studies in schizophrenia. The British journal 
of psychiatry : the journal of mental science, 1987. 150: p. 598-608. 
75. Jorgensen, L., P. Allebeck, and C. Dalman, Prevalence of psychoses in 
Stockholm County--a population-based study using comprehensive 
healthcare registers. Nord J Psychiatry, 2014. 68(1): p. 60-5. 
76. American Psychiatric Association, Diagnostic and statistical manual 
of mental disorders : DSM-IV-TR. 2009, Arlington, VA: American 
Psychiatric Assoc. 
77. Lichtenstein, P., et al., Common genetic determinants of schizophrenia 
and bipolar disorder in Swedish families: a population-based study. 
Lancet, 2009. 373(9659): p. 234-9. 
78. Saha, S., et al., Incidence of schizophrenia does not vary with 
economic status of the country: evidence from a systematic review. 
Social psychiatry and psychiatric epidemiology, 2006. 41(5): p. 338-
40. 
79. World Health Organization. The world health report 2001 mental 
health : new understanding, new hope. 2001; Available from: 
http://www.who.int/whr/2001/en/. Accessed November 30, 2014. 
80. Rossler, W., et al., Size of burden of schizophrenia and psychotic 
disorders. European neuropsychopharmacology : the journal of the 
European College of Neuropsychopharmacology, 2005. 15(4): p. 399-
409. 
81. Gustavsson, A., et al., Cost of disorders of the brain in Europe 2010. 
Eur Neuropsychopharmacol, 2011. 21(10): p. 718-79. 
82. Ekman, M., et al., The societal cost of schizophrenia in Sweden. The 
journal of mental health policy and economics, 2013. 16(1): p. 13-25. 
83. Crump, C., et al., Comorbidities and mortality in persons with 
schizophrenia: a Swedish national cohort study. The American journal 
of psychiatry, 2013. 170(3): p. 324-33. 
84. Thornicroft, G., Shunned : discrimination against people with mental 
illness. 2006, Oxford; New York: Oxford University Press. 
85. Osby, U., et al., Mortality and causes of death in schizophrenia in 
Stockholm county, Sweden. Schizophrenia research, 2000. 45(1-2): p. 
21-8. 
 
 77 
 
86. Popovic, D., et al., Risk factors for suicide in schizophrenia: systematic 
review and clinical recommendations. Acta psychiatrica Scandinavica, 
2014. 130(6): p. 418-26. 
87. Allebeck, P., et al., Are suicide trends among the young reversing? 
Age, period and cohort analyses of suicide rates in Sweden. Acta 
psychiatrica Scandinavica, 1996. 93(1): p. 43-48. 
88. Lindstrom, E., L. Eriksson, and S. Levander, Suicides during 7 years 
among a catchment area cohort of patients with psychoses. Nordic 
journal of psychiatry, 2012. 66(1): p. 8-13. 
89. Kasckow, J., K. Felmet, and S. Zisook, Managing suicide risk in 
patients with schizophrenia. CNS drugs, 2011. 25(2): p. 129-43. 
90. Siris, S.G., Suicide and schizophrenia. Journal of 
psychopharmacology, 2001. 15(2): p. 127-35. 
91. Palmer, B.A., V.S. Pankratz, and J.M. Bostwick, The lifetime risk of 
suicide in schizophrenia: a reexamination. Archives of general 
psychiatry, 2005. 62(3): p. 247-53. 
92. Hor, K. and M. Taylor, Suicide and schizophrenia: a systematic review 
of rates and risk factors. Journal of psychopharmacology, 2010. 24(4 
Suppl): p. 81-90. 
93. Ringback Weitoft, G., et al., Mortality, attempted suicide, re-
hospitalisation and prescription refill for clozapine and other 
antipsychotics in Sweden-a register-based study. 
Pharmacoepidemiology and drug safety, 2014. 23(3): p. 290-8. 
94. Angermeyer, M.C., M. Beck, and H. Matschinger, Determinants of the 
Public's Preference for Social Distance From People With 
Schizophrenia. Canadian Journal of Psychiatry, 2003. 48(10): p. 663-
668. 
95. Corrigan, P.W. On the Stigma of Mental Illness Practical Strategies for 
Research and Social Change. 2004; Available from: 
http://content.apa.org/books/2004-20896-000. Accessed December 3, 
2014. 
96. Read, J., et al., Prejudice and schizophrenia: a review of the 'mental 
illness is an illness like any other' approach. Acta psychiatrica 
Scandinavica, 2006. 114(5): p. 303-18. 
78 
 
97. Grausgruber, A., et al., Patterns of social distance towards people 
suffering from schizophrenia in Austria: a comparison between the 
general public, relatives and mental health staff. Acta psychiatrica 
Scandinavica, 2007. 115(4): p. 310-9. 
98. Jorm, A.F. and K.M. Griffiths, The public's stigmatizing attitudes 
towards people with mental disorders: how important are biomedical 
conceptualizations? Acta psychiatrica Scandinavica, 2008. 118(4): p. 
315-21. 
99. Scambler, G., Stigma and disease: changing paradigms. Lancet, 1998. 
352(9133): p. 1054-5. 
100. Goffman, E., Stigma; notes on the management of spoiled identity. 
1963, Englewood Cliffs, N.J.: Prentice-Hall. 
101. Thornicroft, G., et al., Stigma: ignorance, prejudice or discrimination? 
The British journal of psychiatry : the journal of mental science, 2007. 
190: p. 192-3. 
102. Hinshaw, S.P., The mark of shame : stigma of mental illness and an 
agenda for change. 2007, Oxford; New York: Oxford University Press. 
103. Phelan, J.C., E.J. Bromet, and B.G. Link, Psychiatric illness and family 
stigma. Schizophr Bull, 1998. 24(1): p. 115-26. 
104. Ostman, M. and L. Kjellin, Stigma by association: psychological 
factors in relatives of people with mental illness. The British journal of 
psychiatry : the journal of mental science, 2002. 181: p. 494-8. 
105. Liberman, R.P., et al., Operational criteria and factors related to 
recovery from schizophrenia. International Review of Psychiatry, 
2002. 14(4): p. 256-272. 
106. Schomerus, G., et al., Evolution of public attitudes about mental 
illness: a systematic review and meta-analysis. Acta psychiatrica 
Scandinavica, 2012. 125(6): p. 440-52. 
107. 
108. Kohn, R., et al., The treatment gap in mental health care. Bulletin of 
the World Health Organization, 2004. 82(11): p. 858-66. 
Sartorius, N., H. Schulze, Global Programme of the World 
Psychiatric, Reducing the stigma of mental illness : a report from the 
Global Programme of the World Psychiatric Association. 2005, 
Cambridge: Cambridge University Press. 
 
 79 
 
109. Brohan, E., et al., Experiences of mental illness stigma, prejudice and 
discrimination: a review of measures. BMC health services research, 
2010. 10: p. 80. 
110. Thornicroft, G., Most people with mental illness are not treated. 
Lancet, 2007. 370(9590): p. 807-8. 
111. Beldie, A., et al., Fighting stigma of mental illness in midsize 
European countries. Social psychiatry and psychiatric epidemiology, 
2012. 47 Suppl 1: p. 1-38. 
112. Weiden, P. and W. Glazer, Assessment and treatment selection for 
"revolving door" inpatients with schizophrenia. The Psychiatric 
quarterly, 1997. 68(4): p. 377-92. 
113. Uhlmann, C., et al., Negative impact of self-stigmatization on attitude 
toward medication adherence in patients with psychosis. Journal of 
psychiatric practice, 2014. 20(5): p. 405-10. 
114. Stuart, H.L., J. Arboleda-Flórez, and N. Sartorius, Paradigms lost : 
fighting stigma and the lessons learned. 2012, Oxford; New York: 
Oxford University Press. 
115. Sartorius, N., 
Cambridge University Press. 
116. Leucht, S., et al., Physical illness and schizophrenia: a review of the 
literature. Acta psychiatrica Scandinavica, 2007. 116(5): p. 317-33. 
117. Jones, S., L. Howard, and G. Thornicroft, 'Diagnostic overshadowing': 
worse physical health care for people with mental illness. Acta 
psychiatrica Scandinavica, 2008. 118(3): p. 169-71. 
118. Lambert, M., et al., Prevalence, predictors, and consequences of long-
term refusal of antipsychotic treatment in first-episode psychosis. J 
Clin Psychopharmacol, 2010. 30(5): p. 565-72. 
119. Velligan, D.I., et al., Psychopharmacology: Perspectives on 
medication adherence and atypical antipsychotic medications. 
Psychiatric services, 2003. 54(5): p. 665-7. 
120. Kampman, O. and K. Lehtinen, Compliance in psychoses. Acta 
psychiatrica Scandinavica, 1999. 100(3): p. 167-75. 
. 2002,Fighting for Mental Health: a Personal View
78 
 
97. Grausgruber, A., et al., Patterns of social distance towards people 
suffering from schizophrenia in Austria: a comparison between the 
general public, relatives and mental health staff. Acta psychiatrica 
Scandinavica, 2007. 115(4): p. 310-9. 
98. Jorm, A.F. and K.M. Griffiths, The public's stigmatizing attitudes 
towards people with mental disorders: how important are biomedical 
conceptualizations? Acta psychiatrica Scandinavica, 2008. 118(4): p. 
315-21. 
99. Scambler, G., Stigma and disease: changing paradigms. Lancet, 1998. 
352(9133): p. 1054-5. 
100. Goffman, E., Stigma; notes on the management of spoiled identity. 
1963, Englewood Cliffs, N.J.: Prentice-Hall. 
101. Thornicroft, G., et al., Stigma: ignorance, prejudice or discrimination? 
The British journal of psychiatry : the journal of mental science, 2007. 
190: p. 192-3. 
102. Hinshaw, S.P., The mark of shame : stigma of mental illness and an 
agenda for change. 2007, Oxford; New York: Oxford University Press. 
103. Phelan, J.C., E.J. Bromet, and B.G. Link, Psychiatric illness and family 
stigma. Schizophr Bull, 1998. 24(1): p. 115-26. 
104. Ostman, M. and L. Kjellin, Stigma by association: psychological 
factors in relatives of people with mental illness. The British journal of 
psychiatry : the journal of mental science, 2002. 181: p. 494-8. 
105. Liberman, R.P., et al., Operational criteria and factors related to 
recovery from schizophrenia. International Review of Psychiatry, 
2002. 14(4): p. 256-272. 
106. Schomerus, G., et al., Evolution of public attitudes about mental 
illness: a systematic review and meta-analysis. Acta psychiatrica 
Scandinavica, 2012. 125(6): p. 440-52. 
107. 
108. Kohn, R., et al., The treatment gap in mental health care. Bulletin of 
the World Health Organization, 2004. 82(11): p. 858-66. 
Sartorius, N., H. Schulze, Global Programme of the World 
Psychiatric, Reducing the stigma of mental illness : a report from the 
Global Programme of the World Psychiatric Association. 2005, 
Cambridge: Cambridge University Press. 
 
 79 
 
109. Brohan, E., et al., Experiences of mental illness stigma, prejudice and 
discrimination: a review of measures. BMC health services research, 
2010. 10: p. 80. 
110. Thornicroft, G., Most people with mental illness are not treated. 
Lancet, 2007. 370(9590): p. 807-8. 
111. Beldie, A., et al., Fighting stigma of mental illness in midsize 
European countries. Social psychiatry and psychiatric epidemiology, 
2012. 47 Suppl 1: p. 1-38. 
112. Weiden, P. and W. Glazer, Assessment and treatment selection for 
"revolving door" inpatients with schizophrenia. The Psychiatric 
quarterly, 1997. 68(4): p. 377-92. 
113. Uhlmann, C., et al., Negative impact of self-stigmatization on attitude 
toward medication adherence in patients with psychosis. Journal of 
psychiatric practice, 2014. 20(5): p. 405-10. 
114. Stuart, H.L., J. Arboleda-Flórez, and N. Sartorius, Paradigms lost : 
fighting stigma and the lessons learned. 2012, Oxford; New York: 
Oxford University Press. 
115. Sartorius, N., 
Cambridge University Press. 
116. Leucht, S., et al., Physical illness and schizophrenia: a review of the 
literature. Acta psychiatrica Scandinavica, 2007. 116(5): p. 317-33. 
117. Jones, S., L. Howard, and G. Thornicroft, 'Diagnostic overshadowing': 
worse physical health care for people with mental illness. Acta 
psychiatrica Scandinavica, 2008. 118(3): p. 169-71. 
118. Lambert, M., et al., Prevalence, predictors, and consequences of long-
term refusal of antipsychotic treatment in first-episode psychosis. J 
Clin Psychopharmacol, 2010. 30(5): p. 565-72. 
119. Velligan, D.I., et al., Psychopharmacology: Perspectives on 
medication adherence and atypical antipsychotic medications. 
Psychiatric services, 2003. 54(5): p. 665-7. 
120. Kampman, O. and K. Lehtinen, Compliance in psychoses. Acta 
psychiatrica Scandinavica, 1999. 100(3): p. 167-75. 
. 2002,Fighting for Mental Health: a Personal View
80 
 
121. Goff, D.C., M. Hill, and O. Freudenreich, Strategies for improving 
treatment adherence in schizophrenia and schizoaffective disorder. J 
Clin Psychiatry, 2010. 71 Suppl 2: p. 20-6. 
122. Robinson, D., et al., Predictors of relapse following response from a 
first episode of schizophrenia or schizoaffective disorder. Archives of 
general psychiatry, 1999. 56(3): p. 241-7. 
123. Caseiro, O., et al., Predicting relapse after a first episode of non-
affective psychosis: a three-year follow-up study. Journal of psychiatric 
research, 2012. 46(8): p. 1099-105. 
124. Haijma, S.V., et al., Brain volumes in schizophrenia: a meta-analysis 
in over 18 000 subjects. Schizophrenia bulletin, 2013. 39(5): p. 1129-
38. 
125. van Haren, N.E., et al., Focal gray matter changes in schizophrenia 
across the course of the illness: a 5-year follow-up study. 
Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology, 2007. 32(10): p. 2057-66. 
126. Ascher-Svanum, H., et al., A prospective study of risk factors for 
nonadherence with antipsychotic medication in the treatment of 
schizophrenia. The Journal of clinical psychiatry, 2006. 67(7): p. 1114-
23. 
127. Cooper, D., J. Moisan, and J.P. Gregoire, Adherence to atypical 
antipsychotic treatment among newly treated patients: a population-
based study in schizophrenia. The Journal of clinical psychiatry, 2007. 
68(6): p. 818-25. 
128. Yang, J., et al., Symptom severity and attitudes toward medication: 
Impacts on adherence in outpatients with schizophrenia. Schizophrenia 
Research, 2012. 134(2–3): p. 226-231. 
129. Byerly, M., et al., A comparison of electronic monitoring vs. clinician 
rating of antipsychotic adherence in outpatients with schizophrenia. 
Psychiatry research, 2005. 133(2-3): p. 129-133. 
130. Diaz, E., et al., Use of the Medication Event Monitoring System to 
estimate medication compliance in patients with schizophrenia. Journal 
of Psychiatry and Neuroscience, 2001. 26(4): p. 325. 
 
 81 
 
131. Cramer, J.A. and R. Rosenheck, Enhancing medication compliance for 
people with serious mental illness. The Journal of nervous and mental 
disease, 1999. 187(1): p. 53-5. 
132. Nakonezny, P.A., M.J. Byerly, and A.J. Rush, Electronic monitoring of 
antipsychotic medication adherence in outpatients with schizophrenia 
or schizoaffective disorder: an empirical evaluation of its reliability 
and predictive validity. Psychiatry research, 2008. 157(1-3): p. 259-63. 
133. Farmer, K.C., Methods for measuring and monitoring medication 
regimen adherence in clinical trials and clinical practice. Clinical 
therapeutics, 1999. 21(6): p. 1074-90; discussion 1073. 
134. Velligan, D.I., et al., Defining and assessing adherence to oral 
antipsychotics: a review of the literature. Schizophrenia Bulletin, 
2006. 32(4): p. 724-742. 
135. Kinon, B.J., et al., Olanzapine orally disintegrating tablets in the 
treatment of acutely ill non-compliant patients with schizophrenia. The 
international journal of neuropsychopharmacology / official scientific 
journal of the Collegium Internationale 
Neuropsychopharmacologicum, 2003. 6(2): p. 97-102. 
136. Alvarez-Jimenez, M., et al., Risk factors for relapse following 
treatment for first episode psychosis: a systematic review and meta-
analysis of longitudinal studies. Schizophrenia research, 2012. 139(1-
3): p. 116-28. 
137. Stroup, T.S., et al., The National Institute of Mental Health Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) project: 
schizophrenia trial design and protocol development. Schizophrenia 
bulletin, 2003. 29(1): p. 15-31. 
138. Lambert, M., et al., Impact of present and past antipsychotic side 
effects on attitude toward typical antipsychotic treatment and 
adherence. European psychiatry : the journal of the Association of 
European Psychiatrists, 2004. 19(7): p. 415-22. 
139. Diaz, E., et al., Adherence to conventional and atypical antipsychotics 
after hospital discharge. The Journal of clinical psychiatry, 2004. 
65(3): p. 354-60. 
140. Weiden, P.J., J.A. Mackell, and D.D. McDonnell, Obesity as a risk 
factor for antipsychotic noncompliance. Schizophrenia research, 2004. 
66(1): p. 51-7. 
80 
 
121. Goff, D.C., M. Hill, and O. Freudenreich, Strategies for improving 
treatment adherence in schizophrenia and schizoaffective disorder. J 
Clin Psychiatry, 2010. 71 Suppl 2: p. 20-6. 
122. Robinson, D., et al., Predictors of relapse following response from a 
first episode of schizophrenia or schizoaffective disorder. Archives of 
general psychiatry, 1999. 56(3): p. 241-7. 
123. Caseiro, O., et al., Predicting relapse after a first episode of non-
affective psychosis: a three-year follow-up study. Journal of psychiatric 
research, 2012. 46(8): p. 1099-105. 
124. Haijma, S.V., et al., Brain volumes in schizophrenia: a meta-analysis 
in over 18 000 subjects. Schizophrenia bulletin, 2013. 39(5): p. 1129-
38. 
125. van Haren, N.E., et al., Focal gray matter changes in schizophrenia 
across the course of the illness: a 5-year follow-up study. 
Neuropsychopharmacology : official publication of the American 
College of Neuropsychopharmacology, 2007. 32(10): p. 2057-66. 
126. Ascher-Svanum, H., et al., A prospective study of risk factors for 
nonadherence with antipsychotic medication in the treatment of 
schizophrenia. The Journal of clinical psychiatry, 2006. 67(7): p. 1114-
23. 
127. Cooper, D., J. Moisan, and J.P. Gregoire, Adherence to atypical 
antipsychotic treatment among newly treated patients: a population-
based study in schizophrenia. The Journal of clinical psychiatry, 2007. 
68(6): p. 818-25. 
128. Yang, J., et al., Symptom severity and attitudes toward medication: 
Impacts on adherence in outpatients with schizophrenia. Schizophrenia 
Research, 2012. 134(2–3): p. 226-231. 
129. Byerly, M., et al., A comparison of electronic monitoring vs. clinician 
rating of antipsychotic adherence in outpatients with schizophrenia. 
Psychiatry research, 2005. 133(2-3): p. 129-133. 
130. Diaz, E., et al., Use of the Medication Event Monitoring System to 
estimate medication compliance in patients with schizophrenia. Journal 
of Psychiatry and Neuroscience, 2001. 26(4): p. 325. 
 
 81 
 
131. Cramer, J.A. and R. Rosenheck, Enhancing medication compliance for 
people with serious mental illness. The Journal of nervous and mental 
disease, 1999. 187(1): p. 53-5. 
132. Nakonezny, P.A., M.J. Byerly, and A.J. Rush, Electronic monitoring of 
antipsychotic medication adherence in outpatients with schizophrenia 
or schizoaffective disorder: an empirical evaluation of its reliability 
and predictive validity. Psychiatry research, 2008. 157(1-3): p. 259-63. 
133. Farmer, K.C., Methods for measuring and monitoring medication 
regimen adherence in clinical trials and clinical practice. Clinical 
therapeutics, 1999. 21(6): p. 1074-90; discussion 1073. 
134. Velligan, D.I., et al., Defining and assessing adherence to oral 
antipsychotics: a review of the literature. Schizophrenia Bulletin, 
2006. 32(4): p. 724-742. 
135. Kinon, B.J., et al., Olanzapine orally disintegrating tablets in the 
treatment of acutely ill non-compliant patients with schizophrenia. The 
international journal of neuropsychopharmacology / official scientific 
journal of the Collegium Internationale 
Neuropsychopharmacologicum, 2003. 6(2): p. 97-102. 
136. Alvarez-Jimenez, M., et al., Risk factors for relapse following 
treatment for first episode psychosis: a systematic review and meta-
analysis of longitudinal studies. Schizophrenia research, 2012. 139(1-
3): p. 116-28. 
137. Stroup, T.S., et al., The National Institute of Mental Health Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) project: 
schizophrenia trial design and protocol development. Schizophrenia 
bulletin, 2003. 29(1): p. 15-31. 
138. Lambert, M., et al., Impact of present and past antipsychotic side 
effects on attitude toward typical antipsychotic treatment and 
adherence. European psychiatry : the journal of the Association of 
European Psychiatrists, 2004. 19(7): p. 415-22. 
139. Diaz, E., et al., Adherence to conventional and atypical antipsychotics 
after hospital discharge. The Journal of clinical psychiatry, 2004. 
65(3): p. 354-60. 
140. Weiden, P.J., J.A. Mackell, and D.D. McDonnell, Obesity as a risk 
factor for antipsychotic noncompliance. Schizophrenia research, 2004. 
66(1): p. 51-7. 
82 
 
141. Jonsdottir, H., et al., Predictors of medication adherence in patients 
with schizophrenia and bipolar disorder. Acta psychiatrica 
Scandinavica, 2013. 127(1): p. 23-33. 
142. Gaebel, W., et al., Drug attitude as predictor for effectiveness in first-
episode schizophrenia: Results of an open randomized trial (EUFEST). 
Eur Neuropsychopharmacol, 2010. 20(5): p. 310-6. 
143. Hogan, T.P., A.G. Awad, and R. Eastwood, A self-report scale 
predictive of drug compliance in schizophrenics: reliability and 
discriminative validity. Psychological medicine, 1983. 13(1): p. 177-
83. 
144. Kikkert, M.J., et al., The predictive validity of subjective adherence 
measures in patients with schizophrenia. Int J Methods Psychiatr Res, 
2011. 20(2): p. 73-81. 
145. Maeda, K., et al., Effect of subjective reasoning and neurocognition on 
medication adherence for persons with schizophrenia. Psychiatric 
services, 2006. 57(8): p. 1203-5. 
146. Mingrone, C., et al., Insight in stable schizophrenia: relations with 
psychopathology and cognition. Comprehensive psychiatry, 2013. 
54(5): p. 484-92. 
147. Lincoln, T.M., E. Lullmann, and W. Rief, Correlates and long-term 
consequences of poor insight in patients with schizophrenia. A 
systematic review. Schizophrenia bulletin, 2007. 33(6): p. 1324-42. 
148. Lepage, M., et al., Is there an association between neurocognitive 
performance and medication adherence in first episode psychosis? 
Early intervention in psychiatry, 2010. 4(2): p. 189-95. 
149. Velligan, D.I., et al., The expert consensus guideline series: adherence 
problems in patients with serious and persistent mental illness. The 
Journal of clinical psychiatry, 2009. 70 Suppl 4: p. 1-46; quiz 47-8. 
150. Jeste, S.D., et al., Cognitive predictors of medication adherence among 
middle-aged and older outpatients with schizophrenia. Schizophr Res, 
2003. 63(1-2): p. 49-58. 
151. Kay, S.R., A. Fiszbein, and L.A. Opler, The positive and negative 
syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987. 
13(2): p. 261-76. 
Journal of clinical psychiatry, 2009. 70 Suppl 4: p. 1-46; quiz 47-8. 
 
 83 
 
152. Guy, W., ECDEU assessment manual for psychopharmacology., a.W. 
US Department of Health Education, Public Health Service, Alcohol, 
Drug Abuse, and Mental Health Administration, National Institute of 
Mental Health, Psychopharmacology Research Branch, Division of 
Extramural Research Programs, Rockville., Editor. 1976. 
153. Endicott, J., et al., The global assessment scale. A procedure for 
measuring overall severity of psychiatric disturbance. Archives of 
general psychiatry, 1976. 33(6): p. 766-71. 
154. Brohan, E., et al., Development and psychometric evaluation of the 
Discrimination and Stigma Scale (DISC). Psychiatry research, 2013. 
208(1): p. 33-40. 
155. Thornicroft, G., et al., Global pattern of experienced and anticipated 
discrimination against people with schizophrenia: a cross-sectional 
survey. Lancet, 2009. 373(9661): p. 408-15. 
156. Lindstrom, E., et al., Patient-rated versus clinician-rated side effects of 
drug treatment in schizophrenia. Clinical validation of a self-rating 
version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nordic 
journal of psychiatry, 2001. 55 Suppl 44: p. 5-69. 
157. Stuart, H., R. Milev, and M. Koller, The Inventory of Stigmatizing 
Experiences: its development and reliability. World Psychiatry, 2005. 
4: p. 33-37. 
158. Hjarthag, F., L. Helldin, and T. Norlander, Psychometric properties of 
the burden inventory for relatives of persons with psychotic 
disturbances. Psychol Rep, 2008. 103(2): p. 323-35. 
159. Rey, A., L'examen clinique en psychologie. 1964, Paris: Presses 
universitaires de France. 
160. Schmidt, M., Rey Auditory Verbal Learning Test : RAVLT : a 
handbook. 1996, Los Angeles, CA: Western Psychological Services. 
161. Cornblatt, B.A., et al., The Continuous Performance Test, identical 
pairs version (CPT-IP): I. New findings about sustained attention in 
normal families. Psychiatry research, 1988. 26(2): p. 223-38. 
162. Beck, L.H., et al., A continuous performance test of brain damage. J 
Consult Psychol, 1956. 20(5): p. 343-50. 
lli  DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, et al. 
The use of indiv dually ailo ed environmental supports to improve 
medic tion adherence and outcomes in schizophrenia. Schizophr Bull. 
2008;34(3):483-93.
82 
 
141. Jonsdottir, H., et al., Predictors of medication adherence in patients 
with schizophrenia and bipolar disorder. Acta psychiatrica 
Scandinavica, 2013. 127(1): p. 23-33. 
142. Gaebel, W., et al., Drug attitude as predictor for effectiveness in first-
episode schizophrenia: Results of an open randomized trial (EUFEST). 
Eur Neuropsychopharmacol, 2010. 20(5): p. 310-6. 
143. Hogan, T.P., A.G. Awad, and R. Eastwood, A self-report scale 
predictive of drug compliance in schizophrenics: reliability and 
discriminative validity. Psychological medicine, 1983. 13(1): p. 177-
83. 
144. Kikkert, M.J., et al., The predictive validity of subjective adherence 
measures in patients with schizophrenia. Int J Methods Psychiatr Res, 
2011. 20(2): p. 73-81. 
145. Maeda, K., et al., Effect of subjective reasoning and neurocognition on 
medication adherence for persons with schizophrenia. Psychiatric 
services, 2006. 57(8): p. 1203-5. 
146. Mingrone, C., et al., Insight in stable schizophrenia: relations with 
psychopathology and cognition. Comprehensive psychiatry, 2013. 
54(5): p. 484-92. 
147. Lincoln, T.M., E. Lullmann, and W. Rief, Correlates and long-term 
consequences of poor insight in patients with schizophrenia. A 
systematic review. Schizophrenia bulletin, 2007. 33(6): p. 1324-42. 
148. Lepage, M., et al., Is there an association between neurocognitive 
performance and medication adherence in first episode psychosis? 
Early intervention in psychiatry, 2010. 4(2): p. 189-95. 
149. Velligan, D.I., et al., The expert consensus guideline series: adherence 
problems in patients with serious and persistent mental illness. The 
Journal of clinical psychiatry, 2009. 70 Suppl 4: p. 1-46; quiz 47-8. 
150. Jeste, S.D., et al., Cognitive predictors of medication adherence among 
middle-aged and older outpatients with schizophrenia. Schizophr Res, 
2003. 63(1-2): p. 49-58. 
151. Kay, S.R., A. Fiszbein, and L.A. Opler, The positive and negative 
syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987. 
13(2): p. 261-76. 
Journal of clinical psychiatry, 2009. 70 Suppl 4: p. 1-46; quiz 47-8. 
 
 83 
 
152. Guy, W., ECDEU assessment manual for psychopharmacology., a.W. 
US Department of Health Education, Public Health Service, Alcohol, 
Drug Abuse, and Mental Health Administration, National Institute of 
Mental Health, Psychopharmacology Research Branch, Division of 
Extramural Research Programs, Rockville., Editor. 1976. 
153. Endicott, J., et al., The global assessment scale. A procedure for 
measuring overall severity of psychiatric disturbance. Archives of 
general psychiatry, 1976. 33(6): p. 766-71. 
154. Brohan, E., et al., Development and psychometric evaluation of the 
Discrimination and Stigma Scale (DISC). Psychiatry research, 2013. 
208(1): p. 33-40. 
155. Thornicroft, G., et al., Global pattern of experienced and anticipated 
discrimination against people with schizophrenia: a cross-sectional 
survey. Lancet, 2009. 373(9661): p. 408-15. 
156. Lindstrom, E., et al., Patient-rated versus clinician-rated side effects of 
drug treatment in schizophrenia. Clinical validation of a self-rating 
version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nordic 
journal of psychiatry, 2001. 55 Suppl 44: p. 5-69. 
157. Stuart, H., R. Milev, and M. Koller, The Inventory of Stigmatizing 
Experiences: its development and reliability. World Psychiatry, 2005. 
4: p. 33-37. 
158. Hjarthag, F., L. Helldin, and T. Norlander, Psychometric properties of 
the burden inventory for relatives of persons with psychotic 
disturbances. Psychol Rep, 2008. 103(2): p. 323-35. 
159. Rey, A., L'examen clinique en psychologie. 1964, Paris: Presses 
universitaires de France. 
160. Schmidt, M., Rey Auditory Verbal Learning Test : RAVLT : a 
handbook. 1996, Los Angeles, CA: Western Psychological Services. 
161. Cornblatt, B.A., et al., The Continuous Performance Test, identical 
pairs version (CPT-IP): I. New findings about sustained attention in 
normal families. Psychiatry research, 1988. 26(2): p. 223-38. 
162. Beck, L.H., et al., A continuous performance test of brain damage. J 
Consult Psychol, 1956. 20(5): p. 343-50. 
84 
 
163. Reitan, R.M., Validity of the Trailmaking Test as an indication of 
organic brain damage. Perceptual and Motor Skills, 1958. 8(3): p. 
271-276. 
164. Lezak, M.D., Neuropsychological assessment. 1995, New York: 
Oxford University Press. 
165. Wechsler, D., Wechsler Adult Intelligence Scale – third edition. 1997, 
San Antonio: TX: Psychological Corporation. 
166. Gold, J.M., et al., Auditory working memory and Wisconsin Card 
Sorting Test performance in schizophrenia. Archives of General 
Psychiatry, 1997. 54(2): p. 159-165. 
167. Wechsler, D., Wechsler adult intelligence scale - revised. 1981, New 
York: The Psychological Corporation. 
168. Heaton, R.K., Wisconsin Card Sorting Test manual : revised and 
expanded. 1993, [S.l.]: Psychological Assessment Resources. 
169. Karilampi, U., L. Helldin, and T. Archer, Cognition and global 
assessment of functioning in male and female outpatients with 
schizophrenia spectrum disorders. The Journal of nervous and mental 
disease, 2011. 199(7): p. 445-8. 
170. Nuechterlein, K.H., et al., The MATRICS Consensus Cognitive Battery, 
part 1: test selection, reliability, and validity. Am J Psychiatry, 2008. 
165(2): p. 203-13. 
171. Hosmer, D.W. and S. Lemeshow, Applied Logistic Regression. Vol. 
354. 2000: Wiley-Interscience. 
172. Valencia, M., F. Juarez, and H. Ortega, Integrated treatment to achieve 
functional recovery for first-episode psychosis. Schizophr Res 
Treatment, 2012. 2012: p. 962371. 
173. Bergman, H. and H. Kallmen, Alcohol use among Swedes and a 
psychometric evaluation of the alcohol use disorders identification test. 
Alcohol and alcoholism, 2002. 37(3): p. 245-51. 
174. Berman, A.H., et al., Evaluation of the Drug Use Disorders 
Identification Test (DUDIT) in criminal justice and detoxification 
settings and in a Swedish population sample. European addiction 
research, 2005. 11(1): p. 22-31. 
 
 85 
 
175. Hjarthag, F., et al., Illness-related components for the family burden of 
relatives to patients with psychotic illness. Soc Psychiatry Psychiatr 
Epidemiol, 2010. 45(2): p. 275-83. 
176. Parabiaghi, A., et al., Predictors of changes in caregiving burden in 
people with schizophrenia: a 3-year follow-up study in a community 
mental health service. Acta Psychiatr Scand Suppl, 2007(437): p. 66-
76. 
177. Wancata, J., et al., Gender aspects of parents' needs of schizophrenia 
patients. Social psychiatry and psychiatric epidemiology, 2008. 43(12): 
p. 968-74. 
178. Shi, L., et al., Characteristics and use patterns of patients taking first-
generation depot antipsychotics or oral antipsychotics for 
schizophrenia. Psychiatr Serv, 2007. 58(4): p. 482-8. 
179. Malm, U., et al., Integrated care in schizophrenia: a 2-year 
randomized controlled study of two community-based treatment 
programs. Acta Psychiatr Scand, 2003. 107(6): p. 415-23. 
180. Chen, A., Noncompliance in community psychiatry: a review of 
clinical interventions. Hospital & community psychiatry, 1991. 42(3): 
p. 282-7. 
181. Baumann, P., et al., The AGNP-TDM expert group consensus 
guidelines: therapeutic drug monitoring in psychiatry. 
Pharmacopsychiatry, 2004. 37(6): p. 243-65. 
182. Nose, M., C. Barbui, and M. Tansella, How often do patients with 
psychosis fail to adhere to treatment programmes? A systematic 
review. Psychological medicine, 2003. 33(7): p. 1149-60. 
183. Perkins, D.O., et al., Predictors of treatment discontinuation and 
medication nonadherence in patients recovering from a first episode of 
schizophrenia, schizophreniform disorder, or schizoaffective disorder: 
a randomized, double-blind, flexible-dose, multicenter study. The 
Journal of clinical psychiatry, 2008. 69(1): p. 106-13. 
184. Amador, X.F., et al., Assessment of insight in psychosis. The American 
journal of psychiatry, 1993. 150(6): p. 873-9. 
185. Day, J.C., et al., Attitudes toward antipsychotic medication: the impact 
of clinical variables and relationships with health professionals. 
Archives of general psychiatry, 2005. 62(7): p. 717-24. 
84 
 
163. Reitan, R.M., Validity of the Trailmaking Test as an indication of 
organic brain damage. Perceptual and Motor Skills, 1958. 8(3): p. 
271-276. 
164. Lezak, M.D., Neuropsychological assessment. 1995, New York: 
Oxford University Press. 
165. Wechsler, D., Wechsler Adult Intelligence Scale – third edition. 1997, 
San Antonio: TX: Psychological Corporation. 
166. Gold, J.M., et al., Auditory working memory and Wisconsin Card 
Sorting Test performance in schizophrenia. Archives of General 
Psychiatry, 1997. 54(2): p. 159-165. 
167. Wechsler, D., Wechsler adult intelligence scale - revised. 1981, New 
York: The Psychological Corporation. 
168. Heaton, R.K., Wisconsin Card Sorting Test manual : revised and 
expanded. 1993, [S.l.]: Psychological Assessment Resources. 
169. Karilampi, U., L. Helldin, and T. Archer, Cognition and global 
assessment of functioning in male and female outpatients with 
schizophrenia spectrum disorders. The Journal of nervous and mental 
disease, 2011. 199(7): p. 445-8. 
170. Nuechterlein, K.H., et al., The MATRICS Consensus Cognitive Battery, 
part 1: test selection, reliability, and validity. Am J Psychiatry, 2008. 
165(2): p. 203-13. 
171. Hosmer, D.W. and S. Lemeshow, Applied Logistic Regression. Vol. 
354. 2000: Wiley-Interscience. 
172. Valencia, M., F. Juarez, and H. Ortega, Integrated treatment to achieve 
functional recovery for first-episode psychosis. Schizophr Res 
Treatment, 2012. 2012: p. 962371. 
173. Bergman, H. and H. Kallmen, Alcohol use among Swedes and a 
psychometric evaluation of the alcohol use disorders identification test. 
Alcohol and alcoholism, 2002. 37(3): p. 245-51. 
174. Berman, A.H., et al., Evaluation of the Drug Use Disorders 
Identification Test (DUDIT) in criminal justice and detoxification 
settings and in a Swedish population sample. European addiction 
research, 2005. 11(1): p. 22-31. 
 
 85 
 
175. Hjarthag, F., et al., Illness-related components for the family burden of 
relatives to patients with psychotic illness. Soc Psychiatry Psychiatr 
Epidemiol, 2010. 45(2): p. 275-83. 
176. Parabiaghi, A., et al., Predictors of changes in caregiving burden in 
people with schizophrenia: a 3-year follow-up study in a community 
mental health service. Acta Psychiatr Scand Suppl, 2007(437): p. 66-
76. 
177. Wancata, J., et al., Gender aspects of parents' needs of schizophrenia 
patients. Social psychiatry and psychiatric epidemiology, 2008. 43(12): 
p. 968-74. 
178. Shi, L., et al., Characteristics and use patterns of patients taking first-
generation depot antipsychotics or oral antipsychotics for 
schizophrenia. Psychiatr Serv, 2007. 58(4): p. 482-8. 
179. Malm, U., et al., Integrated care in schizophrenia: a 2-year 
randomized controlled study of two community-based treatment 
programs. Acta Psychiatr Scand, 2003. 107(6): p. 415-23. 
180. Chen, A., Noncompliance in community psychiatry: a review of 
clinical interventions. Hospital & community psychiatry, 1991. 42(3): 
p. 282-7. 
181. Baumann, P., et al., The AGNP-TDM expert group consensus 
guidelines: therapeutic drug monitoring in psychiatry. 
Pharmacopsychiatry, 2004. 37(6): p. 243-65. 
182. Nose, M., C. Barbui, and M. Tansella, How often do patients with 
psychosis fail to adhere to treatment programmes? A systematic 
review. Psychological medicine, 2003. 33(7): p. 1149-60. 
183. Perkins, D.O., et al., Predictors of treatment discontinuation and 
medication nonadherence in patients recovering from a first episode of 
schizophrenia, schizophreniform disorder, or schizoaffective disorder: 
a randomized, double-blind, flexible-dose, multicenter study. The 
Journal of clinical psychiatry, 2008. 69(1): p. 106-13. 
184. Amador, X.F., et al., Assessment of insight in psychosis. The American 
journal of psychiatry, 1993. 150(6): p. 873-9. 
185. Day, J.C., et al., Attitudes toward antipsychotic medication: the impact 
of clinical variables and relationships with health professionals. 
Archives of general psychiatry, 2005. 62(7): p. 717-24. 
86 
 
186. Corker, E.A., et al., Experience of stigma and discrimination reported 
by people experiencing the first episode of schizophrenia and those 
with a first episode of depression: The FEDORA project. Int J Soc 
Psychiatry, Epub ahead of print, Oct 10, 2014. 
187. Ucok, A., et al., Anticipated discrimination among people with 
schizophrenia. Acta psychiatrica Scandinavica, 2012. 125(1): p. 77-83. 
188. Wahl, O.F. and C.R. Harman, Family views of stigma. Schizophrenia 
bulletin, 1989. 15(1): p. 131-9. 
189. Stuart, H., M. Koller, and R. Milev, Appendix Inventories to Measure 
the Scope and Impact of Stigma Experiences from the Perspective of 
those who are Stigmatized – Consumer and Family Versions, in 
Understanding the Stigma of Mental Illness. 2008, John Wiley & Sons, 
Ltd. p. 193-204. 
190. Falloon, I.R., et al., Optimal treatment strategies to enhance recovery 
from schizophrenia. The Australian and New Zealand journal of 
psychiatry, 1998. 32(1): p. 43-9. 
191. Ziguras, S.J. and G.W. Stuart, A meta-analysis of the effectiveness of 
mental health case management over 20 years. Psychiatr Serv, 2000. 
51(11): p. 1410-21. 
192. Phillips, S.D., et al., Moving assertive community treatment into 
standard practice. Psychiatr Serv, 2001. 52(6): p. 771-9. 
193. Miles, A. and J.E. Mezzich, Person-centered healthcare: addressing 
chronic illness and promoting future health. International Journal of 
Person Centered Medicine, 2012. 2(2): p. 149-152. 
 
 
